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Abstract 
Inositol pyrophosphates (PP-InsPs) are an important group of second 
messengers that intersect with a wide range of processes in eukaryotic cells including 
phosphate homeostasis, insulin signaling and apoptosis. However, despite their 
discovery more than two decades ago, elucidating the underlying signaling 
mechanisms still remains a significant challenge due to the limited access of synthetic 
PP-InsPs and a lack of widely available analytical tools. Therefore, a new set of 
chemical and analytical methods was developed to improve our understanding of these 
intriguing molecules on the biochemical and cellular level. 
To overcome the shortage of synthetic PP-InsPs, a highly efficient and scalable 
chemoenzymatic approach was designed. Coupled to a simple purification method 
based on the precipitation with Mg2+ ions, the major mammalian PP-InsPs could be 
obtained in hundreds of milligrams quantities and high purity circumventing labor-
intensive classical organic synthesis. In parallel, a new analytical tools was developed 
to quantify levels of PP-InsPs in complex samples. Chemoenzymatic access to 13C-
labeled myo-inositol and 13C-labeled PP-InsPs enabled the detection of low 
concentrations of PP-InsPs using nuclear magnetic resonance (NMR) spectroscopy. 
In vitro, these compounds were of great use for the biochemical characterization of 
PP-InsPs kinases from mammals and plants. Endogenous pools of PP-InsPs from 
human cell lines could be identified and quantified by metabolic labeling with 13C-
labeled myo-inositol and followed by assignment of characteristic signals using 
synthetic PP-InsP standards. Finally, a new proteomics workflow towards the detection 
of protein pyrophosphorylation, a posttranslational modification (PTM) mediated by 
PP-InsPs, using mass spectrometry (MS) was optimized and endogenously modified 
mammalian proteins could be identified for the first time and with high confidence. In 
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total, 36 pyrophosphorylated proteins could be detected and gene ontology analysis 
suggests a function of this PTM in ribosome biogenesis, cell-cell adhesion and cell 
division. 
Taken together, the chemical and analytical tools presented have great potential 
to accelerate the understanding of PP-InsP signaling and metabolism. The supply of 
large amounts of PP-InsPs to the research community will strongly encourage 
scientists to interrogate these molecules in their biological context. In addition, the 
quantification of PP-InsPs with NMR and the identification of endogenous 
pyrophosphorylation sites by MS are complementary methods that will be essential to 
unraveling the signaling mechanisms underlying the diverse phenotypes associated 
with these metabolites.  
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Zusammenfassung 
Bei den Inositolpyrophosphaten (PP-InsPs) handelt es sich um eine wichtige 
Gruppe eukaryotischer sekundärer Botenstoffe, die mit einer Reihe von verschiedenen 
Prozessen wie Apoptose, Phosphathomeostase und Insulinsignalkaskaden verknüpft 
sind. Trotz ihrer Entdeckung vor mehr als 20 Jahren bleibt es eine große 
Herausforderung, die Mechanismen hinter den Signalwirkungen dieser Moleküle zu 
verstehen. Die Ursache dafür ist der limitierte Zugang zu synthetischen PP-InsPs und 
es einen Mangel an allgemein zugänglichen analytischen Methoden. Daher wurden in 
dieser Arbeit chemische und analytische Methoden entwickelt, um unser Verständnis 
von diesen Molekülen sowohl auf ein biochemischer als auch auf zelluläre Ebene zu 
verbessern. 
Um der Knappheit an synthetischen PP-InsPs entgegen zu wirken, wurde ein 
hocheffizientes synthetisches Verfahren entwickelt. In Kombination mit einer einfachen 
Aufreinigungsmethode, durch Fällung mittels Zugabe von Mg2+ Ionen, konnten mehr 
als 100 mg aller wesentlichen PP-InsPs von Säugern hergestellt werden. Parallel 
wurde ein neues analytisches Werkzeug entwickelt, dass Konzentrationen von PP-
InsPs in komplexen Proben quantifizieren konnte. Mittel Enzymkatalyse konnten 13C-
markiertes myo-inositol und 13C-markierte PP-InsPs hergestellt werden und niedrige 
Konzentrationen mit nuklearer Magnetresonanzspektroskopie (NMR) detektiert 
werden. In vitro waren diese Verbindungen sehr nützlich, um PP-InsP Kinasen von 
Pflanzen und Säugern biochemisch zu charakterisieren. Endogene Konzentrationen 
von PP-InsPs konnten durch metabolisches Markieren mit 13C-markiertem myo-
inositol in humanen Zelllinien identifiziert und quantifiziert werden. Letztendlich wurde 
auch ein neuer proteomischer Ansatz zur Detektion von Proteinpyrophosphorilierung, 
eine von PP-InsP eingebaute posttranslationale Proteinmodifikation (PTM), mittels 
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Massenspektrometrie (MS) optimiert und endogen modifizierte Proteine von 
Säugertieren konnten zum ersten Mal nachgewiesen werden. Insgesamt wurden so 
36 pyrophosphorilierte Proteine gefunden und eine Genanalyse suggerierte 
Funktionen dieser PTM in Ribosombiogenese, Zell-Zell Adhäsion und Zellteilung.  
Zusammenfassend haben die aufgelisteten chemischen und analytischen 
Werkzeuge ein hohes Potenzial das Verständnis von PP-InsPs bedingten Prozessen 
zu beschleunigen. Die Bereitstellung von größeren Mengen an PP-InsPs für die breite 
Forschung wird Wissenschaftler ermutigen diese Moleküle in neuen biologischen 
Kontexten zu studieren. Zusätzlich werden die komplementären Methoden, 
Quantifizierung von PP-InsPs mittels NMR und Identifikation von 
Proteinpyrophosphorilierung mittels MS, essenziell sein, um die Signalmechanismen, 
die den diversen Phänotypen der PP-InsPs zu Grunde liegen zu verstehen. 
  
xiv 
 
List of Figures, Tables and Schemes 
Figure 1.1 Fundamental steps of signal transduction: signal perception, transduction 
relay and response. 
2 
Figure 1.2 Cellular signaling of second messengers cAMP and InsP3. 3 
Figure 1.3 Simplified biochemical pathway of myo-inositol-based molecules starting 
from myo-inositol and glucose. 
6 
Table 1.1  Examples of identified phenotypes associated with IP6Ks and PPIP5Ks. 8 
Figure 1.4 Metabolic labeling of eukaryotic cells with radioactive isotope tracers. 10 
Figure 1.5 Insulin/Akt signaling pathway is regulated via inositol pyrophosphates. 11 
Figure 1.6 In vitro pyrophosphorylation of proteins from cell lysates using 5PP-InsP5-
β32P. 
13 
Figure 1.7 Detection of potential endogenous pyrophosphorylation sites by the ‘back-
pyrophosphorylation assay’. 
14 
Scheme 2.1 Chemical Synthesis of 5PP-InsP5 with 30% overall yield. 24 
Scheme 2.2 Chemical Synthesis of 1PP-InsP5 and 1,5(PP)2-InsP4. 25 
Scheme 2.3 Chemoenzymatic synthesis of PP-InsPs utilizes Vip1 or/and IP6K1.  27 
Scheme 2.4 Chemoenzymatic synthesis and purification of 5PP-InsP5. 29 
Figure 2.1 PAGE purified 5PP-InsP5 is contaminated with buffer components. 30 
Figure 2.2 NMR spectroscopic analysis of 4/6,5(PP)2-InsP4. 31 
Scheme 2.5 Chemoenzymatic synthesis and purification of 1PP-InsP5. 33 
Scheme 2.6 Chemoenzymatic synthesis and purification of 1,5(PP)2-InsP4. 34 
Figure 3.1 Alternative techniques to monitor PP-InsPs in cell extracts avoiding 
radioactivity. 
56 
Figure 3.2 Chemoenzymatic synthesis of [13C6]myo-inositol followed by derivatization 
and purification. 
60 
Figure 3.3 Chemical synthesis of [13C6]InsP5 and [13C6]-InsP6. 62 
Figure 3.4 1H,13C-HSQC spectra of all synthesized 13C-labeled compounds. 63 
Figure 3.5  1H,13C-HMQC-Spectra to determine conversion to [13C6]5PP-InsP5. 65 
Figure 3.6 NMR-based measurements of IP6KA activity. 66 
Figure 3.7 Kinetic characterization of IP6K1. 67 
Figure 3.8 The inhibitory effect of TNP, Myricetin, and Wortmannin. 68 
Figure 3.9 ADP detection by commercially available ADP-GloTM assay. 69 
xv 
 
Figure 3.10  ATP synthase reactions of IP6K1 analyzed by NMR and ATP kinase GloTM 
assay. 
71 
Figure 3.11  Regulation of PHR by SPX protein and PP-InsPs. 73 
Figure 3.12  Biochemical characterization of VIH2KD using [13C6]InsP6 and [13C6]5PP-
InsP5. 
74 
Figure 3.13  Determination of KM for ATP and Vmax for InsP6. 76 
Figure 3.14  Metabolic labeling of mammalian cell line HCT116, followed by NMR 
analysis. 
78 
Figure 3.15 Metabolic labeling of HCT116 with [12C6]myo-inositol and HEK293T with 
[13C6]myo-inositol. 
79 
Figure 3.16  Spike in experiments to confirm the identity of InsP5, InsP6, and 5PP-InsP5 
in HCT116 extracts. 
80 
Figure 3.17  Quantification of PP-InsP pools in HCT116 wt. 81 
Table 3.1 Absolute quantification of InsP5, InsP6, and 5PP-InsP5 in different cell lines. 81 
Figure 3.18  Changes in 5PP-InsP5 levels can be observed by NMR spectroscopy. 82 
Figure 3.19  Overlay of TiO2 enrichment of NaF treated, 13C-labeled HCT116 wt cell 
extract and the original NaF treated, 13C-labeled HCT116 wt cell extract. 
83 
Figure 3.20  Preliminary analysis of unannotated NMR signals. 84 
Figure 3.21  1H,13C-HSQC spectra of extracts from metabolically labeled D. discoideum. 85 
Figure 3.22  1H,13C-HSQC NMR analysis of TiO2/gel-purified bands from wild type D. 
discoideum. 
86 
Figure 3.23  1H,13C-HSQC NMR analysis of TiO2/gel-purified bands from ppip5k-ip6k null 
D. discoideum. 
88 
Figure 4.1 Proposed mechanisms of PP-InsP signaling. 138 
Figure 4.2 Schematic representation of the phosphoproteomics workflow. 139 
Figure 4.3 New chemical biology tools to study protein pyrophosphorylation. 140 
Table 4.1 
  
Potential bottlenecks that may hamper the detection of protein 
pyrophosphorylation. 
143 
Figure 4.4 Analysis of CLK1/4 pyrophosphosite. 147 
Figure 4.5 Optimized pyrophosphoproteomics workflow. 148 
Figure 4.6 Sequence and gene ontology analysis of pyrophosphoproteins. 150 
  
xvi 
 
List of Abbreviations 
[13C6]    uniformly 13C-labeled on 6 carbon atoms (of myo-inositol) 
[13C6]1,5(PP)2-InsP4   [13C6]1,5-bisdiphosphoinositol tetrakisphosphate 
[13C6]1PP-InsP5   [13C6]1-diphosphoinositol pentakisphosphate 
[13C6]5PP-InsP5   [13C6]5-diphosphoinositol pentakisphosphate 
[13C6]InsP5    [13C6]inositol pentakisphosphate 
[13C6]InsP6    [13C6]inositol hexakisphosphate 
1H,1H-COSY   1H,1H correlation spectroscopy 
1H,13C-HMQC    1H,13C Heteronuclear Multiple-Quantum Correlation 
1H,31P-HMBC   1H,31P Heteronuclear Multiple Bond Correlation 
1,5(PP)2-InsP4    1,5-bisdiphosphoinositol tetrakisphosphate 
1PP-InsP5    1-diphosphoinositol pentakisphosphate 
4,5(PP)2-InsP4    4,5-bisdiphosphoinositol tetrakisphosphate 
5PP-InsP5    5-diphosphoinositol pentakisphosphate 
6,5(PP)2-InsP4    6,5-bisdiphosphoinositol tetrakisphosphate 
AC    adenylyl cyclase 
ADP     adenosine diphosphate 
Amp    ampicillin 
AMP    adenosine monophosphate 
Akt     protein kinase B 
AP-3    adaptor protein 3 
Asp1 diphosphoinositol pentakisphosphate kinase from S. pombe 
Arg82 myo-inositol polyphosphate multikinase from S. cerevisiae 
ATP     adenosine triphosphate 
βCN    β-cyanoethyl 
BIRD     bilinear rotation decoupling 
BIRD-HMQC    HMQC experiment with BIRD-pulse 
Bn2    dibenzyl 
BSTFA    N,O-bis(trimethylsilyl)trifluoroacetamide 
cAMP    cyclic adenosine monophosphate 
CID    collision-induced dissociation  
CK2    casein kinase 2 
CREB    cAMP response element binding protein 
CrK    creatine kinase 
CSA    camphorsulfonic acid 
CV     column volume 
DAPI     4’,6-diamidin-2-phenylindol 
DBU    1,8-Diazabicyclo(5.4.0)undec-7-ene 
DCI    4,5-dicyanoethyl imidazole 
DCM     dichloromethane 
xvii 
 
Ddp1  diphosphoinositol-polyphosphate diphosphatase from S. cerevisiae 
DIPP1 diphosphoinositol-polyphosphate diphosphatase from H. sapiens 
DIBAL-H diisobutylaluminiumhydrid 
DMEM    Dulbecco’s Modified Eagle Medium 
DMF     N,N-dimethylformamide 
DMSO    dimethylsulfoxide 
DPA    dipicolylamine 
DTT    dithiothreitol 
EDTA     ethylenediaminetetraacetic acid 
EThcD electron-transfer dissociation combined with higher energy collision 
dissociation 
Fm    fluorenylmethyl  
FPLC     fast protein liquid chromatography 
Gen    Gentamycin 
GDP    guanosine diphosphate 
GLUT4    glucose transporter type 4 
GPCR    G-protein coupled receptor 
GTP    guanosine triphosphate 
HEPES    2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
HPLC    high performance liquid chromatography 
hSAX    hydrophilic interaction strong anion exchange chromatography 
IMAC    immobilized metal affinity chromatography  
Ins    myo-inositol 
InsP3     myo-inositol 1,4,5-trisphosphate 
InsP    myo-inositol phosphate 
InsP5     myo-inositol pentakisphosphate 
InsP6     myo-inositol hexakisphosphate 
IP6K1 inositol hexakisphosphate kinase 1 from H. sapiens (Genbank: 
AC099668) 
IP6KA  inositol hexakisphosphate kinase A from E. histolytica (Genbank: 
XP_648490.2) 
Ipk1 inositol-pentakisphosphate-2-kinase from S. cerevisiae 
IPMK inositol polyphosphate multikinase from H. sapiens 
IPPK inositol-pentakisphosphate 2-kinase from H. sapiens 
Ipk1  inositol-pentakisphosphate 2-kinase S. cerevisiae 
IPS inositol-3-phosphate synthase (WP_010879290.1) 
IPTG  Isopropyl-β-D-thiogalactopyranosid 
IRS1    insulin receptor substrate 1 
LC-MS    liquid chromatography coupled to mass spectrometry 
LIC ligation independent cloning 
Kan Kanamycin 
xviii 
 
kcat     turnover number 
Kcs1 inositol hexakisphosphate kinase from S. cerevisiae and S. pombe 
Kif3A kinesin-like protein 3A 
KM    Michaelis-Menten constant 
MBP maltose binding protein 
mCPBA    meta-chloroperoxybenzoic acid 
MDD    metal dye detection 
MES    2-(N-morpholino)ethanesulfonic acid 
MOPS     3-morpholinopropane-1-sulfonic acid 
MS    mass spectrometry 
MS/MS    tandem mass spectrometry 
mTOR    mammalian target of rapamycin 
NADH     nicotinamide adenine dinucleotide (reduced form) 
NAD+    nicotinamide adenine dinucleotide 
NMR     nuclear magnetic resonance (spectroscopy) 
NTA    nitrilotriacetic acid 
OD600    optical density at 600 nm 
PAGE     polyacrylamide gel electrophoresis 
PBS    phosphate buffered saline 
pCr    creatine phosphate 
PDK1    phosphoinositide-dependent kinase 1 
PH domain   plekstrin homology domain 
Pi    phosphate 
PI3K    phosphoinositide kinase 3-kinase 
PHR    Pi starvation response  
PLC    phospholipase C 
PMB    para-methoxybenzyl 
PPIP5K    diphosphoinositol pentakisphosphate kinase from human 
PPIP5K2KD  (human) diphosphoinositol pentakisphosphate kinase 2 kinase domain 
(Genbank: NP_001263206.1) 
PtdInsP2 phosphatidyl myo-inositol-4,5-diphosphate 
PtdInsP  phosphatidyl myo-inositol phosphate 
PTM posttranslational modification 
rt     room temperature 
SAX    strong anion exchange  
SILAC    stable isotope labeling with amino acids in cell culture 
SIMAC    sequential elution immobilized metal affinity chromatography  
Siw14    protein tyrosine phosphatase 
SMIT1    sodium-myo-inositol co-transporter 
SPX domain   domain found in SYG1/Pho81/XPR1 proteins 
sumo    small ubiquitin like modifier 
xix 
 
TB    Terrific broth medium 
TFA     trifluoroacetic acid 
TLC    thin layer chromatography 
TRIS    tris(hydroxymethyl)-aminomethan 
V0    initial specific velocity 
VIH2    Vip1 homolog kinase  
VIH2KD    kinase domain of Vip1 homolog kinase  
Vip1 diphosphoinositol pentakisphosphate kinase from S. cerevisiae 
Vmax     maximum specific velocity 
wt    wild type 
Xy    xylyl 
  
xx 
 
Publications, Posters and Talks 
Publications 
[1] F. van der Pijl, R. K. Harmel, G. J. J. Richelle, P. Janssen, F. L. van Delft, and 
F. P. J. T. Rutjes, “Organocatalytic Entry into 2,6-Disubstituted Aza-
Achmatowicz Piperidinones: Application to (−)-Sedacryptine and Its Epimer,” 
Org. Lett., vol. 16, no. 7, pp. 2038–2041, Apr. 2014. 
[2] R. K. Harmel, M. M. E. Delville, and F. P. J. T. Rutjes, “Experimental procedures 
for conducting organic reactions in continuous flow,” in Flow Chemistry: Organic 
Synthesis in Motion, Band 1, DE GRUYTER, 2014, pp. 191–250. 
[3] L. G. J. Hammarström, R. K. Harmel, M. Granat, R. Ringom, Y. Gravenfors, K. 
Färnegårdh, P. H. Svensson, D. Wennman, G. Lundin, Y. Roddis, S. S. Kitambi, 
A. Bernlind, F. Lehmann, P. Ernfors, “The Oncolytic Efficacy and in Vivo 
Pharmacokinetics of [2-(4-Chlorophenyl)quinolin-4-yl](piperidine-2-yl)methanol 
(Vacquinol-1) Are Governed by Distinct Stereochemical Features,” J. Med. 
Chem., vol. 59, no. 18, pp. 8577–8592, Sep. 2016. 
[4] R. Harmel and D. Fiedler, “Features and regulation of non-enzymatic post-
translational modifications,” Nat. Chem. Biol., vol. 14, p. 244, Feb. 2018. 
[5] R. K. Harmel*, R. Puschmann*, M. Nguyen Trung, A. Saiardi, P. Schmieder, 
and D. Fiedler, “Harnessing 13 C-labeled myo -inositol to interrogate inositol 
phosphate messengers by NMR,” Chem. Sci., vol. 10, pp. 5267–5274, 2019. 
[6] M. Penkert, A. Hauser, R. Harmel, D. Fiedler, C. P. R. Hackenberger, and E. 
Krause, “Electron Transfer/Higher Energy Collisional Dissociation of Doubly 
Charged Peptide Ions: Identification of Labile Protein Phosphorylations,” J. Am. 
Soc. Mass Spectrom., vol. 30, no. 9, pp. 1578–1585, 2019. 
[7] J. Zhu, K. Lau, R. Puschmann, R. K. Harmel, Y. Zhang, V. Pries, P. Gaugler, L. 
Broger, A. K. Dutta , H. J. Jessen, G. Schaaf, A. R. Fernie, L. A. Hothorn, D. 
Fiedler, M. Hothorn, “Two bifunctional inositol pyrophosphate 
kinases/phosphatases control plant phosphate homeostasis,” Elife, vol. 8, p. 
e43582, Aug. 2019. 
xxi 
 
[8] R. Puschmann*, R. K. Harmel*, and D. Fiedler, “Scalable Chemoenzymatic 
Synthesis of Inositol Pyrophosphates,” Biochemistry, p. Article ASAP, Aug. 
2019. Highlighted in ACS Editor’s Choice. 
(* contributed equally) 
 
Posters 
[1] R. Harmel*, R. Puschmann*, M. Nguyen Trung, A. Saiardi, P. Schmieder, 
D.Fiedler. 13C-Labeled myo-inositol as a tool to interrogate inositol 
polyphosphate messengers. Poster presentation at the EMBO conference 
Chemical Biology 2018, Heidelberg, Germany 
[2] R. Harmel*, R. Puschmann*, M. Nguyen Trung, A. Saiardi, P. Schmieder, 
D.Fiedler. 13C-Labeled myo-inositol as a tool to interrogate inositol 
polyphosphate messengers. Poster presentation at 1st UCSF-Berlin Integrative 
Structural Biology Meeting (ISB Meeting) 2019, Berlin, Germany 
(* contributed equally) 
 
Talks 
[1] R. Harmel, J. A. M. Morgan, M. Penkert, E. Krause, F. Liu, D. Fiedler, Detection 
of Endogenous Protein Pyrophosphorylation Sites by a Tailored Proteomics 
Approach. 15 min talk presented on the Jungchemikerforum (JCF) 2018, Berlin, 
Germany. Awarded for best talk. 
[2] R. Harmel, Session host at 1st UCSF-Berlin Integrative Structural Biology 
Meeting (ISB Meeting) 2019, Berlin, Germany 
  
 
  
 
 
Chapter 1 Introduction: Signal Transduction by 
Inositol Pyrophosphates 
  
2 
 
Cellular Signaling of Second Messengers 
The transfer of information from the exterior to the interior of a cell is pivotal to 
all biological processes including cell proliferation, differentiation and even cell death. 
Disruption of signaling pathways and incorrect processing of cellular information are 
responsible for many diseases including cancer, diabetes and Alzheimer’s disease. A 
better understanding of the mechanisms underlying signal transduction can guide the 
development of bespoke and effective medical therapies, as well as prevention 
strategies.  
Converting extracellular information into a specific cellular response is a very 
complex process. Many signals must be recognized simultaneously, and the sum of 
this information must be combined into an appropriate feedback. Throughout the 
course of evolution, organisms have developed various signal transduction strategies 
that broadly follow three fundamental steps: signal perception, transduction relay and 
response. (Figure 1.1) At first, extracellular stimuli, usually in the form of small 
molecules or proteins (ligands), are recognized by a detector on the cell surface or 
within a cell (receptor).  
 
Figure 1.1: Fundamental steps of signal transduction: signal perception, transduction 
relay and response. Extracellular stimuli (ligands) are recognized by a receptor and 
the information is transferred through the cell by second messengers and/or proteins. 
These events lead to a cellular response, altering cellular processes. 
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The observed signal is then relayed by the receptor through intracellular signaling 
pathways via proteins and/or second messengers. The end of the transduction 
cascade results in an alteration of cellular processes which facilitates an adequate 
phenotypic change tailored to the initial extracellular stimulus. 
An integral part of signaling is the transduction of information by second 
messenger molecules. In the second half of the 20th century, Earl Sutherland (Nobel 
Prize 1971) and colleagues have postulated the idea of a “second messenger” while 
investigating the function of cyclic adenosine monophosphate (cAMP).1 Together with 
the pioneering work of Rodbell and Gilman (Nobel Prize 1994) on G-proteins, we now 
have a detailed mechanistic understanding of this process.2 (Figure 1.2)  
 
Figure 1.2: Cellular signaling of second messengers cAMP and InsP3. (left) Proteome 
alteration via cAMP signaling. A first messenger is recognized by the GPCR and 
stimulates AC through the translocation of the Gα-protein. Activated PKA can 
phosphorylate CREB to alter gene expression. (right) Modulation of protein activity via 
InsP3 signaling. A first messenger is recognized by the GPCR and PLC is activated in 
an analogous fashion as AC. PtdInsP2 is cleaved to form InsP3 which can interaction 
with the InsP3-gated calcium channel. The release of Ca2+ from the endoplasmic 
reticulum leads to a modulation of protein activity inside the cell. 
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In their studies, they showed that neurotransmitters including dopamine and 
epinephrine bound to G protein-coupled receptors (GPCRs) on the cell surface and 
activated the production of cAMP from adenosine monophosphate (AMP) by adenyl 
cyclase (AC).3–8 (Figure 1.2 left)The messenger cAMP then activated protein kinase 
A (PKA) which phosphorylated transcription factors, such as the cAMP response 
element (CREB) to alter gene expression. Today, it is well established that cAMP 
intersects with a plethora of biological functions such as the regulation of transcription 
factors, is associated with diseases such as cancer, and plays a wide role in 
metabolism.9 
The example of cAMP shows how second messengers can directly create a 
response by changing the gene expression of a given cell. However, signal 
transduction chains also include downstream events where the function of already 
existing proteins is modulated. A molecule involved in such a mechanism is inositol 
1,4,5-triphosphate (InsP3) which participates in the regulation of cell proliferation and 
muscle contraction.10 (Figure 1.2 right) Upon ligand binding to the GPCR, 
phospholipase C (PLC) activity is upregulated and cleaves phosphatidyl myo-inositol-
4,5-bisphosphate (PtdInsP2) to liberate InsP3 into the cytosol. Binding of InsP3 to an 
InsP3-gated calcium channel releases Ca2+ from the endoplasmic reticulum into the 
cytosol which subsequently modulates the activity of several proteins.  
In the last five decades, scientists have come to a general understanding of 
second messenger systems and their underlying mechanisms. Particularly, the 
examples of cAMP and InsP3 illustrated the enormous impact that these molecules can 
have on cells. However, over the years, new signaling molecules were found where 
the underlying mechanisms are not well established, yet. Therefore, continuous work 
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in this field will provide future opportunities to find new targets and strategies for 
therapeutic intervention. 
 
Inositol Polyphosphates and Pyrophosphates 
The inositol phosphates are one of the most important and versatile classes of 
second messengers and are based on the myo-inositol scaffold. They consist of two 
major subclasses, characterized by the lipid-anchored phosphatidyl myo-inositol 
phosphates (PtdInsPs) and the diffusible myo-inositol phosphates (InsPs). 
Biochemically, these messengers are synthesized directly from myo-inositol that can 
either be taken up by cells through the sodium-myo-inositol co-transporter (SMIT1) or 
synthesized de novo from glucose.11,12 (Figure 1.3) myo-Inositol is then incorporated 
into the cell membrane as PtdInsPs through a series of enzymatic transformations. 
PtdInsPs consist of several structurally related molecules (not shown) that fulfill 
functions such as synaptic vesicle trafficking and recruitment of proteins to the cell 
membrane, and represent an interesting group of signaling molecules in their own 
right.13,14 Cleavage of PtdInsP2 by PLC leads to the formation of InsP3 which can be 
further elaborated by myo-inositol polyphosphate multikinase (Homo sapiens: IPMK; 
Saccharomyces cerevisiae: Arg82) and inositol-pentakisphosphate-2-kinase (H. 
sapiens: IPPK; S. cerevisiae: Ipk1) to the most abundant InsPs: InsP5 and InsP6 (10–
100 µM in mammalian cells).15 These molecules are densely negatively charged, which 
provides them with distinct properties that enable specific functions. For example, 
InsP6 can strongly chelate di- and trivalent cations but can also bind positively charged 
amino acid side chains.16 In the latter case, it can act as scaffolding molecule that is 
proposed to be involved in the assembly of the Gag hexamer and therefore the 
regulation of capsid stability in HIV.17,18 
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Figure 1.3: Simplified biochemical pathway of myo-inositol-based molecules starting 
from myo-inositol and glucose.  
 
For some time, InsP6 had been considered the highest phosphorylated InsP 
species but in the 1990’s even higher phosphorylated substances were observed using 
ion exchange chromatography.19,20 These experiments revealed a unique subclass of 
the InsPs which are now referred to as the inositol pyrophosphates (PP-InsPs). These 
molecules bear up to 8 phosphate groups that are obtained by installing one or two 
phosphoanhydride bonds around the myo-inositol ring. In mammals and yeast, two 
distinct classes of kinases were identified that synthesize PP-InsPs: the inositol 
hexakisphosphate kinases (H. sapiens: IP6K1/2/3; S. cerevisiae: Kcs1) and the 
diphosphoinositol-pentakisphosphate kinases (H. sapiens: PPIP5K1/2; S. cerevisiae: 
Vip1). IP6Ks phosphorylate InsP5 and InsP6 at the 5-position to form 5PP-InsP4 and 
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5PP-InsP5, respectively.21,22 PPIP5Ks modify InsP6 at the 1-position to deliver 1PP-
InsP5.23,24 Finally, the combined actions of these two kinases produces 1,5(PP)2-InsP4 
which possesses eight phosphoryl groups including two pyrophosphate moieties. 
Theoretically, 1,5(PP)2-InsP4 could be synthesized from either 1PP-InsP5 or 5PP-InsP5 
but it is believed that the main biosynthetic pathway proceeds via a 5PP-InsP5 
intermediate as it is the most abundant PP-InsP (1–3 µM) and a much better substrate 
for PPIP5Ks than InsP6.15,23–26 Compared to the kinases, the PP-InsP phosphatases 
are less well understood. One of the best characterized representatives is 
diphosphoinositol-polyphosphate diphosphatase (H. sapiens: DIPP1–5; S. cerevisiae: 
Ddp1), a member of the nudix hydrolyses, which can dephosphorylate both the 1- as 
well as the 5-position.27–32 Quite recently, protein tyrosine phosphatase (S. cerevisiae: 
Siw14) was shown to dephosphorylate PP-InsPs at the 5-position specifically.33,34  
The initial identification and characterization of PP-InsPs immediately raised 
speculation about their function as signaling molecules, as the cell must invest 
substantial energy in the production of these metabolites. This hypothesis was based 
on the observation that the biosynthesis of PP-InsPs requires at least seven or eight 
equivalents of ATP and that a rapid metabolic turnover of PP-InsP pools had been 
observed.19,20 PP-InsPs were found in yeast (S. cerevisiae, Schizosaccharomyces 
pombe), in the social amoeba Dictyostelium discoideum and in higher organisms like 
Drosophila melanogaster, Mus musculus and H. sapiens and even in plants suggesting 
a conserved and vital role in eukaryotic signaling.35–38 The last two decades have 
amplified the interest in these messengers due to a plethora of strong phenotypic 
associations that were identified, specifically through genetic intervention of the PP-
InsPs biosynthetic pathway. (Table 1.1) For example, knockouts of the murine IP6K 
isoforms led to defects in insulin signaling, impaired spermatogenesis, and caused 
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resistance to fat-induced obesity.39–41 In mammalian cell lines, genetic perturbation of 
IP6Ks reduced migration and invasion of cells, and apoptosis was promoted.42–52 In 
yeast, the overexpression of Kcs1 perturbed the length of telomeres and changed cell 
cycle progression.53–55 The activity of PPIP5Ks has also been associated with distinct 
phenotypes. A PPIP5K missense mutation in humans was identified as a locus of 
hearing loss which could be recapitulated in PPIP5K2-/- deficient mice.56 In yeast, 
changes of Asp1 (the PPIP5K of S. pombe) or Vip1 (the PPIP5K of S. cerevisiae) were 
identified to regulate the dimorphic switch.57,58  
 
Table 1.1: Examples of identified phenotypes associated with IP6Ks and PPIP5Ks. 
Enzyme Organism Effect Reference 
IP6K1 mouse insulin signaling and sensitivity 35,40,59,60 
 mouse impaired spermatogenesis 40,41,61 
 mouse, human reduced cell migration and invasion 42,43 
IP6K2 mouse, human promoting apoptosis 44–52 
 mouse cancer metastasis and cell migration 43,62 
IP6K3 mouse life span 63 
 human susceptibility to Alzheimer’s disease 64 
Kcs1 yeast regulation of rRNA transcription 65 
 yeast cell cycle progression 55 
 yeast phosphate homeostasis 66 
 yeast telomere maintenance 53,54 
PPIP5K1 human bioenergetics homeostasis 67 
 human downregulation of apoptosis 68 
 human cell migration 69 
PPIP5K2 mouse, human hearing loss 56 
Vip1 yeast regulation of dimorphic shift 57,58 
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Together, these discoveries have painted myo-Inositol-based messengers as 
an interesting class of signaling molecules that are involved in many cellular processes. 
In particular, the unique PP-InsP subclass is associated with many intriguing 
phenotypes, which emerge upon genetic perturbation of the biochemical pathway, and 
remain an exciting area of investigation today. 
 
Towards a Better Understanding of Inositol Pyrophosphate Signaling 
The development of genetic model systems and the identification of PP-InsP-specific 
phenotypes was greatly aided by analytical tools that could elucidate the metabolism 
of these messengers and monitor levels of PP-InsP. Due to the absence of a UV-
absorbing group in these molecules, the main methods used to visualize PP-InsPs 
strongly relied on radioactive labeling with 3H and 32P.19,20 In vitro, radioactively-labeled 
PP-InsP became the tool of choice for the identification of IP6Ks and PPIP5Ks in 
metazoan and yeast cells. Here, the purification of the enzyme could be followed by 
assaying the conversion of 3H or 32P-labeled InsP6 or PP-InsPs to the corresponding 
PP-InsP product on polyethyleneimine-cellulose TLC plates. This method established 
a thorough understanding of PP-InsPs metabolism. In vivo, one of the major tools to 
analyze PP-InsPs pools was radioactive labeling of cells (yeast, D. doscoideum, 
human) with [3H]myo-inositol or [32P]orthophosphate. Upon incoporation of these 
radioactive labels, PP-InsPs were extracted using perchloric acid and separated by 
strong anion exchange (SAX) high performance liquid chromatography (HPLC) 
followed by their detection through scintilation counting of the collected fractions. 
(Figure 1.4). This method facilitated the discovery of these messengers and identified 
cellular conditions that modulate the PP-InsPs levels in vivo. For example, studies in 
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yeast cells indicated that PP-InsP levels are dependent on cell cycle progression and 
on phosphate availabililty.55,70 
 
Figure 1.4: Metabolic labeling of eukaryotic cells with radioactive isotope tracers.  
 
Genetic perturbation of PP-InsP metabolism and the analytical detection of 
these molecules by radioactivity had led to a good understanding of the processes PP-
InsPs are involved in, but how these molecules induce their multifaceted phenotypes 
remained unclear in most cases. What were their underlying signaling mechanisms? 
A more elaborate understanding of this fundamental question required new biochemial 
methods that would offer a more detailed analysis of PP-InsPs signal transduction. The 
development of such techniques had been supported by the preparation of PP-InsPs 
as standards, reagents and even chemical probes. Traditionally, radioactively labeled 
PP-InsPs had been synthesized with the help of enzymes using short synthetic routes 
on a small scale.71,72 In order to produce highly pure material on a larger scale, 
chemists designed multistep syntheses that are challenging but delivered low milligram 
quantities.73,74 Regardless of their synthetic origin, PP-InsPs standards and reagents 
were provided to a wider scientific community by both methods. Unfortunately, the 
distribution of these small molecule messengers in sufficient amounts, especially in the 
case of the unsymmetrical PP-InsPs, is far from optimal and remains a major bottle 
neck in this field. 
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In the meantime, scientists that had access to these molecules started to 
investigate their underlying signaling mechanisms. Based on the chemical structure of 
these compounds it was obvious to draw a connection to the lower phosphorylated 
InsPs. Both classes have a high charge density, can chelate divalent metals and the 
pKa of the phosphoryl groups is perturbed.16,75 InsPs like InsP3, InsP4 and InsP6 are 
known to interact with proteins and modulate their activity through binding of positively 
charged domains.76–78 Consequently, this mechanism of action had also been 
proposed for PP-InsPs. So far, only a few cases were identified where PP-InsPs 
specifically modulated biological processes as compared to other InsPs. A prominent 
example is the regulation of protein kinase B (Akt) by 5PP-InsP5. (Figure 1.5)  
 
Figure 1.5: Insulin/Akt signaling pathway is regulated via inositol pyrophosphates. Akt 
is recruited to the membrane upon insulin signaling by PtdInsP3 and activates GLUT4 
an mTOR which leads to glucose uptake and protein translation. Simultaneously, the 
insulin receptor stimulates the production of 5PP-InsP5 which competes with PtdInsP3 
for the PH domain of Akt and inhibits its translocation to the membrane. (Figure 
adapted from ‘Insulin Signaling: Inositol Phosphates Get Into the Akt’.79). 
 
After the observation of insulin hypersensitivity in IP6K1-/- mice, the underlying 
mechanism was investigated.59 Canonically, upon binding of insulin to its receptor, 
insulin receptor substrate 1 (IRS1) activates phosphoinositide 3-kinase (PI3K). 
PtdInsP2 is phosphorylated at the 3-position by PI3K to form PtdInsP2 which recruits 
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Akt and phosphoinositide-dependent kinase-1 (PDK1) to the cell membrane by binding 
to their plekstrin homology (PH) domain. Here, Akt is activated by phosphorylation 
through PDK1 and stimulates downstream protein translation via mammalian target of 
rapamycin (mTOR) signaling and supports glucose uptake via glucose transporter type 
4 (GLUT4). 5PP-InsP5 is a physiological regulator of this process and its biosynthesis 
is elevated through insulin. It acts by binding to the PH domain of Akt and prevents its 
translocation to the membrane. In IP6K1-/- mice, Akt activity cannot be perturbed by 
5PP-InsP5 leading to insulin hypersensitivity. Conversely, increased stimulation of 
5PP-InsP5 synthesis might lead to reduced activity of Akt and therefore insulin 
resistance. A similar effect was obtained upon delivery and subsequent photorelease 
of exogenous 5PP-InsP5 into cells.80 Beside the PH domain, PP-InsP are known to 
bind to C2B domains and SPX domains suggesting a role in exocytosis and phosphate 
homeostasis.77,81,82 
In an effort to identify more binding interactions between PP-InsPs and proteins, 
an unbiased proteomics pull-down approach using a non-hydrolyzable analog of 5PP-
InsP5 identified more than 100 proteins in yeast that are selectively enriched over 
immobilized phosphate.83 Interestingly, most of these proteins had an affinity for InsP6 
and only in a few cases, selectivity for 5PP-InsP5 was observed. In this study, two 
distinct sets of proteins were found to bind 5PP-InsP5 either in the absence or presence 
of Mg2+ ions with only little overlap in between. This observation indicated the presence 
of two different sets of interacting partners – and potentially signaling mechanisms – 
where one of these was essentially dependent on divalent metal cations. 
Indeed, besides binding to proteins in a manner comparable to the lower InsPs, 
a second mechanism of action was proposed for PP-InsPs that utilizes their unique 
phosphoanhydride bond. Interestingly, it was found that cell invest a lot of energy into 
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the regeneration of this moiety, resulting in up to 50% turnover of InsP6 into PP-InsPs 
every hour.19,84 Moreover, the energy of hydrolysis of the pyrophosphate bond in 5PP-
InsP5 and 5,6(PP)2-InsP4 was predicted to be in between the values of ATP (–30.5 
kJ/mol) and ADP (–26.7 kJ/mol) or even higher.85 These observations led to the 
hypothesis that PP-InsPs might be able to transfer their β-phosphoryl group onto a 
given substrate. 
This proposed mechanism had been investigated by Snyder and coworkers in 
the mid 2000’s. Using 5PP-InsP5-β32P, they detected in vitro phosphorylation of 
proteins in cell lysate samples from yeast, fruit flies, and mice but not in bacterial 
extracts.86 (Figure 1.6) In this report, it was shown that the phosphoryl transfer is likely 
to occur via an enzyme-independent mechanism, requiring only Mg2+ or Ca2+ as a co-
factor. In a follow-up article, the phosphorylation of proteins by PP-InsPs was found to 
be resistant to some phosphatases, like λ-phosphatase, and was localized at 
polyacidic stretches that bear a consensus motive for casein kinase 2 (CK2).87  
 
Figure 1.6: In vitro pyrophosphorylation of proteins from cell lysates using 5PP-InsP5-
β32P. Proteins that are substrates of CK2 become pyrophosphorylated while non-CK2 
site and unphosphorylated proteins remain unmodified.  
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Finally, more detailed analysis of the modified sites showed that the phosphoryl 
transfer was only possible on CK2-phosphorylated serine residues. Together with the 
previous findings, this new posttranslational modification (PTM) became known as 
protein pyrophosphorylation. Besides mechanistic aspects, the work from the Snyder 
laboratory also identified several in vitro pyrophosphorylated proteins from yeast 
(NSR1, SRP40, YGR130c, APL6) and mammals (Nopp140, AP3β3A, and TCOF1). 
These proteins are associated with essential cellular processes such as ribosome 
biogenesis, nucleocytoplasmic transport and regulation of translation. 
Since the discovery of protein pyrophosphorylation, there had been various 
efforts to show the significance of this modification in vivo. This was achieved in an 
indirect fashion by comparing the in vitro pyrophosphorylation of proteins from lysates 
with different genetics backgrounds: wild type and IP6K-/-. (Figure 1.7)  
 
Figure 1.7: Detection of potential endogenous pyrophosphorylation sites by the ‘back-
pyrophosphorylation assay’. In wild type cells, 5PP-InsP5 pyrophosphorylates proteins 
thereby reducing pyrophosphorylation by 5PP-InsP5-β32P. In IP6K-/- cells, 5PP-InsP5 
is not present which maximizes the signal intensity induced by the pyrophosphorylation 
with 5PP-InsP5-β32P. Radioactive proteins are usually analyzed by PAGE.  
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The so-called ‘back-pyrophosphorylation assay’ was based on the assumption that 
IP6K-/- cell lines were unable to produce 5PP-InsP5 which should significantly lower the 
pyrophosphorylation of proteins, allowing more in vitro phosphoryl group transfer to 
subsequently occur. Consequently, in vitro pyrophosphorylation by 5PP-InsP5-β32P 
should create a higher radioactive signal compared to the wild type sample. Using this 
method, it was demonstrated that protein pyrophosphorylation can modulate protein-
protein interactions. Specifically, pyrophosphorylation prevented the interaction of the 
adaptor protein 3 (AP-3) complex with kinesin-like protein 3A (Kif3A), thus modulating 
its ability to regulate the HIV-1 gag release.88 On the other hand, pyrophosphorylation 
of dynein enhanced its interaction with dynactin, thereby regulating cytoplasmic 
dynein-driven transport.89 Interestingly, protein pyrophosphorylation was also identified 
as a regulator of RNA transcription.65 These results were not obtained by the back-
pyrophosphorylation assay but by investigating a phenotype in kcs1 Δ cell lines. 
Transcription by RNA polymerase 1 was compromised in these cells and three 
subunits of this enzyme were identified as substrates for in vitro pyrophosphorylation. 
Taken together, all of these finding slowly solidified pyrophosphoserine residues as 
signaling entities but up until now endogenous protein pyrophosphorylation has never 
been detected directly. Therefore, some scientists in the field raised reasonable 
concerns over the current methods, and the overall impact of this modification in vivo 
remains controversial.90,91 
The field of PP-InsP research has come from correlating PP-InsP levels with 
different genetic backgrounds to a more mechanistic understanding of how PP-InsP 
fulfil their multifaceted functions. This transition was possible through the development 
of more elaborate biochemical techniques that disentangle different signaling aspects 
of PP-InsPs such as protein binding or protein pyrophosphorylation. A deeper 
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understanding of these processes will enable future scientists to identify new 
checkpoints in signal transduction pathways and potentially lead to the discovery of 
new targets for pharmacological intervention. 
 
Conclusions  
Second messenger-based signaling is a very important process that plays a 
central role in many cellular functions as well as in severe diseases. Among these 
messengers, the PP-InsPs family is associated with many intriuging phenotypes 
suggesting a significant impact within signaling cascades. In the last 25 years, 
scientists have pursued a deeper understanding of the underlying mechanisms of 
these small molecules and have proposed binding interactions with proteins and 
protein pyrophosphorylation as the two major mechanisms of action. So far, many 
aspects of the binding-related modulation of proteins by PP-InsPs remain unclear and 
many proteins that were identified as potential binders have not been fully 
characterized yet. In the case of protein pyrophosphorylation, we are even further away 
from a thorough understanding. Neither the existence nor the biological significance of 
this PTM in vivo has been proven so far and the mechanisms that regulates temporal 
and spacial distribution or dynamics are unknown. To enable a broader scientific 
community to engage with PP-InsP research and to accelerate this field, widely 
available and sophisticated methods are necessary to study new aspects of PP-InsPs 
signaling in vitro and especially in vivo. This should be accompanied by the 
replacement of the traditional methods that are based on radioactivity. Even though 
radiolabeling is one of the most sensitive techniques, in vivo applications are limited 
and combinations with modern high resolution techniques like nuclear magnetic 
resonance (NMR) spectroscopy, mass spectrometry (MS) or cryo electron microscopy 
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are not possible. Finally, the development of novel methods and their usage will be 
highly dependent on the availability of the PP-InsPs molecules, so novel procedures 
to produce large amounts of these messengers are desperately needed. 
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Introduction: Design of a Scalable Synthesis of PP-InsPs 
 The synthesis of PP-InsPs has been pursued using two main approaches: 
classical organic chemical synthesis and chemoenzymatic synthesis. The chemical 
syntheses employed orthogonally protected myo-inositol to introduce the 
pyrophosphate groups at the desired positions. In case of 5PP-InsP5, myo-inositol was 
converted into an orthobenzoate ester followed by PMB protection. (Scheme 2.1) The 
resulting compound 1 was selectively deprotected by DIBAL-H at the 5-position to yield 
acetal 2. The 5-position was phosphorylated with β-cyanoethyl (βCN) phosphoamidite 
followed by global acid deprotection. Pentaol 3 was then phosphorylated on positions 
1–4 and 6 using xylyl (Xy) phosphoamidite to give 4, followed by βCN deprotection and 
pyrophosphorylation at the 5-position with dibenzyl (Bn2) phosphoamidite. Global 
hydrogenation of compound 5 afforded 7 mg of 5PP-InsP5 in 30% yield over 7 steps 
starting from myo-inositol.1–5 
 
Scheme 2.1: Chemical Synthesis of 5PP-InsP5 with 30% overall yield. a) PhC(OMe)3, 
CSA, DMSO b) NaH, PMB-Cl, DMF c) DIBAL-H, DCM d) βCE phosphoamidite, DCI, 
MeCN, then tBuOOH e) 5 % TFA, DCM f) Xy phosphoamidite, DCI, MeCN/DMF, then 
mCPBA g) DBU, BSTFA, MeCN, then MeOH, TFA, then Bn2- phosphoamidite, 
tetrazole, MeCN then mCPBA h) NaHCO3, Pd(black)/H2, H2O/tBuOH. 
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Compared to 5PP-InsP5, the synthesis of the asymmetric 1PP-InsP5 and 
1,5(PP)2-InsP4 molecules was more challenging and lower yielding.2,3 (Scheme 2.2) 
For 1PP-InsP5, 2 was protected with PMB at the 5-position and the acetal was removed 
by acid hydrolysis to give 6a. Phosphorylation at the 1- and the 3-positions with a chiral 
phosphoamidite led to a mixture of diastereoisomers which could be separated using 
silica chromatography. The PMB groups of the obtained 7a were deprotected with acid 
and global phosphorylation of 8a yielded the pentaphosphate ester 9a. Selective 
deprotection and pyrophosphorylation of the 1-position yielded 10a as the DBU salt 
which could be globally deprotected to afford 6 mg of 1PP-InsP5 in 4.8% yield over 9 
steps from myo-inositol. The chemical synthesis of 1,5(PP)2-InsP4 was performed in 
an analogous fashion. 
 
Scheme 2.2: Chemical Synthesis of 1PP-InsP5 and 1,5(PP)2-InsP4. a) 6a: NaH, PMB-
Cl, DMF; 6b: Fm phosphoamidite, phenyl tetrazole, MeCN, then tBuOOH b) pTsOH, 
H2O/MeOH or DCM/MeOH c) Rα phosphoamidite, tetrazole, MeCN, then mCPBA d) 
2.5–5% TFA in CHCl3 e) Xy phosphoamidite, DCI, MeCN, then mCPBA f) DBU, 
BSTFA, MeCN, then TFA, MeOH g) then Bn2 phosphoamidite, tetrazole, MeCN, then 
mCPBA h) NaHCO3, Pd(black)/H2, H2O/tBuOH. 
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Here, a third orthogonal phosphoryl protecting group was introduced at the 5-position 
that facilitated the introduction of the pyrophosphate in compound 10b. Global 
deprotection afforded 11 mg of 1,5(PP)2-InsP4 in 4.4% yield over 9 steps from myo-
inositol. Overall, organic syntheses of the PP-InsPs have been improved in recent 
years, but they still require multi-step procedures and remain viable only in the hands 
of skilled organic chemists in the context of an appropriately equipped laboratory. 
Organic chemistry, however, remains the only scalable solution to obtain milligram 
quantities of PP-InsPs in high purity. 
An alternative route to generate PP-InsPs is their synthesis from InsP6 using 
two distinct classes of small molecule kinases: IP6Ks and PPIP5Ks.6,7 (Scheme 2.3) 
IP6K1 has been applied in the synthesis of 5PP-InsP5 and the kinase domain (KD) of 
PPIP5Ks either from S. cerevisiae or H. sapiens can be utilized for the synthesis of 
1PP-InsP5. The combined action of IP6K1 and PPIP5KKD can provide access to 
1,5(PP)2-InsP4. This approach has been in particular useful for the synthesis of 
radioactively labeled compounds where long syntheses are not suitable.6 While the 
number of synthetic steps is strongly reduced compared to chemical synthesis, the 
challenge of this chemoenzymatic approach lies in separation of the PP-InsPs from 
other reaction components such as salts, buffer, proteins or other small molecules. 
HPLC and preparative polyacrylamide gel electrophoresis (PAGE) have been valuable 
tools to purify PP-InsP (discussed in detail in Chapter 3). Unfortunately, these 
techniques lack scalability and have thus far disqualified chemoenzymatic approaches 
as major sources for PP-InsPs. 
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Scheme 2.3: Chemoenzymatic synthesis of PP-InsPs utilizes Vip1 or/and IP6K1.  
 
In Chapter 2, a new strategy that merges the high efficiency of the enzymatic 
synthesis with the scalability of a classical synthetic approach is reported. High yielding 
procedures for the chemoenzymatic synthesis of 5PP-InsP5, 1PP-InsP5 and 1,5(PP)2-
InsP4 on a 100–350 mg scale were developed, using the recently identified inositol 
hexakisphosphate kinase A (IP6KA) from Entamoeba histolytica and the kinase 
domain of human PPIP5K2 (PPIP5K2KD). Coupled to a purification method that relies 
on precipitation of the PP-InsP-Mg complexes and strong anion exchange 
chromatography on a SAX fast protein liquid chromatography (FPLC) system, the PP-
InsPs could be obtained in high purity. In the long term, easily accessible PP-InsP 
syntheses will enable researchers in fields removed from synthetic chemistry to 
investigate these molecules in a variety of biological contexts, enhancing our molecular 
understanding of PP-InsP signaling in healthy and diseased states. 
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Chemoenzymatic Synthesis of 5PP-InsP5 
 To synthesize 5PP-InsP5 chemoenzymatically, we recombinantly expressed 
IP6KA, an InsP6 kinase from the parasitic amoeba E. histolytica.8,9 The advantage of 
this enzyme, compared to the commonly used human IP6K1, is the fast enzyme 
reaction kinetics, good stability, and high expression yield (ca. 100 mg of protein per 
1L of E. coli culture). Initially, we obtained an MBP-tagged IP6KA construct from 
Shears and co-workers that was only catalytically active upon TEV-mediated removal 
of the MBP-tag. The MBP-tag was replaced by a His-tag which allowed expression of 
a catalytically active IP6KA, circumventing the TEV cleavage. The substrate for IP6KA, 
InsP6, was prepared from myo-inositol using a straightforward two step literature 
procedure.10 
With substrate and enzyme in hand, reaction conditions were optimized (pH, 
time, enzyme- and Mg2+-concentration) by monitoring PP-InsP kinase activity using 
NMR spectroscopy and uniform 13C-labeled ([13C6]) InsP6. This new spectroscopic 
approach was developed in parallel with the synthetic effort reported here, and is 
explained in detail in Chapter 3.11 Full conversion of InsP6 to the 5PP-InsP5 product 
was achieved within 30 min, applying 0.3 µM of IP6KA at pH 6.4 in combination with 
an ATP recycling system (Scheme 2.4 a). The recycling of the ATP was necessary 
because accumulation of ADP favors the reverse reaction, resulting in an overall 
conversion to 5PP-InsP5 of only 30%. Determining the optimal ratio of phosphate-
containing species, Mg2+ ions, and pH was an integral consideration in preventing the 
precipitation of InsP6 during the reaction. Therefore, the Mg2+ ion concentration was 
kept slightly below or equal to the combined concentration of phosphocreatine and 
ATP.  
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Scheme 2.4: Chemoenzymatic synthesis and purification of 5PP-InsP5. a) Optimized 
conditions for the conversion of InsP6 by IP6KA. Conditions: 250 µM InsP6, 2 mM ATP, 
7 mM MgCl2, 5 mM creatine phosphate (pCr) and 1 U/mL creatine kinase (CrK), 0.3 
µM IP6KA, 50 mM NaCl, 20 mM MES pH 6.4. b) Separation of the 5PP-InsP5 from the 
reaction components. Enzymes were removed by a C18 plug and the product 
precipitation as a PP-InsP-Mg complex by addition of excess MgCl2. that forms an 
insoluble PP-InsP-Mg complex. Mg2+ions were subsequently exchanged by solid 
phase chelation in ammonium carbonate buffer and lyophilization afforded the product 
as the ammonium salt. 
 
Employing the optimized conditions, the reaction was scaled up to 350 mg of 
InsP6 starting material (based on the free acid) and a total reaction volume of 2 L. To 
accurately control the reaction time, it was crucial to preincubate the reaction mixture 
at 37 °C before the addition of IP6KA, and to quench the solution by cooling to 4 °C 
within 3–5 min using a –78 °C dry ice bath. For large scale purification, the proteins 
were removed by passing the solution through a fritted filter carrying a short plug of 
C18 reversed phase silica gel (Scheme 2.4 b). To separate 5PP-InsP5 from other 
components in the mixture, we took advantage of the magnesium-chelating properties 
of InsPs and PP-InsPs.12,13 At basic pH these highly negatively charged molecules 
form strong Mg-complexes and precipitate almost quantitatively. Therefore, an excess 
of MgCl2 was added to the reaction mixture and the pH was raised to 8.8–9.0. The 
resulting precipitate could easily be isolated by centrifugation and separated from 
soluble impurities. To redissolve the 5PP-InsP5-Mg complex, and to remove the Mg2+ 
ions, we applied an immobilized chelator (Amberlite® IRC 748) in NH4HCO3 buffer (pH 
7.5). Initial attempts using water instead of buffer led to substantial hydrolysis of the 
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phosphoanhydride bond during this step, due to exposure of the product to elevated 
pH (up to 12). The instability of 5PP-InsPs in unbuffered solutions was a particular 
problem during upscaling because the incubation times with the chelator resin became 
longer compared to the smaller scale reactions. Finally, 5PP-InsP5 was isolated by 
lyophilization as the ammonium salt in 80% yield (312 mg, >95% purity determined by 
NMR). 
While 5PP-InsP5 had been synthesized enzymatically before by Saiardi and co-
workers, the scale of those reactions was substantially smaller. 7 The purification of 
the product was accomplished by preparative PAGE, followed by gel extraction (100–
200 µg 5PP-InsP5 per gel). We have reproduced this purification step on 5PP-InsP5 
mixed together with all reaction components except IP6KA. The gel band was cut, 
extracted and analyzed by NMR spectroscopy. (Figure 2.1)  
 
Figure 2.1: PAGE purified 5PP-InsP5 is contaminated with buffer components. Pure 
chemoenzymatically prepared 5PP-InsP5 was mixed with all kinase reaction 
components except IP6KA and purified by PAGE followed by gel extraction. 
a) 1H NMR spectrum shows several highly abundant species that are a 10–100 fold 
higher in intensity which precludes the observation of the inositol protons. 
b) 31P NMR spectrum shows 5PP-InsP5 and no other PP-InsP species. 
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While the 31P NMR showed only the expected 5PP-InsP5 peaks, several 
impurities were observed in the 1H NMR that are 10–100 fold higher in intensity and 
precluded the observation of the myo-inositol signals. These results indicate that our 
precipitation-based purification is superior to the isolation by preparative PAGE with 
respect to scalability and purity of the final product. 
During the optimization of the 5PP-InsP5 synthesis, we were surprised to 
observe the formation of one major side product during extended reaction times. It was 
speculated that this species could be another PP-InsP5 regioisomer or even an (PP)2-
InsP4 species. The unknown compound was isolated by SAX-FPLC using NH4HCO3 
(pH 7.5) as elution buffer. After lyophilization, analysis by one- and two-dimensional 
NMR spectroscopy revealed the unknown product as 4,5(PP)2-InsP4 or 6,5(PP)2-InsP4 
(the enantiomers are not distinguishable by NMR). (Figure 2.2)  
 
Figure 2.2: NMR spectroscopic analysis of 4/6,5(PP)2-InsP4. a) 1H NMR spectrum with 
the positions on the myo-inositol ring depicted as C1–6 as determined by 1H,1H-COSY 
NMR analysis. Green boxes show the positions that correlate with the pyrophosphate 
region of the 31P NMR spectrum. b) 31P NMR spectrum shows 4 monophosphates 
around 0 ppm and 2 pyrophosphates between –10 and –12 ppm. 
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Interestingly, previous reports that utilized IP6KA or IP6K1 in enzymatic reactions did 
not mention the formation of this product, and whether this compound has a 
physiological relevance has not been determined yet. However, 6,5(PP)2-InsP4 is the 
dominant (PP)2-InsP4 regioisomer in the slime mold D. discoideum.14–16 Synthetic 
access to this compound could therefore be of use to study PP-InsP signaling in this 
organism. 
In summary, our chemoenzymatic synthesis of 5PP-InsP5 outperforms classical 
organic chemistry approaches in yield and accessibility. The precipitation of the 5PP-
InsP5-Mg complex offers a scalable purification procedure that can deliver hundreds of 
milligrams large amounts of high purity 5PP-InsP5. 
 
Chemoenzymatic Synthesis of 1PP-InsP5 and 1,5(PP)2-InsP4 
The successful, large-scale chemoenzymatic synthesis of 5PP-InsP5 
encouraged us to apply our strategy to the synthetically more challenging asymmetric 
PP-InsPs: 1PP-InsP5 and 1,5(PP)2-InsP4. Pyrophosphorylation at the 1-position of 
InsP6 and 5PP-InsP5 is known to be catalyzed by PPIP5Ks. We thus expressed the 
His-tagged kinase domain of human PPIP5K2 (PPIP5K2KD), but low solubility resulted 
in low overall protein yields. To increase the solubility, the His-tag of PPIP5K2KD was 
replaced with a solubility-enhancing SUMO-tag, leading to the isolation of the desired 
protein in sufficient yield (25 mg of protein per 1L of E. coli culture). Next, the 
biochemical reaction for the formation of 1PP-InsP5 was optimized with labeled 
[13C6]InsP6 as substrate. Extended reaction time of 18 hours and an increased enzyme 
concentration of 2 µM were necessary to guarantee full conversion. (Scheme 2.5 a) 
33 
 
 
Scheme 2.5: Chemoenzymatic synthesis and purification of 1PP-InsP5. a) Optimized 
conditions for the synthesis of 1PP-InsP5: 250 µM InsP6, 2 mM ATP, 6 mM MgCl2, 5 
mM creatine phosphate (pCr) and 1 U/mL creatine kinase (CrK), 2 µM PPIP5K2KD, 250 
mM NaCl, 20 mM MES pH 6.4. b) Separation of the 1PP-InsP5 from the reaction 
components was performed analogous to 5PP-InsP5 followed by SAX FPLC to remove 
remaining side products.  
 
Following precipitation and Mg2+-chelation, 1PP-InsP5 still contained impurities, 
probably due to the formation of side products under the prolonged reaction times. To 
remove these compounds, 1PP-InsP5 was subjected to SAX-FPLC (Scheme 2.5 b), 
allowing for the isolation of ca. 100 mg of 1PP-InsP5 in two purification runs. After 
lyophilization, 1PP-InsP5 was isolated as the ammonium salt in 68% yield (77 mg, 
>95% purity determined by NMR).  
With robust procedures for enzymatic pyrophosphorylation at the 5- and the 1-
position of the inositol ring in hand, we lastly sought to synthesize the most densely 
phosphorylated PP-InsP: 1,5(PP)2-InsP4. Full conversion from InsP6 to 1,5(PP)2-InsP4 
using both enzymes in a one-pot reaction proved to be challenging. Therefore, a one-
step protocol starting from purified 5PP-InsP5 was pursued. (Scheme 2.6) Reaction 
optimization with [13C6]5PP-InsP5 confirmed that 5PP-InsP5 is the preferred substrate 
for human PPIP5K2KD, compared to InsP6, and full conversion could be obtained with 
1.5 µM enzyme in 5.5 hours. 1,5(PP)2-InsP4 was purified analogously to 5PP-InsP5 by 
precipitation with Mg2+ ions. The product was isolated as the ammonium salt in 77% 
yield (111 mg, >85% purity determined by NMR). 
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Scheme 2.6: Chemoenzymatic synthesis and purification of 1,5(PP)2-InsP4. Optimized 
conditions for the synthesis of 1,5(PP)2-InsP4: 250 µM 5PP-InsP5, 2 mM ATP, 5 mM 
MgCl2, 5 mM creatine phosphate (pCr) and 1 U/mL creatine kinase (CrK), 1.5 µM 
PPIP5K2KD, 250 mM NaCl, 20 mM MES pH 6.4.  
 
Overall, the synthesis of asymmetric 1,5(PP)2-InsP4 was achieved in an 
analogous fashion to 5PP-InsP5 with only minor changes in the purification protocol. 
The purification of 1PP-InsP5, by contrast, required an additional step, limiting access 
to this compound to ca.100 mg batches. Preparation of similar amounts of 1PP-InsP5 
by chemical means, however, also remains challenging and demands specialized 
chemistry equipment that is typically not present in biochemistry and molecular biology 
laboratories.  
 
Conclusion and Outlook 
Over the last decade we have witnessed significant progress in the synthesis of 
PP-InsPs. Still, the general availability of these compounds in good quantities, 
especially of the asymmetric regioisomers, has been limited. Here, we have 
established a robust workflow for PP-InsP synthesis and purification. With the required 
enzymes and relevant substrates in hand, all characterized mammalian PP-InsPs were 
synthesized on at least a 100 mg scale in one or two steps, without the need for 
specialized chemistry equipment. While our method is efficient in synthesizing the 
reported PP-InsPs, some limitations remain to be addressed in the future. The current 
protocol is restricted by the availability and activity of the small molecule kinases that 
selectively install the pyrophosphate groups. For example, D. discoideum, a slime mold 
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containing the highest concentration of PP-InsPs measured to date, produces PP-InsP 
regioisomers that bear pyrophosphate groups at the 5- or 6-position or on both.15 In 
addition, our method is not suited to synthesize analogs of PP-InsPs, such as non-
hydrolyzable bisphosphonate analogs or photo-caged derivatives. Especially in the 
case of large structural perturbations of the PP-InsPs we envision that those syntheses 
remain in the realm of classical organic chemistry. Overall, the scalable biochemical 
syntheses of the major mammalian PP-InsPs make these compounds readily available 
to a broader research community and will greatly aid a thorough analysis of the varied 
properties of PP-InsPs. Just as access to other second messengers greatly aided the 
structural and biochemical elucidation of their signaling function, the method presented 
here will facilitate a thorough and granular analysis of the varied properties of PP-
InsPs. Such detailed investigations are much needed, to determine the molecular 
mechanisms underlying the pleiotropic phenotypes associated with PP-InsP signaling, 
and ultimately guide the development of novel therapeutic strategies.  
Thus far, the biochemically prepared PP-InsPs have enabled a broad use of 
these molecules in many research projects. The facile precipitation procedure of PP-
InsPs proved to be equally useful on a small scale, as demonstrated for the synthesis 
of 5PP-InsP5-β32P.17 In this case, HPLC purification of the radioactive compound was 
no longer necessary to obtain high purity 5PP-InsP5-β32P. The route to this material 
can be easily reproduced without high instrumental hurdles and will be a valuable 
source to study protein pyrophosphorylation. Access to large amounts of 5PP-InsP5 
also enabled the development of a stringent high throughput screen with 35,000 
compounds to identify inhibitors of IP6K. The rationale for these experiments were 
developed in Chapter 3 and will be explained in detail. Using 1,5(PP)2-InsP4 as a 
substrate an analogous approach is planned for the PPIP5Ks in the near future.  
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Recently, providing larger amounts of PP-InsPs established several new 
collaborations. Together with the Moldoveanu laboratory, we started to investigate the 
role of PP-InsPs in necroptosis through activation of MLKL, a known allosteric 
substrate of InsPs.18 Furthermore, 5PP-InsP5 was provided to the Hothorn group to aid 
crystallization studies of plant proteins. We also working together with the Saiardi group 
on PP-InsPs in D. discoideum and therefore pursue the synthesis to the specific 
regioisomers from this organism. It is planned to optimize the reaction conditions for 
the synthesis of 4/6,5(PP)2-InsP4 using IP6KA and together with Siw14, a selective 
5PP-InsP pyrophosphatase, we will try to synthesize also 4/6PP-InsP5.19,20 
Finally, the access to large amounts of PP-InsPs can also contribute to the study 
of protein pyrophosphorylation. With this material in hand, the energy of hydrolysis can 
be experimentally determined to confirm and rank the ability of these molecules to 
transfer the β-phosphoryl group onto proteins. At the moment, it is only known that all 
PP-InsPs have pyrophosphorylation potential but the differences between PP-InsPs – 
whether these are different substrate specificities or distinct reaction rates – have not 
been investigated. In line with this, we also want to observe and optimize the in vitro 
pyrohosphorylation of proteins in combination with MS or/and NMR spectroscopy. 
Currently, radiolabeling is the only method that can detect pyrophosphorylation in vitro, 
probably due to the low efficiency of this reaction.6,21 Flexible use of PP-InsPs will allow 
a thorough identification and analysis of important parameters that govern the 
formation of this modification. Overall, the chemoenzymatic synthesis of PP-InsPs 
expands the use of the molecules to many new applications and will allow more groups 
to study their biological role and function.  
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Methods 
General Information 
All chemicals were purchased from Sigma Aldrich, VWR, Carl Roth, Thermo 
Fisher Scientific, Alfa Aesar, TCI and used without further purification unless stated 
otherwise. All dry solvents were purified using a solvent purification system MBRAUN 
MB-SPS-5 by passing through activated alumina columns. Deuterated solvents were 
purchased from Euriso-Top. The C18 reversed phase silica was purchased from Carl 
Roth. Telos® was ordered from Kinesis. Automated flash chromatography was 
performed using gradient grade solvents on a CombiFlash® Rf from Teledyne Isco 
using prepacked CombiFlash® columns (40–63 µm). LC-MS analysis was carried out 
with an Agilent 1260 Infinity Binary LC system connected to an Agilent 6130 
Quadrupole LC-MS system with a ZORBAX Rapid Resolution HT Narrow Bore SB-
C18 1.8 μm column (2.1 x 50mm) at 30 °C using API-ESI (atmospheric pressure 
ionization-electrospray) in positive ion mode. The eluent consisted of 10% ACN in 
water with 0.1% formic acid at 0.7 mL/min flow rate.  
NMR spectra were recorded on Bruker spectrometers operating at 300 or 600 
MHz for proton nuclei, 75 or 151 MHz for carbon nuclei or 122 and 244 MHz for 
phosphorous nuclei. NMR data are given as follows: chemical shift δ in ppm 
(multiplicity, coupling constant(s) J Hz, relative integral) where multiplicity is defined 
as: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad or 
combinations of the above. Measurement for the determination of enzyme activity was 
performed on Bruker AV-III spectrometers (Bruker Biospin, Rheinstetten, Germany) at 
310 K using cryogenically cooled 5 mm TCI-triple resonance probe equipped with one-
axis self-shielded gradients. The software used to control the spectrometer was 
topspin 3.5 pl6. Temperature had been calibrated using d4-methanol and the formula 
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of Findeisen et al.22 High-resolution mass spectrometer was performed by direct inject 
on an OrbitrapTM Q-Exactive mass spectrometer (Thermo Fisher Scientific). For the 
purification via FPLC an NGC QuestTM 10 Chromatography System from Bio-Rad was 
used with an integrated NGCTM Sample Pump Module and a BioFracTM Fraction 
Collector. For the spin filtration Amicon Ultra 0.5 mL centrifugal filters with a cut off of 
10 kDa or 3 kDa from Merck Millipore were used.  
 
Recombinant Protein Expression 
Inositol Hexakisphosphate Kinase A (IP6KA) 
The procedure was adopted from.11 In short: The codon optimized Entamoeba 
histolytica IP6KA-gene in a pET15b plasmid was transformed into E. coli BL21 Arctic 
Express (DE3) and an overnight culture of this strain was diluted into 1 L of TB-
Amp/Gen to a final density of OD600 0.1. The cells were grown for 6 h at 37 °C. The 
culture was then switched to 18 °C for 30 min before induction with 0.1 mM IPTG for 
18 hours. The cells were harvested by centrifugation (3,000 g for 10 min at 4 °C) and 
washed with ice cold water. The cell pellet was resuspended in lysis buffer (25 mM Tris 
HCl pH 7.4, 500 mM NaCl, 50 mM imidazole). For 1 g wet weight 10 mL lysis buffer 
was used. The cell suspension was supplemented with lysozyme, DNase I, and 1 tablet 
cOmpleteTM protease inhibitor (Roche), and incubated for 15 min on ice. The cells were 
lysed with a Microfluidizer™ LM10 at 15,000 psi with five iterations. The lysate was 
clarified by centrifugation (30,000 g for 30 min at 4 °C). The supernatant was filtered 
(VWR® vacuum filter, PES 0.45 µm), and loaded onto a Ni-NTA column (GE, 5 mL, 
HiTrap IMAC HP) equilibrated with lysis buffer with a flowrate of 2.5 mL/min. The 
column was washed with lysis buffer until the absorption was constant. IP6KA was 
eluted with a gradient of elution buffer (25 mM Tris HCl pH 7.4, 200 mM NaCl, 500 mM 
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imidazole) in lysis buffer from 0–100 % over 10 CV. 1.5 mL fractions were collected. 
The fractions containing IP6KA were concentrated by spin filtration (Amicon® Ultra 0.5 
mL 10K) and dialyzed overnight against dialysis buffer (20 mM Tris HCl pH 7.4, 200 
mM NaCl, 1 mM DTT). The following day the protein was adjusted to 25 % glycerol, 
frozen in liquid nitrogen and stored at –80 °C. 
 
Diphosphoinositol Pentakisphosphate Kinase 2 Kinase Domain (PPIP5K2KD) 
The codon optimized human PPIP5K2KD-gene was subcloned from a pET21a 
vector into a pSumo vector using the restriction sites NdeI and XhoI. The resulting 
vector was transformed into E. coli Arctic Express (DE3) and an overnight culture of 
this strain was diluted into 2 L of TB-Kan/Gen to a final density of OD600 0.1. The cells 
were grown for 4 h at 37 °C. The culture was then switched to 15 °C for 30 min before 
induction with 0.2 mM IPTG for 18 hours. The cells were harvested by centrifugation 
(3,000 g for 10 min at 4 °C) and washed with ice cold water. The cell pellet was 
resuspended in lysis buffer (20 mM Tris HCl pH 7.5, 500 mM NaCl). For 1 g wet weight 
10 mL lysis buffer was used. The cell suspension was supplemented with lysozyme, 
DNase I, and 2 tablets cOmpleteTM protease inhibitor (Roche), and incubated for 15 
min on ice. The cells were lysed using a Microfluidizer™ LM10 at 15,000 psi with five 
iterations. The lysate was clarified by centrifugation (30,000 g for 30 min at 4 °C). The 
supernatant was filtered (VWR® vacuum filter, PES 0.45 µm), and loaded onto a Ni-
NTA column (GE, 5 mL, HiTrap IMAC FF) equilibrated with lysis buffer with a flowrate 
of 3.5 mL/min. The column was washed with 3 CV lysis buffer and 10 CV of 10 % 
elution buffer (20 mM Tris HCl pH 7.5, 500 mM NaCl, 600 mM imidazole) in lysis buffer 
or until the absorption was constant. PPIP5K2 was eluted with 100 % elution buffer 
over 10 CV. 1.4 mL fractions were collected. The fractions containing PPIP5K2 were 
40 
 
dialyzed overnight against dialysis buffer (20 mM Tris HCl pH 7.4, 500 mM NaCl, 1 mM 
DTT). The following day the protein was adjusted to 20 % glycerol, frozen in liquid 
nitrogen and stored at –80 °C. 
 
Chemical Synthesis of InsP6 
 
The compound was synthesized as described before in two steps starting from myo-
inositol. Analytical data were identical with the values reported in the literature.23,24 
 
The compound was synthesized as described before in two steps starting from myo-
inositol. Analytical data were identical with the values reported in the literature.10 
  
41 
 
Chemoenzymatic Synthesis of Inositol Pyrophosphates 
For all enzymatic syntheses the following stock solutions were prepared: 
Creatine kinase stock solution: 350 U/mL creatine kinase in 200 mM MOPS pH 6.5, 20 
mM MgCl2, 20 mM DTT 
IP6KA stock solution: 10 mg/mL IP6KA in 20 mM Tris HCl pH 7.4, 200 mM NaCl, 1 
mM DTT 
PPIP5K2KD stock solution: 10 mg/mL 20 mM Tris HCl pH 7.4, 500 mM NaCl, 1 mM 
DTT, 40% glycerol 
ATP stock solution: 100 mM in MilliQ® water pH 6.4; (Note: Concentration was 
determined via UV-Vis analysis at 259 nm; ε259 = 15.4 E/mmol/cm) 
Amberlite® IRC-748 resin was prepared as follows:  
500 mL resin was placed on a big fritted filter and washed with 1 L MeOH and 1 L H2O 
and stored at 4 °C in 20 % MeOH. For a 100 mg reaction roughly 30 mL of resin were 
placed on a filter, washed with 500 mL H2O and acidified with 250 mL of 1 M HCl. The 
resin was washed with H2O (usually 1–2 L) until it reached pH 6–7 and the resin was 
equilibrated with 250 mL 1 M NH4HCO3 pH 7.5–8. The resin was washed with 1 L H2O 
and left dry on the filter until use. 
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Synthesis of 5PP-InsP5 
 
MilliQ® water was prewarmed to 37 °C by incubation in a water bath. A solution of 
InsP6 (250 µM, 350 mg based on free acid 647.9 g/mol), MES (20 mM, pH 6.4), NaCl 
(50 mM), ATP (disodium salt, 2 mM), creatine phosphate (5 mM), MgCl2 (7 mM), DTT 
(1 mM) in 2.16 L prewarmed MilliQ® water was prepared. The solution was evenly split 
among 3 × 1 L Schott bottles and the bottles were incubated in the water bath at 37 °C 
for 10 min. IP6KA (1 µM) and creatine kinase (1 U/mL) were added and the Schott 
bottles were gently inverted several times to homogenize and left to react for 30 min 
without shaking. (Note: The correct temperature was essential to assure full conversion 
of the starting material within 30 min. Prolonged reaction times above 1 h led to side 
reactions. However, the speed of the reaction will depend on the batch and quality of 
the recombinantly expressed IP6KA.) 
Purification: The reaction was stopped by cooling the reaction mixture down to 4 °C 
within 5 min with the help of a dry ice isopropanol bath. A fritted filter was loaded with 
21 g of C18 reversed phase silica gel suspended in MeCN and sand was added on 
top. The C18 plug was washed with 100 mL MeCN and 100 mL H2O and the complete 
reaction mixture was passed through the filter under vacuum. The C18 plug was 
washed with 2 × 100 mL H2O and all the combined flow through was supplemented 
with 12.5 mM MgCl2. The pH was adjusted to 8.8–9.0 by drop wise addition of 10 mM 
NaOH solution which leads to precipitation of the PP-InsPs as magnesium complex 
within 1 h at room temperature. (The precipitation can also be performed overnight at 
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room temperature.) The suspension was collected in 4 canonical 50 mL tubes by 
centrifugation (2 min at 3000 g) and the supernatant was removed. The precipitate of 
each tube was washed 3 times with 15 mL MgCl2 solution (8 mM, pH 9 adjusted with 
NaOH). 
The precipitate of each tube was resuspended in 20 mL NH4HCO3 buffer (10 mM, pH 
8) and vortexed with Amberlite® IRC-748 (20 mL wetted bed volume, pre-equilibrated 
with NH4HCO3, pH 7.5–8) until the precipitate dissolved. The buffer/resin suspension 
of each tube was added to a short Amberlite® IRC-748 column (5 mL bed volume, pre-
equilibrated with NH4HCO3, pH 8) to remove excess Mg2+. The product was flushed 
through the column with 50 mL water and all eluents were collected, combined and 
lyophilized in a round-bottom flask to afford the ammonium salt of the product as white 
solid. The solids were dissolved in D2O and the concentration of the solution was 
determined by NMR against a standard (phosphonoacetic acid) to determine yield and 
purity: 30 mL of 14.3 mM solution were obtained which corresponds to 312 mg (80% 
yield, purity > 95%) 5PP-InsP5 based on the free acid 726.9 g/mol.  
1H NMR (300 MHz, Deuterium Oxide, pD 5.0) δ 4.46 (q, J = 9.4 Hz, 2H), 4.27 (q, J = 
9.4 Hz, 1H), 4.10 (t, J = 9.6 Hz, 2H). 
13C NMR (151 MHz, D2O, pD 5.0) δ 77.57, 75.81, 75.69, 73.20. 
31P NMR (243 MHz, Deuterium Oxide, pD 5.0) δ 0.60, 0.53, -0.42, -10.31 (d, J = 19.9 
Hz), -10.86 (d, J = 19.9 Hz). 
HRMS (ESI) calculated for C6H17O27P7(M-) 738.8204, found 738.8222. 
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Synthesis of 1PP-InsP5 
 
MilliQ® water was prewarmed to 37 °C by incubation in a water bath. A solution 
of InsP6 (250 µM, 100 mg based on free acid 647.9 g/mol), MES (20 mM, pH 6.4), 
NaCl (250 mM), ATP (disodium salt, 2 mM), creatine phosphate (5 mM), MgCl2 (6 mM), 
DTT (1 mM) in 617 mL prewarmed MilliQ® water was prepared in a 1 L Schott bottles 
and incubated in a water bath at 37 °C for 10 min. PPIP5K2KD (2 µM) and creatine 
kinase (1 U/mL) were added and bottle gently inverted several times to homogenize 
and left to react overnight for 18 h without shaking.  
Purification: The reaction was stopped by cooling the reaction mixture down to 
4 °C within 5 min with the help of a dry ice isopropanol bath. A fritted filter was loaded 
with 6 g of C18 reversed phase silica gel suspended in MeCN and sand was added on 
top. The C18 plug was washed with 30 mL MeCN and 30 mL H2O and the complete 
reaction mixture was passed through the filter under vacuum. The C18 plug was 
washed with 2 × 30 mL H2O and all the combined flow through was supplemented with 
12.5 mM MgCl2. The pH was adjusted to 8.8–9.0 by drop wise addition of 10 mM NaOH 
solution which leads to precipitation of the PP-InsPs as magnesium complex within 1 
h at room temperature. (The precipitation can also be performed overnight at room 
temperature.) The suspension was collected in 2 canonical 50 mL tubes by 
centrifugation (2 min at 3000 g) and the supernatant was removed. The precipitates of 
each tube were washed 3 times with 15 mL MgCl2 solution (8 mM, pH 9 adjusted with 
NaOH). 
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The precipitate of each tube was resuspended in 15 mL NH4HCO3 buffer (10 
mM, pH 8) and vortexed with Amberlite® IRC-748 (15 mL wetted bed volume, pre-
equilibrated with NH4HCO3, pH 7.5–8) until the precipitate dissolved. The buffer/resin 
suspension of each tube was added to a short Amberlite® IRC-748 column (5 mL bed 
volume, pre-equilibrated with NH4HCO3, pH 8) to remove excess Mg2+. The product 
was flushed through the column with 40 mL H2O and all eluents were collected, 
combined and lyophilized in a round-bottom flask. The resulting white solid was purified 
in 2 runs using a SAX-FPLC (HiPrepTM Q HP 16/10, GE Healthcare) and H2O as buffer 
A and 1 M NH4HCO3 as buffer B. The column was washed with 100% B and 
equilibrated at 1% B. The sample was dissolved and loaded in 1% B and, followed by 
a gradient from 1% to 20% in 1 CV. The product was eluted in a gradient from 20%–
40% over 10 CV. Fractions were analyzed by a metal dye detection assay25 in a 96-
well plate format and product containing fractions were combined and lyophilized in a 
round-bottom flask. The solids were dissolved in D2O and the concentration of the 
solution was determined by NMR against a standard (phosphonoacetic acid) to 
determine yield and purity: 20 mL of 5.3 mM solution were obtained which corresponds 
to 77 mg (68% yield, purity > 95%) 1PP-InsP5 based on the free acid 726.9 g/mol.  
1H NMR (600 MHz, Deuterium Oxide, pD 5.0) δ 5.08 (d, J = 9.8 Hz, 1H), 4.40 (p, J = 
9.7 Hz, 2H), 4.21 (t, J = 9.8 Hz, 1H), 4.15 (q, J = 9.5 Hz, 1H), 4.09 (t, J = 9.2 Hz, 1H). 
13C NMR (151 MHz, D2O, pD 5.0) δ 77.32, 76.11, 75.68, 75.58, 73.70, 73.08. 
31P NMR (243 MHz, Deuterium Oxide, pD 5.0) δ 1.64, 0.90, 0.40, 0.32, -0.94, -8.70, -
10.89 (d, J = 18.7 Hz). 
HRMS (ESI) calculated for C6H17O27P7(M-) 738.8204, found 738.8198. 
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Synthesis of 1,5(PP)2-InsP4 
 
MilliQ® water was prewarmed to 37 °C by incubation in a water bath. A solution 
of 5PP-InsP5 (250 µM, 100 mg based on free acid 726.9 g/mol), MES (20 mM, pH 6.4), 
NaCl (250 mM), ATP (disodium salt, 2 mM), creatine phosphate (5 mM), MgCl2 (5 mM), 
DTT (1 mM) in 715 mL prewarmed MilliQ® water was prepared in a 1 L Schott bottles 
and incubated in the water bath at 37 °C for 10 min. PPIP5K2KD (1.5 µM) and creatine 
kinase (1 U/mL) were added and bottle gently inverted several times to homogenize 
and left to react overnight for 5.5 h without shaking. 
Purification: The reaction was stopped by cooling the reaction mixture down to 
4 °C within 5 min with the help of a dry ice isopropanol bath. A fritted filter was loaded 
with 6 g of C18 reversed phase silica gel suspended in MeCN and sand was added on 
top. The C18 plug was washed with 30 mL MeCN and 30 mL H2O and the complete 
reaction mixture was passed through the filter under vacuum. The C18 plug was 
washed with 2 × 30 mL H2O and all the combined flow through was supplemented with 
12.5 mM MgCl2. The pH was adjusted to 8.8–9.0 by drop wise addition of 10 mM NaOH 
solution which leads to precipitation of the PP-InsPs as magnesium complex within 1 
h at room temperature. (The precipitation can also be performed overnight at room 
temperature.) The suspension was collected in 2 canonical 50 mL tubes by 
centrifugation (2 min at 3000 g) and the supernatant was removed. The precipitates of 
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each tube were washed 3 times with 15 mL MgCl2 solution (8 mM, pH 9 adjusted with 
NaOH). 
The precipitate of each tube was resuspended in 15 mL NH4HCO3 buffer (10 
mM, pH 8) and vortexed with Amberlite® IRC-748 (15 mL wetted bed volume, pre-
equilibrated with NH4HCO3, pH 7.5–8) until the precipitate dissolved. The buffer/resin 
suspension of each tube was added to a short Amberlite® IRC-748 column (5 mL bed 
volume, pre-equilibrated with NH4HCO3, pH 8) to remove excess Mg2+. The product 
was flushed through the column with 40 mL H2O and all eluents were collected, 
combined and lyophilized in a round-bottom flask to afford the ammonium salt of the 
product as white solid. The solids were dissolved in D2O and the concentration of the 
solution was determined by NMR against a standard (phosphonoacetic acid) to 
determine yield and purity: 12 mL of 12.7 mM solution were obtained which 
corresponds to 111 mg (77% yield, purity > 85%) 1,5(PP)2-InsP4 based on the free 
acid 805.9 g/mL.  
1H NMR (600 MHz, Deuterium Oxide, pD 5.0) δ 5.01 (d, J = 9.6 Hz, 1H), 4.55 (p, J = 
9.9 Hz, 2H), 4.36 (q, J = 9.8 Hz, 1H), 4.25 (t, J = 9.4 Hz, 1H). 
31P NMR (243 MHz, Deuterium Oxide, pD 5.0) δ 0.56, 0.33, -0.26, -1.04, -10.34 (dd, 
J = 29.9, 19.2 Hz), -11.03 (dd, J = 60.0, 19.3 Hz). 
13C NMR (151 MHz, D2O, pD 5.0) δ 77.42, 76.05, 75.53, 74.78, 73.53, 73.18. 
HRMS (ESI) calculated for C6H17O27P7(M-) 818.7868, found 818.7865.  
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reactions. Experiments with enzymes from A. thaliana were performed in collaboration 
with the Hothorn and the Schaaf groups. D. discoideum was metabolically labeled by 
Saiardi and coworkers.  
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Introduction: New Methods to Monitor PP-InsPs in Complex Mixtures 
Monitoring PP-InsPs levels and dynamics is one of the major readouts to identify 
and characterize biological functions of these second messengers. Since the first 
discovery of these small molecules, radioactively-labeled myo-inositol and PP-InsPs 
have been among the most applied tools to interrogate PP-InsP signaling. (Chapter 1, 
Figure 1.4) This approach established the existence of PP-InsPs as well as their 
participation in phosphate homeostasis and cell cycle progression.1–4 The use of 
radioactive methods prevented many groups from entering the PP-InsP field and 
limited analysis of these small molecules to yeast, D. discoideum and a few 
mammalian cell lines. Therefore, new methods were developed over the last three 
decades. Early on, Mayr and coworkers used an alternative HPLC-based method that 
allowed label-free analysis of PP-InsP content from cell extracts by metal-dye detection 
(MDD).5 (Figure 3.1 a)  
 
Figure 3.1: Alternative techniques to monitor PP-InsPs in cell extracts avoiding 
radioactivity. a) Analysis of PP-InsPs by SAX-HPLC using MDD detection. b) Analysis 
of PP-InsP by TiO2 enrichment followed by PAGE separation and staining with toluidine 
blue.  
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The method relies on the detection of the specific absorption of a metal dye complex. 
In presence of InsPs and PP-InsPs, the metal-chelating dye is displaced from the metal 
centre, resulting in a decrease in absorbance of the complex. This approach allowed 
relative and absolute quantification and has been used since the initial characterization 
of PP-InsPs in D. discoideum.2 MDD requires a three pump HPLC system which is not 
readily implemented. Eversince this method was published, only the Mayr laboratory 
had this setup available which made it overall sparsly used in the field. More recently, 
a new method avoided the use of rather harsh HPLC conditions for the separation.6 
PP-InsPs were enriched from acidified cell extracts by TiO2 beads, followed by their 
separation on high percentage acrylamide gels. (Figure 3.1 b) Unlabeled PP-InsPs 
were visualized using a cationic dye like toluidine blue that binds PP-InsPs and were 
analyzed quantitatively using a gel imager. This method showed systematically 
increased PP-InsP concentrations compared to radiolabeling and MDD, which can be 
attributed to the milder separation conditions.6 The relatively low technical 
requirements and the independence from radioactive tracers have allowed more 
laboratories to employ this approach, but the lack of an InsP-specific analytical handle 
entailed a more elaborate sample preparation and is limited to the detection of only the 
most highly phosphorylated InsPs.  
While all methods mentioned above have been instrumental to understand PP-InsP 
function, they are only able to discriminate InsP and PP-InsP based on their charge 
and lack a clear distinction of the structural isomers of InsPs and PP-InsPs. These 
methods also lack the ability to monitor conversion of InsP species in real time in vitro, 
thereby losing informative kinetic insight contained within biochemical experiments. 
Furthermore, various separation and resolution steps were required and direct 
measurements in complex environments like cell extracts have not been possible so 
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far. Therefore, novel approaches that discriminate PP-InsPs based on their structure 
and that generate reliable information quickly with limited sample preparation are 
highly needed. 
NMR spectroscopy is a non-invasive analytical method that can provide detailed 
information about the chemical and structural environment of a nucleus solely based 
on the chemical shift and magnetic couplings between nuclei. For example, two-
dimensional 1H,31P-NMR has been used to elucidate the structure of PP-InsPs.7,8 
Since experiments utilizing the 3J(1H,31P) coupling are of limited sensitivity due to the 
inefficient magnetization transfer via these couplings, high analyte concentrations were 
necessary. In addition, the low chemical shift dispersion and the broad lines of 31P can 
limit the information content.7,8 In contrast, the chemical shift dispersion of the NMR-
active nucleus 13C is superior to 31P and magnetization transfer via 1J(1H,13C) one-
bond couplings is much more efficient. Unfortunately, the sensitivity of NMR 
experiments including 13C is strongly hampered by the low natural abundance of this 
isotope of approx. 1 %. In the past, this disadvantage could be overcome by the use 
of 13C isotope-labeled small molecules and has been widely applied to elucidate 
various metabolic pathways and processes.9–11 The 100-fold higher concentration of 
13C nuclei enhanced the detectability of labeled compounds with respect to sample 
background and experimental noise, thereby providing targeted information on these 
molecules in complex environments. Consequently, we envision that 13C-labeled myo-
inositol, and the corresponding labeled InsPs and PP-InsPs, could enable NMR 
measurements at low, biologically relevant analyte concentrations and within intricate 
samples. 
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In this chapter, a new a tool that combines NMR spectroscopy and 13C-labeled myo-
inositol to study InsP and PP-InsPs is reported. To this end, a high yielding, gram-scale 
synthesis of highly pure uniformly 13C-labeled ([13C6]) myo-inositol was developed. In 
combination with synthetic procedures from the literature and the chemoenzymatic 
efforts, provided in chapter 2, [13C6]InsPs and [13C6]PP-InsPs were prepared. We 
employed the [13C6]InsPs and [13C6]PP-InsPs to monitor in vitro activity of PP-InsP 
metabolizing enzymes from H. sapiens and A. thaliana and characterized the kinetic 
parameters of these kinases. Moreover, we demonstrate metabolic labeling of two 
mammalian cell lines (HCT116 and HEK293T) and the social amoeba D. discoideum 
with [13C6]myo-inositol, and subsequent detection of the in vivo generated [13C6]InsPs 
and [13C6]PP-InsPs species within a complex cell extract. These findings highlight the 
utility and applicability of 13C-labeled InsPs to improve our understanding of InsP and 
PP-InsP biochemistry and metabolism, and to interrogate and elucidate their cellular 
functions.  
 
Chemoenzymatic Synthesis of 13C-labeled PP-InsPs 
Enzymatic Synthesis of [13C6]myo-Inositol on a Gram Scale1 
To analyze inositol-based signaling molecules by NMR we first sought to 
prepare pure [13C6]myo-inositol on a large scale. The approaches to obtain 13C-labeled 
myo-inositol reported to date have either relied on expensive [13C6]glucose-6-
phosphate as a starting material (7000 €/g) or – when starting from [13C6]glucose – 
were low yielding (9.9 % and 6.7 %, respectively).12–14 In addition, all procedures 
lacked a scalable purification strategy for the product, precluding the isolation of large 
                                                            
1 Optimization of the enzymatic synthesis was conducted by R. Puschmann. Optimization of the chemical 
derivatization and purification was performed by R. K. Harmel. [13C6]myo-inositol was synthesized on a large 
scale by R. Puschmann and R. K. Harmel. 
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and pure amounts of product. Consequently, these methods have only been applied 
on a small scale. To circumvent these limitations, and to subsequently synthesize 
sufficient quantities of [13C6]InsPs, we pursued a 3-step enzymatic synthesis that uses 
affordable [13C6]glucose (80 €/g) as a starting material and employed a chemical 
purification strategy at the end. (Figure 3.2) 
 
Figure 3.2: Chemoenzymatic synthesis of [13C6]myo-inositol followed by derivatization 
and purification. a) [13C6]glucose, MOPS pH 6.5, creatine phosphate, ATP, DTT, 
MgCl2, hexokinase, creatine kinase, H2O. b) Tris pH 8.0, NAD+, NaCl, MgCl2, inositol 
phosphate synthase in H2O. c) Glycine pH 9.8, ZnCl2, alkaline phosphatase in H2O. d) 
Ac2O, pyridine. e) NaOMe in MeOH. 
 
As a first step, [13C6]glucose was phosphorylated at the 6-position using 
commercially available hexokinase in a modified literature procedure.15 Next, we 
optimized and scaled up the isomerization reaction of [13C6]glucose-6-phosphate (11) 
to [13C6]myo-inositol-3-phosphate (12) published by Saiardi and coworkers.12 During 
this step the conditions were altered to use Mg2+ rather than paramagnetic Mn2+, so 
the progress of the reaction could be monitored by 13C NMR spectroscopy. Securing 
full conversion to 12 was crucial for the overall synthetic strategy, as it bypasses the 
discrimination between 11 and 12 in the subsequent dephosphorylation step. Thereby, 
[13C6]myo-inositol could be obtained by dephosphorylation with robust and 
commercially available alkaline phosphatase instead of using recombinantly 
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expressed inositol monophosphatase. While the desired product was clearly visible in 
the 13C NMR spectrum, the isolated yield exceeded 100%, indicative of contamination 
with salts and buffer components. Because purification of [13C6]myo-inositol by ion-
exchange, normal- phase, and reverse-phase chromatography proved difficult, we 
applied a chemical derivatization strategy in which the product mixture containing 
[13C6]myo-inositol was treated with an excess of acetic anhydride in pyridine. The 
resulting [13C6]myo-inositol hexakisacetate (13) could be purified by normal-phase 
chromatography and subsequent saponification and precipitation provided gram 
amounts of [13C6]myo-inositol in excellent purity with a 50% overall yield (with respect 
to [13C6]glucose). In comparison to previous syntheses, our approach provides a 
simpler and shorter route with greatly improved yield. 
 
Chemical Synthesis and Characterization of [13C6]InsPs and [13C6]PP-InsPs 
With large quantities of pure [13C6]myo-inositol in hand, we prepared [13C6]InsP5 and 
[13C6]InsP6; as they are the most abundant inositol polyphosphates.16 (Figure 3.3) 
[13C6]InsP6 was obtained analogous to the procedure used in chapter 2 in two steps 
with 35% yield via the xylyl protected intermediate 14.17 Unfortunately, efforts to 
optimize the solvent system or use of other reported protecting groups (9-
fluoenylmethyl- or benzyl) led to no significantly improved yield.18 The synthesis of 
[13C6]InsP5 consists of 5 steps and was optimized using unlabeled myo-inositol, then 
performed with [13C6]myo-inositol. The synthetic route started with the formation of the 
orthobenzoate ester 15.19 While the published procedure suggested recrystallization 
from EtOAc, we found that precipitation with water simplified the product purification 
due to the easy removal of the DMSO. Acidic hydrolysis of 15 followed by 
phosphitylation with xylyl phosphoamidite generated and oxidation by mCPBA 
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compounds 16. Removal of the xylyl- and the benzoyl groups afforded [13C6]InsP5 in 
38% overall yield which is consistent with the literature yields.  
Compared to the syntheses of [13C6]InsP5 and [13C6]InsP6, obtaining [13C6]PP-
InsPs by chemical means would require large amounts of starting material and be quite 
challenging.20–22 Fortunately, we could easily adopt the new findings described in 
chapter 2 to produce large amounts PP-InsPs enzymatically in high purity. Using this 
method, 100 mg of [13C6]5PP-InsP5 and 50 mg of each [13C6]1PP-InsP5 and 
[13C6]1,5(PP)2-InsP4 were synthesized chemoenzymatically. 
 
 
Figure 3.3: Chemical synthesis of [13C6]InsP5 and [13C6]-InsP6. a) Xy phosphoamidite, 
5-Phenyltetrazol, DCM, then mCPBA. b) Pd(OH)2/H2, MeOH/H2O. c) trimethyl 
orthoformate, camphorsulfonic acid, DMSO. d) 10% TFA. e) Xy phosphoramidite, 1H-
tetrazole, mCPBA, DCM. f) Pd(OH)2/H2, MeOH/H2O. g) conc. NH3(aq) 
 
We examined all prepared 13C-labeled compounds by 1H,13C-HMQC 
spectroscopy. In general, 13C and 1H nuclei of phosphorylated positions are more 
deshielded compared to their unphosphorylated counterparts and displayed higher 
chemical shifts which was most pronounced in the 1H-dimension. (Figure 3.4 a, b) The 
spectra of [13C6]myo-inositol, [13C6]InsP5, [13C6]InsP6 and [13C6]5PP-InsP5 showed four 
resonances due to the plane of symmetry in these molecules. (Figure 3.4 a–d) 
[13C6]1PP-InsP5 and [13C6]1,5(PP)2-InsP4 exhibited six signals as the symmetry is 
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broken through the pyrophosphate group at the 1-position and the signals at the 1/3 
positions are clearly split. (Figure 3.4 e, f) Importantly, the spectra revealed unique 
peaks for each of the InsPs which was very promising with respect to the analysis of 
complex mixtures and unpurified cell extracts. Especially, the chemical shift of the 2-
position was strongly affected by the given phosphorylation pattern. Remarkably, 
spectra could be obtained using only 32 scans (2 h) at 5 µM for [13C6]InsP6 which 
illustrates the high visibility provided by labeling with 13C. 
 
 
Figure 3.4: 1H,13C-HSQC spectra of all synthesized 13C-labeled compounds. a) 
[13C6]myo-inositol b) [13C6]InsP5 c) [13C6]InsP6 d) [13C6]5PP-InsP5 e) [13C6]1PP-InsP5 f) 
[13C6]1,5(PP)2-InsP4. 
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In Vitro Characterization of PP-InsP Metabolizing Enzymes 
Biochemical Characterization of IP6KA and IP6K12 
With the synthetic 13C-labeled standards in hand, we pursued the in vitro 
characterization of PP-InsP kinases by NMR spectroscopy. To date, enzymatic 
activities of IP6Ks and PPIP5Ks were mostly assessed by monitoring PP-InsP 
conversion using radioactivity or MDD, or were measured indirectly via quantification 
of ADP content using bioluminescent assays.1–5,23 We envisioned that an NMR-based 
method could resemble a valuable alternative to these methods. The NMR workflow 
would avoid the use of radioactive compounds and cumbersome HPLC purification. In 
addition, atomic resolution provided by the NMR spectra would give high confidence 
about the identity of the substrate. Overall, this could simplify sample preparation and 
analysis, and could minimize the risk of false interpretation of the obtained data. 
As proof of principle, the kinase activities of IP6KA and IP6K1 were investigated. 
While optimizing the enzymatic synthesis of [13C6]5PP-InsP5 with IP6KA, we noted that 
the progression of the reaction could be followed readily by NMR, even in the presence 
10% H2O and high concentrations of non-deuterated buffer and ATP (Figure 3.5). 
Specifically, the diagnostic signals for the protons at the 2-position of the inositol ring 
of [13C6]InsP6 and [13C6]5PP-InsP5 were baseline-separated in the 1H-dimension (5.2 
ppm for [13C6]InsP6, 5.1 ppm for [13C6]5PP-InsP5) and showed no overlap with signals 
from other compounds within the mixture. 
                                                            
2 Optimization and biochemical characterization of IP6K1 was performed by both R. K. Harmel and R. 
Puschmann. Kinetic data were analyzed and illustrated by R. Puschmann.  
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Figure 3.5: 1H,13C-HMQC-Spectra to determine conversion to [13C6]5PP-InsP5. a) 
Control reaction without IP6KA shows no conversion of [13C6]InsP6. b) Full conversion 
of [13C6]InsP6 to [13C6]5PP-InsP5. c) Overlay of a and b to illustrate that the C2 peaks 
(highlighted with green circle) are well resolved and can be used to monitor the reaction 
progress. 
 
The ability to resolve the 1H-signals at the 2-position provided the opportunity to 
monitor the enzymatic reaction in a time-resolved fashion, using a pseudo-2D spin-
echo difference experiment. This pulse sequence was similar to the 1H,13C-HMQC 
experiments and resulted in a series of one-dimensional spectra that only displayed 
resonances for 1H-nuclei that are bound to 13C-nuclei. By plotting the peak intensity of 
the 1H-nuclei at the 2-position against time (each experiment required only 75 seconds 
at a substrate concentration of 175 µM) the progress of the kinase reaction could be 
observed. (Figure 3.6) The non-invasive nature of the NMR measurements allowed 
for continuous reaction monitoring, providing time-resolved data from one sample.  
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Figure 3.6: NMR-based measurements of IP6KA activity. a) Superimposed pseudo-
2D spin-echo difference spectra at different time points (6 min, 28 min, 50 min, 73 min, 
95 min, 118 min, 455 min). The InsP6 and 5PP-InsP5 peaks are labeled and the change 
over time is indicated by the arrows. The intensity of the ATP-peak hardly changed due 
to the ATP regenerating system. b) Progress curves of [13C6]5PP-InsP5 synthesis at 
different IP6KA concentrations. An individual NMR-spectrum was recorded every 75 
seconds. The [13C6]5PP-InsP5 peak height was normalized against the HEPES signal 
and the data was fitted with a first order decay model. 
 
With a fast and robust workflow to determine kinase activity set up, the kinetic 
parameters for human IP6K1 were determined to validate our NMR analysis. (Figure 
3.7) Measurement of the initial rates at constant [13C6]InsP6 concentration (175 µM) 
and varying ATP concentrations (62.5 µM to 8 mM) provided the Michalis-Menten 
constant. In this assay, we decided to use time points rather than continuous time 
curves in order to save experimental and instrument time. IP6K activity is dependent 
on Mg2+ ions and therefore we chose to quench each time point by addition of EDTA. 
The KM measured for ATP (353 ± 167 µM) was comparable to previous reports and is 
close to cellular ATP concentrations, which supports the assertion that the IP6Ks are 
uniquely sensitive to ATP availability.23,24 The Vmax value (192 ± 41 nmol min-1 mg-1) for 
IP6K1 was also within the range of published literature values, which varied greatly 
depending on the protein-tag and purification strategy employed (37.3 nmol min-1 mg-
1 to 1410 nmol min-1 mg-1).24,25 Interestingly, we found that ATP concentrations above 
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2 mM led to substrate inhibition of IP6K1 (Ki 7.48 mM), which had not been quantified 
before.25 The robust measurements of InsP conversion by NMR spectroscopy has 
provided kinetic data with low experimental error, which, in turn, allowed the 
observation of substrate inhibition by ATP. 
 
Figure 3.7: Kinetic characterization of IP6K1. Michaelis-Menten kinetics for IP6K1. 
The initial velocity was measured in triplicates at different ATP concentrations and fitted 
against a model for substrate inhibition. 
 
All in all, biochemical characterization of IP6K1 showed great potential to monitor 
conversion of PP-InsPs in general. Consequently, this approach became the method 
of choice to optimize reaction conditions for the large-scale synthesis of PP-InsPs 
described in chapter 2 and to compensate for batch-dependent variations in enzyme 
activity. In the future, the developed NMR workflows can be adapted for the analysis 
of other PP-InsPs metabolizing enzymes.  
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Evaluation of IP6K1 Inhibitors3 
IP6Ks regulate important aspects of metabolism and signaling in mammals and 
in pathogenic microorganisms like Trypanosoma brucei and therefore increased efforts 
to identify selective inhibitors have been made.23,26,27 Thus far, two molecules, TNP 
(N2-(m-Trifluorobenzyl)-N6-(p-nitrobenzyl)purine), and Myricetin were shown to inhibit 
IP6K1 activity at low micromolar concentrations. TNP was identified in a study that 
tested InsP3-3-kinase inhibitors on IP6Ks.26 Here, the conversion of radioactive 
[3H]InsP6 was followed by TLC or HPLC assays. In an attempt to find more potent 
inhibitors for IP6K1, a high-throughput-screening approach using a bioluminescence-
based ADP detection assay identified myricetin among a few others hits.23  Given that 
we could directly measure product formation, we expanded the scope of our NMR 
method towards the characterization of IP6K1 inhibitors. (Figure 3.8)  
 
Figure 3.8: The inhibitory effect of TNP (N2-(m-Trifluorobenzyl)-N6-(p-
nitrobenzyl)purine), Myricetin, and Wortmannin were tested at different concentrations 
and the IC50 values were determined. The ATP concentration was 2.5 mM for all 
inhibitor measurements. (‡ enzyme activity at 0 µM inhibitor). 
 
                                                            
3 Evaluation of inhibitors was performed by both R. K. Harmel and R. Puschmann. Inhibition data were analyzed 
and illustrated by R. Puschmann. 
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Indeed, we found that TNP and myricetin inhibited IP6K1 with IC50 values of 2.25 µM 
and 0.6 µM, respectively, while Wortmannin (a PI3K inhibitor) did not affect enzyme 
activity even at high concentrations. All in all, we found that the NMR-based method 
represented a good alternative to the radioactive assay and the direct read-out of the 
substrate and the reaction product provided data with high certainty. 
 
Evaluation of the ATP Synthase Reaction as a Tool for High-Throughput-Screening of 
IP6K1 Inhibitors 
 Our newly established NMR assay was not suitable to rapidly screen for new 
inhibitors of PP-InsPs kinases. However, the high reliability of our approach inspired 
us to utilize this technique as a tool to develop and validate new high-throughput-
screening platforms for the discovery of selective IP6K inhibitors. Such inhibitors are 
potentially of value as lead compounds for pharmaceutical intervention in PP-InsP-
mediated diseases or as chemical probes for further interrogation of PP-InsPs 
signaling. In 2017, Wei and coworkers developed a homogeneous high-throughput 
screen for IP6K1 inhibitors.23 Kinase activity was assessed by the detection of the 
produced ADP using a commercially available ADP-GloTM assay kit. (Figure 3.9)  
 
Figure 3.9: ADP detection by commercially available ADP-GloTM assay. 
 
Unfortunately, the most potent hits identified in this screen were flavonoids like 
myricetin which are known to interact with many other kinases.28–30 This 
polypharmacological behaviour disqualifies these compounds as chemical probes to 
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study PP-InsP signaling in cells. Therefore, new approaches to identify IP6K specific 
or even IP6K isoform specific inhibitor are highly needed. 
 In previous NMR experiments to optimize the synthesis of [13C6]5PP-InsP5, it 
was found that the kinase reaction would reach an equilibrium at roughly 30% 
conversion of [13C6]InsP6, even though the concentration of the generated ADP was 
low. According to Snyder and coworkers, the reverse reaction, also referred to as ATP 
synthase reaction, was strongly dependent on the ADP concentration (KM for ADP: 
1.57 mM) and displayed a Vmax value roughly twice as high, compared to the forward 
reaction.31 Together these results indicated that the ATP synthase reaction could be 
readily favored over the kinase reaction. Since we were now able to produce large 
amounts of 5PP-InsP5 with the methods developed in Chapter 2, the reverse reaction 
of IP6K1 could be explored as a platform to screen inhibitors for this enzyme.  
Most kinase inhibitors compete for the nucleotide binding site and we postulated 
that the KD for ATP and ADP should similar so our new approach could work. 
Unfortunately, these values were not published so there was no biochemical evidence 
that the aforementioned assumption was correct. However, an array of experiments 
was conducted to support the initial hypothesis. To this end, we first validated that ADP 
is not an inhibitor of the forward reaction but rather induces the reversed reaction. 
Therefore, the ATP synthase reaction had been performed with ADP and [13C6]5PP-
InsP5 and the formation of ATP and InsP6 was observed by NMR. (Figure 3.10 a, b) 
A reaction with 20 µM TNP was included in one of these samples and showed a 
reduction of ATP synthase activity by 78% compared to the DMSO control.  
The indication that TNP is indeed an inhibitor of the reverse reaction motivated 
us to investigate the compatibility of this reaction with the Kinase GloTM assay that 
monitors ATP synthesis. (Figure 3.10 c) The commercial kit was adapted to a 96-well 
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plate format using total reaction volumes of 200 µL. Triplicate experiments were set-
up to test the activity of IP6K1 against DMSO and TNP, including two controls either 
lacking 5PP-InsP5 or enzyme. (Figure 3.10 d) After 30 min, the Kinase GloTM reagent 
was added directly to the wells, and luminescence intensity was analyzed using a gel 
imager.  
 
Figure 3.10: ATP synthase reactions of IP6K1 analyzed by NMR and ATP kinase 
GloTM assay. Formation of a) [13C6]InsP6 and b) ATP analyzed by NMR. c) ATP 
detection by commercially available Kinase GloTM assay. d) Quantification of 
luminescence obtained from Kinase GloTM assay corrected to the average of no IP6K1 
and no 5PP-InsP5 controls and normalized to average of kinase reaction with DMSO 
added. 
 
As for the NMR experiment, we observed robust kinase reactivity in the positive control 
and strongly reduced activity for the samples containing the inhibitor. The reduction in 
kinase activity by TNP was in line with the NMR experiments. Both negative controls 
showed no reaction and only background signal from the already yellowish Kinase 
GloTM assay solution. Notably, the error between replicates is quite small compared to 
the differences found in these samples.  
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All in all, these preliminary experiments paved the way for the optimization and 
setup of a high-throughput-screening assay to find specific inhibitors against IP6K1 
using the ATP synthase reaction. Previously, a comparable assay would not have been 
a valid option because the high amounts of 5PP-InsPs required for large screen where 
inaccessible by organic synthesis. However, together with the newly developed 
enzymatic synthesis described earlier in chapter 2, this screen became feasible and is 
currently pursued by a postdoc and a PhD student in our lab. 
 
Biochemical Characterization of VIH2 and ITPK1 from Arabidopsis Thaliana4 
The in vitro characterization of IP6K1 showed great potential to be expanded 
towards other PP-InsP metabolizing enzymes. Therefore, we sought to apply our new 
NMR approach to investigate PP-InsP metabolism in A. thaliana, in collaboration with 
the Hothorn (University of Geneva) and Schaaf groups (University of Bonn). In plants, 
the biosynthesis of PP-InsPs as well as their biological function remains an 
understudied field compared to yeast and mammalian cells. So far, only a kinase called 
VIH2 was demonstrated to have PPIP5K-like behavior using a genetic model in 
yeast.32,33 The IP6K family enzymes were completely unknown. Consequently, only a 
few phenotypes had been recognized in plants that intersect with PP-InsPs. For 
examples, it had been shown that jasmonate specifically increased 1,5(PP)2-InsP4 
pools and that these changes were dependent on VIH2.33 These experiments indicated 
that this kinase is involved in jasmonate perception and plant defenses against 
herbivorous insects and necrotrophic fungi. Another intriguing observation in A. 
thaliana was the role of PP-InsPs in phosphate (Pi) homeostasis.21 PP-InsPs strongly 
                                                            
4 Biochemical characterization of full length Vip1 was performed by R- Puschmann. 
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interact with SPX domains. These evolutionary conserved elements are either stand-
alone proteins or located in proteins that support Pi uptake, storage and signaling.21,34–
42 In plants, the Pi starvation response (PHR) transcription factor binds SPX protein in 
a PP-InsPs dependent fashion.43–46 (Figure 3.11) During low Pi availability PHR 
attaches to the DNA and mediates the expression of Pi starvation-induced genes. 
During high Pi supply, the PP-InsP levels are elevated compared to low Pi availability. 
Thereby, the formation of the PHR-SPX complex is promoted and PHR dissociates 
from its target promoter. While these studies indicated a vital role of PP-InsPs in Pi 
homeostasis in A. thaliana, it remained unclear how Pi availability was sensed and 
communicated within these cells. To get more insight in the underlying mechanisms a 
thorough biochemical characterization of PP-InsPs metabolizing enzymes is highly 
needed.  
 
Figure 3.11: Regulation of PHR by SPX protein and PP-InsPs.  
 
In recent attempt to understand Pi starvation response in plants, the Hothorn 
group found that VIH2 knockout plants responded sensitively to external Pi levels and 
suspected a major switch for Pi starvation response in this enzymes. To better 
understand how this enzyme senses levels of Pi, VIH2 was characterized 
biochemically. Like all PPIP5K enzymes, VIH2 contained a phosphatase domain and 
a kinase domain that was expected to be catalytically active on PP-InsPs. We focused 
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on the kinase domain (VIH2KD) and identified substrates and reaction products by NMR 
spectroscopy. (Figure 3.12)  
 
Figure 3.12: Biochemical characterization of VIH2KD using [13C6]InsP6 and [13C6]5PP-
InsP5. a) Time-resolved analysis of [13C6]InsP6 consumption and [13C6]1PP-InsP5 
synthesis. b) 1H,13C-HMQC analysis of reaction product from VIHKD with [13C6]InsP6 as 
substrate and comparison to reaction product from PPIP5K2KD with [13C6]InsP6 as 
substrate. c) 1H,31P-HMBC analysis of reaction product from VIHKD with [13C6]InsP6 as 
substrate. d) Time-resolved analysis of [13C6]5PP-InsP5 consumption and 
[13C6]1,5(PP)2-InsP4 synthesis. e) 1H,13C-HMQC analysis of reaction product from 
VIHKD with [13C6]5PP-InsP5 as substrate and comparison to reaction product from 
PPIP5K2KD with [13C6] 5PP-InsP5 as substrate. f) 1H,31P-HMBC analysis of reaction 
product from VIHKD with [13C6]5PP-InsP5 as substrate. 
 
Continuous reaction monitoring was performed and estimated the initial rates 
by fitting data points within 20% conversion. A 4.9-fold higher activity for [13C6]5PP-
InsP5 (21.1 nmol min-1 mg-1) compared to [13C6]InsP6 (4.3 nmol min-1 mg-1) was found. 
(Figure 3.12 a, d) Next, the identity of the reaction products was elucidated by 
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comparison to an analogous, well-characterized reaction with PPIP5K2KD, as no 
purified standards were available at this time. Additionally, the position of the 
pyrophosphate was verified by 1H,31P-HMBC. (Figure 3.12 b,c,e,f) The 1H,13C-HSQC 
spectra of PPIP5K2 and VIH2KD samples showed good overlap between the reaction 
products. The pyrophosphate could be localized at the 1- or 3-position. Notably, no 
further products were observed in theses reactions even after long incubations of more 
than 10 h. All in all, these experiments confirm that VIH2 belongs indeed to the PPIP5K 
family. 
After completion of the analysis of the VIH2 kinase activity, the Hothorn group 
wanted to further investigated the influence of Pi levels on the activity of VIH2 full length 
proteins including the phosphatase domain. Unfortunately, they were unable to purify 
active protein and therefore all of the experiments were performed using the yeast 
homolog Vip1 (full length) as a mimic. In brief, we could show that high Pi availability 
led to an increase of [13C6]1PP-InsP5 and [13C6]1,5(PP)2-InsP4 and a significant 
decrease of [13C6]5PP-InsP5 compared to samples without Pi. Especially 1,5(PP)2-
InsP4 is expected to bind strongly to SPX domain containing proteins leading to a 
downregulation of the Pi starvation response. These results corroborated the 
hypothesis that VIH2 activity was regulated in response to Pi availability. 
 At this point, all phenotypes associated with PP-InsPs in plants were explained 
by the regulation of VIH2. On the other hand, phenotypes associated with IP6K family 
enzymes were completely unknown because no IP6K-like activity had been 
discovered. In an effort to identify this missing kinase, the Schaaf group examined the 
sequence homology of different InsP kinases and found an analog of human ITPK1, 
an InsP3 kinase, that could effectively convert InsP6 and 1PP-InsP5 into 5PP-InsP5 and 
1,5(PP)2-InsP4, respectively. Using our approach we enabled the determination of the 
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Vmax (106,1 ± 3.7 nmol · min-1 · mg-1) and the KM (965.5 ± 107.4 µM) for ATP for this 
enzyme called now AtITPK1. (Figure 3.13) At this time, no [13C6]1PP-InsP5 was 
available and only the reaction with [13C6]InsP6 as substrate was characterized. As 
expected for enzymes of the IP6K family, the KM was remarkably high indicative of a 
strong dependence of the enzyme activity on cellular ATP levels. Unlike IP6K1, we 
found no substrate inhibition at high ATP concentrations for AtITPK1.  
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Figure 3.13: Determination of KM for ATP and Vmax for InsP6. Initial rates (v) plotted 
against multiple ATP concentrations in triplicate. 
 
All In all, the robust and straightforward analysis of PP-InsP metabolizing 
enzymes by NMR spectroscopy allowed us to produce qualitative and quantitative data 
with low experimental error and high confidence. Especially, the discrimination 
between the different PP-InsP5 isomers in complex samples was useful to aid the 
identification of the Pi starvation response in plants and to confirm the identity of VIH2 
as PPIP5K class enzyme. 
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 Ex Vivo Analysis of Metabolically Labeled Eukaryotic Cells 
Metabolic Labeling of Mammalian Cells5 
In the previous sections we showed that 13C-labeled PP-InsPs are useful tools 
to study and monitor kinase activity of PPIP5Ks and IP6Ks in vitro by NMR 
spectroscopy without the need for isolation of PP-InsPs. Encouraged by these results, 
we decided to apply our NMR analysis to much more complex samples. As explained 
in chapter 1, metabolic labeling of yeast and mammalian cells by 3H-inositol is one of 
the most widely used methods to assay cellular InsP and PP-InsP ratios until today. 
Considering our access to [13C6]myo-inositol, we envisioned an analogous method that 
analyzes full cell extracts by NMR spectroscopy and tested the metabolic labeling of 
the human colon cancer cell line HCT116. (Figure 3.14 a) HCT116 cells were grown 
in the presence of 100 µM [13C6]myo-inositol and subsequently lysed using 1 M HClO4. 
The extract was neutralized, lyophilized, dissolved in D2O, and a 1H,13C-HMQC 
spectrum was recorded. (Figure 3.14 b) 
                                                            
5 Metabolic labeling of HCT116 cells was performed by R. Puschmann and R. K. Harmel. Spike in experiments, 
TiO2 enrichments, and preliminary experiment for the identification of unknown NMR signals were performed 
by R. Puschmann. Calibration curves with Me4PBr were produced by R. Puschmann. 
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Figure 3.14: Metabolic labeling of mammalian cell line HCT116, followed by NMR 
analysis. (a) General workflow for the preparation of whole cell extracts for NMR 
spectroscopy. (b) Left: 1H,13C-HMQC spectrum of an HCT116 extract. The peaks from 
80 to 100 ppm in the F1 and between 0 and 3 ppm are folded into an empty region of 
the spectrum. Right: the inositol phosphate region of the spectrum is depicted in more 
detail. The identified InsPs are annotated while peaks that exhibit the expected splitting 
pattern in the carbon dimension but could not be attributed to either myo-inositol (Ins), 
InsP5, InsP6, nor 5PP-InsP5 are highlighted by red arrows. 
 
The spectrum displayed several strong peaks in the characteristic chemical shift region 
for InsPs and PP-InsPs (1H: 5.0–3.6 ppm; 13C: 81–71 ppm). At high spectral resolution 
a characteristic triplet pattern emerged due to the coupling of neighboring 13C nuclei in 
the myo-inositol ring. Comparison to an extract prepared with [12C6]myo-inositol 
confirmed that these peaks were a result of labeling with [13C6]myo-inositol (Figure 
3.15 a, b). To verify that the labeling success was not limited to HCT116 cells, we next 
treated human embryonic kidney cells (HEK293T) with [13C6]myo-inositol and 
observed robust labeling again. (Figure 3.15 c) 
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Figure 3.15: Metabolic labeling of HCT116 with [12C6]myo-inositol and HEK293T with 
[13C6]myo-inositol. a) Inositol phosphate region of the unlabeled HCT116 wt extract. b) 
Inositol phosphate regions of overlay between [13C6]myo-inositol-labeled (red) and 
unlabeled (black) HCT116 wt extracts. c) HEK293T cell extract. HEK293T cells were 
extracted with 1 M HClO4 and the soluble fraction was measured by NMR-
spectroscopy. The relevant InsP peaks are labeled and additional peaks displaying the 
triplet pattern are highlighted by red arrows.  
 
To annotate characteristic resonances for endogenous InsP5, InsP6 and 5PP-InsP5, we 
performed spike-in experiments with synthetic standards on the labeled extracts 
(Figure 3.16 a–c) and confirmed the presence of the above mentioned InsPs. We 
further added a mixture containing synthetic InsP5, InsP6 and 5PP-InsP5 to an 
unlabeled extract from HCT116 and detected all signals at their expected chemical 
shifts (Figure 3.16 d). 
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Figure 3.16: Spike in experiments to confirm the identity of InsP5, InsP6, and 5PP-
InsP5 in HCT116 extracts. a) Extract + InsP5. (10 µM final concentration). b) Extract + 
InsP6. (10 µM final concentration). c) Extract + 5PP-InsP5 (5 µM final concentration). 
d) spike in of PP-InsPs into unlabeled cell extract. 
 
For absolute quantification of InsP5, InsP6 and 5PP-InsP5, we prepared 
[13C6]myo-inositol labeled HCT116 extracts containing a known concentration of an 
internal standard (tetramethyl phosphonium bromide, PMe4Br). Resonances 
corresponding to the C2-position were integrated and referenced to a set of calibration 
curves (Figure 3.17 a). Assuming full replacement of the unlabeled InsP pools, we 
calculated respective concentrations of 26.7 ± 2.3 µM InsP5, 29.4 ± 7.6 µM InsP6, and 
1.9 ± 0.5 µM PP-InsP5, based on packed cell volume (Figure 3.17 b; Table 3.1). The 
measured concentrations are consistent with previous publications with respect to 
InsP5 and InsP6, however, the amount of 5PP-InsP5 determined by NMR is at least 2-
fold higher.16,47 These results underline the mild sample preparation and the 
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quantitative nature of NMR spectroscopy and highlight its potential for future 
measurements of labeled cells or tissues. 
 
Figure 3.17: Quantification of PP-InsP pools in HCT116 wt. a) Calibration curves for 
InsP C2 peak intensities normalized to the reference standard PMe4Br. Changes in 
5PP-InsP5 levels can be observed by NMR spectroscopy. b) 1H,13C-HMQC spectrum 
of a HCT116 wild type cell extract for quantitative analysis. 
 
Table 3.1: Absolute quantification of InsP5, InsP6, and 5PP-InsP5 in different cell lines. 
Cell line Condition Cellular Concentration (µM)(a) 
 
InsP5 InsP6 5PP-InsP5 
HCT116 wt no treatment 26.7 ± 2.3 29.4 ± 7.6 1.9 ± 0.5 
 10 mM NaF(b) 18.6 ± 0.7 11.0 ± 0.9 14.7 ± 2.0 
PPIP5K-/- no treatment 19.4 ± 6.1 33.7 ± 7.8 5.1 ± 2.3 
 10 mM NaF(b) 11.2 ± 1.0 9.3 ± 0.7 23.8 ± 3.1 
(a) The C2 peak was used for quantification. The concentration in the NMR sample was calculated based on PMe4Br as an 
internal standard and the cellular concentration was calculated based on the packed cell volume. 
(b) Cells were treated with 10 mM NaF 1 hour before extraction. Packed cell volume was based on untreated sample. 
 
The ability to quantify mixtures of InsP messengers prompted us to analyze the 
concentrations of InsP5, InsP6 and 5PP-InsP5 in HCT116 cells with perturbed PP-InsP 
metabolism. When HCT116 cells were treated for one hour with 10 mM sodium fluoride 
(NaF), an agent previously shown to elevate 5PP-InsP5 levels,48 the content of 5PP-
InsP5 increased dramatically to an absolute concentration of 14.7 ± 2.0 µM (Figure 
3.18 a; Table 3.1). Elevated concentrations of 5PP-InsP5 were also reported in cells 
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lacking PPIP5K1 and PPIP5K2.49 We therefore grew PPIP5K-/- cells and indeed, a 
general increase of 5PP-InsP5 was detected compared to HCT116 wt cells (Figure 
3.18 b, Table 3.1). Addition of NaF to this knock-out cell line resulted in extracts which 
contained more 5PP-InsP5 than InsP6 or InsP5 (Figure 3.18 c, Table 3.1). These trends 
of increasing 5PP-InsP5 concentrations had been observed before and the ratio of 
5PP-InsP5 to InsP6 in all our samples was consistent with previous publications.49  
 
 
 
Figure 3.18: Changes in 5PP-InsP5 levels can be observed by NMR spectroscopy. a) 
1H,13C-HMQC spectrum of an extract of HCT116 wt cells treated with 10 mM NaF 
before extraction. b) 1H,13C-HMQC spectrum of HCT116 PPIP5K-/- cell extract. c) 
1H,13C-HMQC spectrum of an extract of HCT116 PPIP5K-/- cells treated with 10 mM 
NaF before extraction. The inserts display triplicates of absolute cellular concentration 
of InsP5, InsP6 and 5PP-InsP5 based on packed cell volume. 
 
To our surprise, the analysis of the mammalian extracts uncovered additional 
NMR signals that displayed a triplet-pattern in the carbon-dimension. These signals 
were absent in the corresponding samples prepared with unlabeled myo-inositol and 
must therefore stem from metabolic labeling with [13C6]myo-inositol (Figure 3.14 b, 
Figure 3.15 a). Interestingly, several of these signals increased upon NaF treatment 
(Figure 3.18 a). To determine whether these signals correspond to other InsP or PP-
InsP species, the 13C-labeled, NaF treated HCT116 wt extract was incubated with TiO2 
beads, which enrich phosphate containing molecules.6,50 In addition to retaining InsP5, 
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InsP6 and 5PP-InsP5, a putative asymmetrical InsP species (InsP1 or InsP2) could be 
observed (Figure 3.19).  
 
Figure 3.19: Overlay of TiO2 enrichment of NaF treated, 13C-labeled HCT116 wt cell 
extract (red) and the original NaF treated, 13C-labeled HCT116 wt cell extract (black). 
One set of 6 peaks (green circles) was retained that corresponds to a putative 
unsymmetrical InsP1 or InsP2 species. All other labeled unassigned peaks were 
removed.  
 
Nevertheless, most unassigned labeled resonances were not bound by the TiO2 
beads. To test for conversion of myo-inositol to related metabolites, spectra of D-chiro-
inositol, scyllo-inositol and glucuronic acid were recorded (Figure 3.20 a–c), none of 
which were superimposable with our unassigned labeled species.51,52 Lastly, we 
considered that the additional peaks corresponded to PtdInsPs. However, after a 
phospholipid extraction, the aqueous layer still contained the unidentified resonances, 
strongly implying a non-lipid, hydrophilic character of these molecules (Figure 3.20 a–
d). These observations suggest that the supplemented [13C6]myo-inositol has been 
diverted into an unknown metabolic pathway. Detection of these unanticipated species 
was only possible because the NMR-analysis was conducted on the crude extract and 
did not require a separation step. Elucidating the structure and function of these 
molecules connected to inositol metabolism will be of interest in the future.  
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Figure 3.20: Preliminary analysis of unannotated NMR signals. HMQC spectrum of 
1 mM a) scyllo-inositol, b) D-chiro-inositol, and c) glucuronic acid (highlighted with red 
arrows) in KClO4 saturated D2O. 1 mM myo-inositol was included as an internal 
reference (black arrows). d) Lipid extraction of HCT116 wt retained all unassigned 
peaks except for the putative unsymmetrical InsP1 or InsP2 species. 
 
Metabolic Labeling of D. Discoideum 
After we established the metabolic labeling with [13C6]myo-inositol in 
mammalian cells, we started to expand our method towards the model organism D. 
discoideum, together with A. Saiardi and coworkers (UCL). This social amoeba marks 
an evolutionary transition between unicellular and multicellular organisms and has 
been applied as a model to study the transition from uniform to differentiated cells.53,54 
Interestingly, D. discoideum was the first organism in which PP-InsPs were identified, 
and were subsequently shown to play a role in chemotaxis.2,55 Opposed to mammalian 
cells and yeast, the main PP-InsP species were characterized as 6PP-InsP5 and 
5,6(PP)2-InsP4 and were present at a much higher concentration of 60 µM and 180 µM 
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respectively.7,8,56 Retrospectively, the presence of another set of regioisomers was 
confounding because the kinases that form the pyrophosphate moieties show a high 
sequence homology between D. discoideum and H. sapiens. Therefore, the Saiardi 
group wanted to revisit these findings and hypothesized that either the isomers were 
incorrectly assigned or that the enzymology differs to other eukaryotic cells.  
To this end, wild type D. discoideum and genetically modified stains (ppip5k null 
and ip6k/ppip5k null amoeba) were labeled with [13C6]myo-inositol and unpurified 
acidic extracts from wild type samples were measured. The 1H,13C-HSQC spectrum 
showed four intense signals between 3.4 and 4.2 ppm and four signals between 4.2 
and 5.2 ppm, corresponding to myo-inositol and InsP6, respectively.(Figure 3.21 a)  
 
Figure 3.21: 1H,13C-HSQC spectra of extracts from metabolically labeled D. 
discoideum. a) High abundant species: InsP6 and myo-inositol. b) Lower abundant 13C-
labeled compounds circled in red. 
 
In contrast to mammalian extracts, InsP6 was present at a higher concentration than 
myo-inositol in these samples and there was no indication of an InsP5 species. Upon 
increasing the counter levels, lower abundant 13C-labeled species became visible, 
which we suspected to be PP-InsPs. (Figure 3.21 b) Unfortunately, the potentially 
different isomeric PP-InsP forms and the high sample complexity, made a clear 
analysis difficult. To deconvolute the sample, the Saiardi group provided extracts that 
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were resolved by PAGE and purified by TiO2 beads. Individual gel bands were cut, 
extracted and analyzed by NMR spectroscopy. (Figure 3.22 a) In the wild type, four 
different InsP- or PP-InsP species were observed (column 1−4). The InsP5 species 
showed 6 resonances and did not match the synthetically prepared (1,3,4,5,6)-InsP5 
which was mostly found in mammalian cells. (Figure 3.22 b) The chemical shift of the 
resonance corresponding to the unphosphorylated position suggested that the free 
OH-group is most likely located at the 1- or 3-position. HSQC-COSY experiments 
confirmed this proposal, as strong cross peaks with the 4/6-position were displayed. 
(Figure 3.22 c)  
 
Figure 3.22: 1H,13C-HSQC NMR analysis of TiO2/gel-purified bands from wild type D. 
discoideum. a) PAGE analysis of individual bands from wild type, ppip5k null and 
ip6k/ppip5k null amoeba b) black: column 1, InsP5; red: synthetic (1,3,4,5,6)InsP5 
standard. c) black: column 1, InsP5; red: 1H,13C-HSQC-COSY of InsP5; green: cross 
correlation between 4/6- and putative 1/3-positions. d) black: column 2, InsP6 species; 
red: synthetic InsP6 standard e) black: column 3, 6PP-InsP5; red: synthetic 5PP-InsP5 
standard; green: synthetic 1PP-InsP5 standard. f) black: column 4, 5,6(PP)2-InsP4; red: 
synthetic 1,5(PP)2-InsP4 standard. 
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The InsP6 of wild type amoeba nearly matched the human InsP6. (Figure 3.22 d). 
Spectral differences especially visible at the 2-position were probably due to different 
ionic strength of the samples. No evidence of PP-InsPs like PP-InsP4 was found. In 
agreement with previous reports we found 6PP-InsP5 and 5,6(PP)2-InsP4. (Figure 3.22 
e−g) Compared to the mammalian PP-InsPs we saw a splitting of the 4/6-positions 
rather than of the 1/3-positions as exemplified for 5,6(PP)2-InsP4. For 6PP-InsP5 we 
observed 5 signals which did not match the spectra of 5PP-InsP5 which typically have 
only 4 signals.  
After the identification of the different InsP and PP-InsP species in the wild type, 
we further investigated the ppip5k null and the ip6k/ppip5k null amoeba. Surprisingly, 
NMR analysis of the PP-InsPs in the ppip5k knockout showed no difference as 
compared to the wild type but a higher concentration of PP-InsP overall, which could 
also be observed via PAGE analysis. (Figure 3.22 a, column 5–7) The presence of 
5,6(PP)2-InsP4 in the ppip5k null amoeba suggested that Ppip5k is either not the main 
PPIP5K species in D. discoideum, or a complementary biosynthetic pathway exists. 
As explained already for VIH2 of A. thaliana Ppip5k is expected to have a kinase and 
a phosphatase domain. Apparently, the main effect observed from the absence of 
Ppip5k was the depletion of the phosphatase domain that could no longer 
dephosphorylate PP-InsPs, thereby raising PP-InsP levels in general. Compared to 
the knockout of Ppip5k, the change in PP-InsPs in the ip6k/ppip5k null amoeba was 
rather dramatic. These samples showed barely detectable amounts of PP-InsPs and 
mainly InsP6 and several InsP5 species as shown in the PAGE analysis. (Figure 3.22 
a, column 8, 9) An NMR analysis of the InsP5 species in a mixture was performed, 
suggested the presence of four different InsP species which could be derived from the 
observation of 4 peaks for the 2-position in this sample. (Figure 3.23 a)  
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Figure 3.23: 1H,13C-HSQC NMR analysis of TiO2/gel-purified bands from ppip5k-ip6k 
null D. discoideum. a) column 9; mixture of InsP6 and InsP5 species. b) black: column 
9, mixture of InsP6; red: column 1, wild type InsP5. c) black: column 9, mixture of InsP6 
and InsP5 species; red: synthetic (1,3,4,5,6)InsP5 standard. d) black: column 9, mixture 
of InsP6 and InsP5 species; red: 1H,13C-HSQC-COSY of mixture of InsP6 and InsP5 
species; green: cross correlation between 4/6- and putative 5-position. 
 
In line with the PAGE analysis we saw InsP6 in these samples and probably 3 different 
InsP5 species. As observed previously for the wild type, we presumed one of the 
asymmetric species to be (2,3,4,5,6)InsP5 or (1,2,4,5,6)InsP5. (Figure 3.23 b) 
Furthermore, we suggest the presence of (1,3,4,5,6)InsP5 by comparison to our 
synthetically prepared standard. (Figure 3.23 c) Finally, we performed HSQC-COSY 
analysis on this sample and identified an additional signal at 3.8 ppm that coupled to 
the 4/6 positions and that did not belong to any of the other species. (Figure 3.23 d) 
Since unphosphorylated 1/3-positions carbons tend to appear at a lower chemical shift 
in the carbon dimension, this resonance might be an unphosphorylated 5-position 
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hinting towards the presence of (1,2,3,4,6)InsP5 in the sample. The analysis of the 
mixture should only be recognized as preliminary because the strong overlap between 
the resonances of different InsP species in the 1H,13C-HSQC made a thorough and 
fully conclusive analysis difficult. However, the presence of these 3 different InsP5 
species was surprising and warrants further investigation. 
The analysis of [13C6]myo-inositol labeled D.discoideum samples that were 
purified with TiO2 and SDS PAGE provided a good method to structurally analyze PP-
InsPs. It was confirmed that this slime mold can produce different InsP5 species 
compared to mammalian cells and that the presence of the PP-InsPs is not affected 
by knockout of Ppip5k but only in combination with an Ip6k deletion. These 
observations suggest substantially altered biosynthetic pathways for PP-InsPs 
compared to other eukaryotic organisms.  
 
Conclusions and Outlook 
 Inositol-containing molecules are ubiquitous in nature. Yet, their detection and 
quantification has proven to pose a formidable challenge, as these molecules typically 
lack a handle that would facilitate their analysis. Therefore, researchers in the field rely 
strongly on separation techniques and radioactive tools to answer the biological 
questions surrounding these metabolites.57 We now provide a new set of methods, 
which emanate from access to benign 13C-labeled compounds, in combination with 
commonly accessible NMR technology. This approach has enabled the detection and 
quantification of InsPs and PP-InsPs within complex mixtures including cell extracts 
and minimized sample purification. Specifically, the 13C-labeled compounds could be 
employed to biochemically characterize the enzymatic activity of kinases of the IP6K 
and the PPIP5K family from H. sapiens and A. thaliana. In the case of IP6K1, we 
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investigated forward and reversed enzyme activity in response to inhibitors and 
established the foundation for the development of a new bioluminescent high-
throughput-screening assay. In plants, we determined kinetic parameters for AtITPK1 
and VIH2 and enabled the identification of VIH2 in combination with PP-InsP as a 
possible sensor of phosphate availability. In addition, the non-toxic nature of [13C6]myo-
inositol allowed for metabolic labeling of mammalian cells and D. discoideum, followed 
by detection of the generated InsP and PP-InsP species. Furthermore, the structural 
information gained by the NMR analysis ensured reliable assignment of the identity of 
the detected InsP species but revealed previously unknown small molecules.   
 In the future, the facile applicability of this method will allow for the interrogation 
of new, or more complex, biological questions. On the biochemical side, for example, 
further characterization of kinase like human PPIP5Ks could aid the validation and 
identification of inhibitors as we have done for IP6Ks. The characterization of InsP- and 
PP-InsP phosphatases will benefit greatly from the structural information provided by 
the NMR measurements, and the substrate specificity of these enzymes can be 
unequivocally determined. Additionally, new enzymes that have been, or will be, found 
to metabolize InsPs can be characterized more easily, and the reaction products can 
be assigned with certainty.   
 We also envision to an important application for the labeled InsPs and PP-InsPs 
to gain better structural insights into their interactions with proteins. To date, the only a 
few canonical binding domains are known for the highly phosphorylated inositols, but 
many other proteins physically interact with these metabolites.58 Instead of isotopically 
labeling these proteins to investigate their ligand-binding via NMR, applying a labeled 
ligand can have advantages. For example, using a 13C-labeled mannose trisaccharide 
has recently informed the binding mode between the sugar and its protein binding 
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domain.59 By analogy, the 13C-labeled compounds reported here could help to obtain 
structural information on the conformation and the biochemical environment of the InsP 
ligands.  
 Closely related to InsP messengers are the lipid-anchored phosphatidyl inositols 
(PtdInsPs), which are crucial in signaling and occupy a pivotal role in health and 
disease.60 Following the procedure established here for metabolic labeling, but 
isolating and analyzing the membrane fractions instead, may provide important 
information on this group of messengers. Considering that the PtdInsPs and InsPs are 
metabolically linked, concomitant analysis of both groups of molecules could uncover 
unprecedented information on the coordination of these two messenger networks. 
While NMR suffers from an innate low sensitivity, advances using hyperpolarization 
methods in recent years have greatly enhanced the signal of 13C nuclei and could help 
to increase the sensitivity of our method in order to reliably detect inositol phosphates 
of low abundance, such as 1PP-InsP5 and 1,5(PP)2-InsP4, or PtdInsPs via NMR.61,62 
Overall, [13C6]InsPs will expand the analytical tool box to interrogate inositol based 
messengers and their role and regulation at a biochemical and cellular level. 
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Methods 
General Information 
Please see method section of chapter 2. 
 
Recombinant Protein Expression 
Inositol Phosphate Synthase (IPS) 
The IPS-gene from A. fulgidus cloned into a pET23a vector (Prof. Helena 
Santos, Universidade Nova de Lisboa)63 was transformed into E. coli BL21(DE3). Two 
0.8 liter overnight cultures (37 °C) in TB supplemented with Ampicillin were each 
diluted with 400 mL TB, prewarmed to 37 °C. After 30 min the expression was induced 
with 0.25 mM IPTG. After 4 hours the cells were harvested by centrifugation (3,000 g 
for 10 min at 4 °C) and washed with ice cold water. The pellet was stored at –80 °C 
until further use. The frozen cells were resuspended in lysis buffer (50 mM Tris HCl pH 
8, 250 mM NaCl). For 1 g cell pellet wet weight, 5 mL lysis buffer was used. The cell 
suspension was supplemented with lysozyme and DNase I, and incubated for 15 min 
on ice. The cells were lysed with a Microfluidizer™ LM10 at 15,000 psi with five 
iterations. The lysate was clarified by centrifugation (30,000 g for 30 min at 4 °C). The 
supernatant was incubated for 30 min at 80 °C and the precipitate was removed by 
centrifugation (30,000 g for 30 min at 4 °C). The volume of the heat-treated supernatant 
was reduced to 22 mL with spin filtration (Amicon® Ultra 15 mL 10K) and the solution 
was dialyzed against lysis buffer overnight. The protein solution was adjusted to 33 % 
(v/v) glycerol, aliquoted, frozen in liquid nitrogen, and stored at –80 °C. 
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Inositol Hexakisphosphate Kinase 1 (IP6K1) 
The procedure is adapted from.64 In short: The codon optimized human IP6K1-
gene was subcloned via LIC into a in a pET-MBP vector and transformed into E. coli 
arctic express (DE3). An 800 mL expression culture (37 °C) was inoculated at OD600 
0.1 in TB-Amp/Gen and grown for 4 h. The culture was switched to 15 °C for 30 min 
the expression was induced with 0.1 mM IPTG. The Expression occurred overnight. 
The cells were harvested by centrifugation (3,000 g for 10 min at 4 °C) and washed 
with ice cold water. The pellet was stored at –80 °C until further use. The frozen cells 
were resuspended in lysis buffer (20 mM Tris HCl pH 7.4, 150 mM NaCl). For 1 g wet 
weight 10 mL lysis buffer was used. The cell suspension was supplemented with 
lysozyme, DNase I and 1 tablet cOmpleteTM protease inhibitor (Roche), and incubated 
for 15 min on ice. The cells were lysed with a Microfluidizer™ LM10 at 15,000 psi with 
five iterations. The lysate was clarified by centrifugation (30,000 g for 30 min at 4 °C). 
The supernatant was adjusted to 0.1 % (v/v) Triton X-100, filtered (VWR® vacuum 
filter, PES 0.45 µm), and loaded onto a Co-NTA column (GE, 1 mL, HiTrap IMAC HP) 
that was equilibrated with lysis buffer with a flowrate of 1 mL/min. The column was 
washed with wash buffer (20 mM Tris HCl pH 7.4, 500 mM NaCl, 50 mM imidazole, 
0.1 % (v/v) Triton X-100) until the absorption was constant. IP6K1 was eluted with a 
gradient of elution buffer (20 mM Tris HCl pH 7.4, 500 mM NaCl, 500 mM imidazole, 
0.1 % (v/v) Triton X-100) in wash buffer from 0–100 % over 10 CV. 1 mL fractions were 
collected. The fractions containing IP6K1 were concentrated and dialyzed overnight 
against dialysis buffer (20 mM Tris HCl pH 7.4, 500 mM NaCl, 1 mM DTT). The protein 
was adjusted to 20 % (v/v) glycerol and stored at –80 °C. 
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NMR experiments 
Progress Curve Measurements with IP6KA 
Progress curves were recorded for different IP6KA concentrations ranging from 
0.2–1 µM. The reactions contained 20 mM HEPES NaOD pH* 7.0, 50 mM NaCl, 1 mM 
DTT, 10 mM ATP, 11 mM MgCl2, 176 µM [13C6]InsP6Na12 (6), 5 mM creatine 
phosphate, 2 mM Me4PBr, and 1 U/mL creatine kinase in D2O. All stock solutions were 
prepared in D2O. The reactions were run in a total volume of 650 µl and equilibrated 
at 37 °C. The reactions were transferred into a 5 mm NMR tube and the reaction was 
started by the addition of the appropriate amount of IP6KA (in D2O buffer). The NMR 
tubes were inserted into the NMR instrument, locked, tuned and matched, and 
shimmed.  A spin echo difference pulse was used to measure consecutively 75 sec 
spectra until the reaction was finished. 
 
Kinetic Characterization of IP6K1 
The KM,ATP and Vmax were determined for IP6K1. The buffer contained 20 mM 
HEPES NaOD pH* 7.0, 50 mM NaCl, 1 mM DTT, 1 mg/mL BSA, 1 µM IP6K1, 5 mM 
creatine phosphate, and 1 U/mL creatine kinase in D2O. The ATP concentration ranged 
from 8 mM to 62.5 µM (two-fold dilution series) and the MgCl2 concentration was 
adjusted to be 5 mM plus the ATP concentration. The reaction volume was 500 µL and 
the reaction was started after 10 min equilibration at 37 °C by the addition of 175 µM 
[13C6]InsP6. The reaction was quenched with 38 µL 0.7 M EDTA (in D2O, pH* 8.0) after 
approximately 20 % conversion (5 min for IP6K1). Before the NMR measurements the 
pH* was adjusted to 8, if needed. The conversion of [13C6]InsP6 at different ATP 
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concentration was determined by NMR spectroscopy. The data was fitted against a 
kinetic model for substrate inhibition: 𝑣 = 𝑉𝑚𝑎𝑥
1+𝐾𝑚𝑆 +
𝑆
𝐾𝑖
 using SigmaPlot 12.5. 
 
Determination of IC50 Values for IP6K1 Inhibitors 
For the IC50 value determination a two-fold dilution series of the appropriate 
inhibitor in DMSO-d6 was used. The reactions were run in a total volume of 500 µL and 
contained 20 mM HEPES NaOD pH* 7.0, 50 mM NaCl, 1 mM DTT, 2.5 mM ATP, 
7.5 mM MgCl2, 0.2 µM IP6K1, 1 mg/mL BSA, 5 mM creatine phosphate, and 1 U/mL 
creatine kinase in D2O. The inhibitor concentration ranged from 50 µM to 195 nM (200 
x stock solutions were used). The reactions were equilibrated to 37 °C for 10 min and 
initiated by the addition of 175 µM [13C6]InsP6. The reactions were quenched after 3 
hours by the addition of 38 µL of 0.7 M EDTA (in D2O, pH* 8.0). Before the NMR 
measurements the pH* was adjusted to 8, if needed. The conversion of [13C6]InsP6 at 
different inhibitor concentrations was determined by NMR spectroscopy. The data was 
fitted against a kinetic model for dose response inhibition: 𝑣 = 𝑏𝑜𝑡𝑡𝑜𝑚+(𝑡𝑜𝑝−𝑏𝑜𝑡𝑡𝑜𝑚)
1+
𝑥
𝐼𝐶50
𝐻𝑖𝑙𝑙𝑠𝑙𝑜𝑝𝑒  using 
SigmaPlot 12.5. 
 
Metabolic Labeling of Mammalian Cell Lines  
HCT116 wt, HCT116 PPIP5K-/- (a kind gift from Stephen Shears)49 and 
HEK293T cells were grown in DMEM lacking myo-inositol and supplemented with 10 
% dialyzed fetal bovine serum, 100 µM either [12C6]- or [13C6]myo-inositol, and 
Penicillin/Streptomycin at 37 °C and 5 % CO2. 1 liter DMEM w/o inositol was prepared 
from pre-mixed medium components (8.1 g, Dulbecco), NaHCO3 (3.7 g), HEPES (10 
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mL of a 1 M stock, pH 7.4), L-glutamine (584 mg), L-serine (42 mg), D-glucose (4.5 g), 
and NaH2PO4 (125 mg). The cells were grown in 15 cm dishes (for one experiment we 
used five to ten plates) until they reached 80–90 % confluency. For harvesting, cells 
were washed with PBS and 0.9 % NaCl solution, and trypsinized. The trypsin was 
quenched with regular DMEM. The cells were collected and washed two more times 
with PBS before lysis and extraction. The packed cell volume and the cell number of 
the preparations were determined. If needed, the cells were incubated with 10 mM NaF 
for one hour before harvest. 
 
Inositol Phosphate Extraction 
All steps were performed at 4 °C. The protocol was adapted from Azevedo et 
al.65 For HCT116 wt we used ten 15 cm dishes and for HCT116 wt with NaF treatment, 
HCT116 PPIP5K-/- and HCT116 PPIP5K-/- with NaF treatment we used three 15 cm 
dishes. Cell pellets were lysed with 5 mL of 1 M HClO4, containing 3 mM EDTA, by 
vortexing. The lysate was incubated on ice for 30 min before the precipitate was 
removed by centrifugation. The supernatant was neutralized with 2 M KOH, containing 
3 mM EDTA, and the pH was adjusted to 5.8–6. The resulting KClO4 precipitate was 
removed by centrifugation and the supernatant was lyophilized. After lyophilization the 
supernatant was redissolved in 1 mL D2O and the resulting precipitate was removed 
by centrifugation. The supernatant was lyophilized again and the residue was 
redissolved in 600 µL D2O containing the 50–150 µM Me4PBr standard for absolute 
quantification. 
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TiO2 Enrichment 
All steps were performed at 4 °C. The protocol was adapted from Wilson et al.6 
TiO2 beads 4-5 mg were washed with 500 µL of water and 500 µL of 1 M HClO4. Cell 
extract was adjusted to pH 1 with 1 M HClO4 and added to the beads. The beads were 
rotated for 5 min and after centrifugation, the supernatant was discarded. The beads 
were washed twice with 500 µL of 1 M HClO4 and the InsPs were eluted by incubating 
the beads twice with 200 µL 2.8 % NH4OH solution. The eluate was lyophilized and 
the dry residue was dissolved in 600 µL of 1 mM MES (pH* 6.0) in D2O. 
 
Lipid Extraction 
The lipid extraction was adopted from Clark et al.66 In summary: The cells from 
3 15 cm dishes were trypsinized and washed twice with PBS. The cells were 
resuspended in 1.7 mL Milli-Q water and 7.5 ml quench mix (48.4 mL MeOH, 24.2 mL 
CHCl3, 2.4 mL 1 M HClO4) was added. The cells were lysed by vortexing for 30 sec. 
1.7 mL 1 M HClO4 and 7.25 mL CHCl3 were added to induce phase separation and the 
mixture was vortexed for 30 sec. The sample was centrifuged at 3000 g for 5 min to 
facilitate phase separation. The top aqueous layer was collected and washed with 7 
mL CHCl3. The aqueous layer was collected and neutralized with 2 M KOH containing 
3 mM EDTA. The KClO4 salt was removed by centrifugation and the sample was 
lyophilized. After lyophilization the supernatant was redissolved in 1 mL D2O and the 
resulting precipitate was removed by centrifugation. The supernatant was lyophilized 
again and the residue was redissolved in 600 µL D2O.  
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Synthesis of [13C6]myo-Inositol 
 
The following stock solutions were prepared: 
Hexokinase stock solution: 1000 U/mL in 50 mM citrate pH 7, 10 mM MgCl2, 1 mg/mL 
BSA. 
Creatine kinase stock solution: 350 U/mL in 200 mM MOPS pH 6.5, 20 mM MgCl2, 
20 mM DTT. 
Inositol phosphate synthase stock solution: 4 mg/mL in 20 mM Tris HCl pH 7.4, 
200 mM NaCl, 1 mM DTT. 
Alkaline phosphatase stock solution: 100 U/mL, 10 mM Tris pH 8.5, 5 mM MgCl2, 
0.2 mM ZnCl2, 50 % (v/v) glycerol. 
A solution containing D-[13C6]glucose (83 mM, 1000 mg, 5.4 mmol), MOPS (100 
mM, pH 6.5), creatine phosphate (87 mM), ATP (1 mM), DTT (20 mM) and MgCl2 (20 
mM) in MilliQ® water (65 mL total reaction volume) was prepared and evenly split (32.5 
mL each) into two 50 mL conical tubes. Hexokinase (1 U/mL) and creatine kinase (1.75 
U/mL) were added and the reaction incubated at 30 °C overnight. The resulting solution 
was monitored by TLC (MeOH:H2O:NH4OH:AcOH, 50:30:15:5; stained by KMnO4 or 
excessive heating) and upon completion diluted 5-fold with 320 mL of water. An anion-
99 
 
exchange column (DOWEX® 1X8) was equilibrated with 1 M NH4HCO3 and washed 
with water. The reaction mixture was loaded onto the column followed by washing with 
water to remove unreacted D-[13C6]glucose. [13C6]glucose-6-phosphate (11) was eluted 
by 0.1 M (NH4)2CO3 and lyophilized to obtain product 11 in combination with high 
amount of salts (4 g) as a white solid.  
The product/salt mixture was redissolved in 40 mL MilliQ® water and added to 
a solution of Tris (50 mM, pH 8.0), NAD+ (0.5 mM), NaCl (50 mM) and MgCl2 (2 mM) 
in MilliQ® (196 mL total reaction volume). The pH was adjusted to 8.0, if necessary, 
and the mixture was evenly split (49 mL each) into four 50 mL conical tubes. 
Recombinantly expressed inositol-3-phosphate synthase (IPS) (500 µL of 4 mg/mL 
stock) was added to each tube and the reaction mixture was incubated at 85 °C 
monitoring conversion by NMR. After 4 h, NAD+ (10 mg, 0.8 mM total) and IPS (500 
µL, 4 mg/mL) were added to each tube and the mixture was incubated for additional 4 
h at 85 °C. After full conversion of 11 into [13C6]myo-inositol-3-phosphate (12) was 
observed by 13C NMR the reaction mixture was directly used for the subsequent 
dephosphorylation reaction.  
For the dephosphorylation reaction, the 200 mL reaction mixture was split 
evenly across 5 conical tubes (40 mL each). For a total reaction volume of 50 mL, 
glycine (50 mM, pH 9.8) was added and the pH adjusted to 9.8. ZnCl2 (0.25 mM) and 
alkaline phosphatase (0.5 U/mL) were added and the solution was filled up to 50 mL 
with MilliQ® water. After incubation at 35 °C overnight, all tubes were combined (250 
mL total) and diluted with 300 mL MilliQ® water and the reaction mixture was applied 
to an ion exchange column (DOWEX® 1×8 in HCO3- form). The flow-through was 
collected and lyophilized to afford [13C6]myo-inositol with salts (7.5 g) as a brown solid 
which was directly used for the acetylation reaction. 
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[13C6]Inositol Hexakisacetate (13) 
The crude and unpurified [13C6]myo-inositol (7.5 g) was suspended in pyridine 
(161 mL) and treated with acetic anhydride (68.5 mL) at 120 °C overnight. The black 
solution was concentrated to minimize the amount of pyridine, re-dissolved in DCM 
(500 mL), and 1 M HCl was added. The resulting suspension was filtered and the filter 
washed with DCM and water. All filtrates were combined and organic and aqueous 
phase were separated. (Note: Phase separation is hard to see because of the black 
solution so use a flash light to find the separation layer.) The aqueous layer was 
extracted twice with DCM and the combined organic layers were washed with 1 M 
NaHCO3. The aqueous layer was washed twice with DCM and the combined organic 
layers were washed with brine, dried with Na2SO4 and concentrated under reduced 
pressure. The residue was immobilized on Telos® and purified by column 
chromatography on silica gel changing the eluent step wise (hexane:EtOAc, 10:1 → 
5:1 → 1:1 → 1:2) assisted by analysis of the fractions by LCMS to afford compound 
13 (1200 mg, 2.7 mmol) as a white solid in 50% overall yield from D-[13C6]glucose. 
1H NMR (600 MHz, CDCl3) δ 5.79 – 5.54 (m, 1.5H), 5.53 – 5.32 (m, 1.5H), 5.32 – 
5.12 (m, 1.5H), 5.11 – 4.82 (m, 1.5H), 2.20 (s, 3H), 2.01 (s, 3H), 2.01 (s, 6H), 2.00 (s, 
6H). 
13C NMR (151 MHz, CDCl3) δ 169.94, 169.81, 169.56, 71.68 – 70.65 (m), 70.11 – 
69.15 (m), 69.11 – 67.90 (m), 20.89, 20.69, 20.60. 
HRMS (ESI/Orbitrap) m/z: [M + K]+ calcd. for C1213C6H24KO12 477.1101; Found 
477.1091. 
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[13C6]myo-Inositol 
 To a solution of 13 (1200 mg, 2.7 mmol) in methanol (249 mL), 5.4 M NaOMe 
in MeOH (3.35 mL, 18.1 mmol) was added and the reaction was left to stir for 2 hours. 
The resulting suspension was neutralized by the addition of DOWEX 50W x 8 (H+ form) 
followed by filtration. The residue was washed with methanol (100 mL) and water (100 
mL) to dissolve all precipitated [13C6]myo-inositol and the filtrate was evaporated. The 
resulting solids were redissolved in H2O and precipitated by the addition of MeCN. 
Subsequently, the solids were redissolved in H2O and lyophilized to afford [13C6]myo-
inositol (505 mg, 2.7 mmol) as white solid in 99% yield. 
1H NMR (600 MHz, D2O, pD 7.0) δ 4.29 – 4.14 (m, 0.5H), 4.03 – 3.90 (m, 0.5H), 3.82 
– 3.60 (m, 2H), 3.59 – 3.34 (m, 2.5H), 3.25 – 3.12 (m, 0.5H). 
13C NMR (151 MHz, D2O, pD 7.0) δ 74.96 – 73.80 (m), 72.86 – 71.71 (m), 71.60 – 
70.50 (m). 
HRMS (ESI/Orbitrap) m/z: [M – H]– Calcd for 13C6H11O6 185.0762; Found 185.0814. 
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Synthesis of [13C6]InsP6  
 
 
Xylyl-protected [13C6]InsP6 (14) 
Xylyl-protected [13C6]InsP6 (14) was synthesized according to a modified 
procedure of Podeschwa and coworkers.17 Under nitrogen atmosphere a suspension 
of [13C6]myo-inositol (100 mg, 0.54 mmol) and Xy phosphoamidite (900 mg, 3.76 mmol) 
in dry DCM (38.65 mL) was prepared and sonicated for 1 min. 1H-tetrazole in 
anhydrous MeCN (14.33 mL, 6.45 mmol, 0.45 M) was added and the solution was 
stirred at rt overnight. For workup the solution was cooled to –40 °C and an anhydrous 
solution of mCPBA in DCM (30 mL dried with Na2SO4) was added. The solution was 
allowed to warm to rt, and the stirring was continued for another hour. The reaction 
mixture was diluted with DCM (300 mL) and washed consecutively with aqueous 
sodium bisulfite (20%, 2 × 50 mL), saturated NaHCO3 (3 × 100 mL), and then with 
brine. After evaporation of the solvents, the crude was immobilized on Telos® and 
purified by CombiFlash® chromatography on silica gel (12 g column, gradient: 0% → 
2% → 4% → 10% MeOH in DCM) and afforded the product (221 mg, 0.173 mmol) as 
a white solid in 32% yield. 
1H NMR (600 MHz, Chloroform-d) δ 7.60 – 7.49 (m, 18H), 7.44 (d, J = 7.7 Hz, 6H), 
5.93 (dd, J = 13.8, 9.5 Hz, 2.5H), 5.84 (dd, J = 13.7, 9.1 Hz, 2H), 5.79 – 5.70 (m, 6H), 
5.66 (s, 0.5H), 5.55 (dd, J = 13.9, 12.4 Hz, 3H), 5.50 – 5.16 (m, 15H), 5.12 (s, 1H). 
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13C NMR (151 MHz, Chloroform-d) δ 135.94, 135.91, 135.73, 135.69, 135.52, 134.62, 
129.72, 129.60, 129.47, 129.45, 129.42, 129.40, 129.39, 129.36, 129.19, 129.13, 
78.48 – 76.20 (m), 73.92 (dd, J = 43.9, 34.0 Hz), 69.84, 69.79, 69.68, 69.62, 69.57, 
69.51, 69.45. 
31P NMR (122 MHz, Chloroform-d) δ -2.80, -3.57, -4.48, -4.71.  
HRMS (ESI/Orbitrap) m/z: [M + H]+ Calcd for C4813C6H54O24P6 1279.1705; Found 
1279.1676. 
 
 
[13C6]InsP6 
[13C6]InsP6 was synthesized according to a modified procedure of Godage and 
coworkers.19 Compound 14 (148 mg 0.12 mmol) was dissolved in methanol (10.53 mL) 
and water (2.63 mL) and 20% Pd(OH)2/C (50% wetted with water) (68 mg, 0.49 mmol) 
was added. The resulting suspension was stirred at room temperature overnight under 
hydrogen atmosphere. The reaction mixture was passed through a PTFE syringe filter 
and the filtrate was evaporated under reduced pressure. The free acid was treated with 
NaOH (1 M) to afford the dodecasodium salt of [13C6]InsP6 as a white solid (136 mg, 
0.10 mmol, 66 w/w%) in 83% yield. 
1H NMR (600 MHz, Deuterium Oxide, pD 7.0) δ 5.01 – 4.90 (m, 0.5H), 4.71 – 4.63 
(m, 0.5H), 4.48 – 4.34 (m, 1H), 4.22 – 4.04 (m, 2.5H), 3.95 – 3.78 (m, 1.5H). 
13C NMR (151 MHz, Deuterium Oxide, pD 7.0) δ 79.99 (d, J = 35.7 Hz), 78.52 (t, J = 
40.0 Hz), 77.60 – 74.58 (m). 
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31P NMR (122 MHz, Deuterium Oxide, pD 7.0) δ 1.99, 1.04, 0.77. 
HRMS no ion detected. 
 
Synthesis of [13C6]InsP5 
 
 
[13C6]myo-Inositol-(1,3,5)-orthobenzoate ester (15) 
[13C6]inositol-(1,3,5)-orthobenzoate (15) ester was synthesized according to a 
modified procedure of Godage and coworkers.19 A suspension of [13C6]myo-inositol 
(1.045 g, 5.61 mmol) and CSA (26.08 mg, 0.11 mmol) in DMSO (3.74 mL) was heated 
to 80 °C under vacuum (Rotovap, 30–40 mbar) to remove residual water. Upon the 
addition of trimethyl orthobenzoate (1.125 g, 6.17 mmol, 1.061 mL), the mixture was 
left at 80 °C under vacuum (Rotovap, 30–40 mbar) until the suspension became clear. 
The resulting solution was quenched with TEA (62.5 mg, 0.62 mmol, 86 µL). (Note: 
Quenching of acid is highly important to assure the stability of the formed orthoester 
during the workup.) The product was slowly precipitated through the addition of water 
105 
 
(16 mL) at 4 °C and the solids were filtered and washed with ice cold water 3 times. 
The mother lye was combined with the washings and applied to reversed phase 
chromatography changing the eluent step wise (5 % → 25 % → 50 % MeCN in H2O) 
to separate residual product from DMSO. The product containing fractions were 
lyophilized and the precipitates were dissolved in 50 % MeCN in H2O and lyophilized 
to afford the product 15 (1.300 g, 4.78 mmol) as white solid in 85% yield. 
1H NMR (600 MHz, Methanol-d4) δ 7.71 – 7.64 (m, 2H), 7.42 – 7.30 (m, 3H), 4.70 (s, 
1H), 4.45 (s, 2.5H), 4.37 (s, 0.5H), 4.18 (s, 1.5H), 4.13 (s, 0.5H). 
13C NMR (151 MHz, Methanol-d4) δ 130.12, 128.58, 126.74, 77.50 (t, J = 37.2 Hz), 
71.63 (t, J = 37.7 Hz), 68.98 (t, J = 37.7 Hz), 60.20 (t, J = 36.8 Hz). 
HRMS no ions detected. 
 
 
[13C6]2-Benzoyl inositol (S16) 
[13C6]2-Benzoyl inositol (S16) was synthesized according to a procedure of 
Godage and coworkers.19 A mixture of TFA (1.8 mL) and water (180 µL) was added 
to 15 (300 mg, 1.1 mmol) and the solution was stirred for 1 h and the conversion was 
followed by TLC (100 % EtOAc; starting material Rf 0.6; product Rf 0.0). The reaction 
mixture was then co-evaporated with water in vacuo, redissolved in water and 
lyophilized to obtain the product S16 (314 mg, 1.08 mmol) as a white solid in 
quantitative yield. 
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1H NMR (600 MHz, Deuterium Oxide, pD 7.0) δ 8.10 (d, J = 7.8 Hz, 2H), 7.74 (d, J = 
7.5 Hz, 1H), 7.59 (t, J = 7.7 Hz, 2H), 5.86 (s, 0.5H), 5.60 (s, 0.5H), 4.02 – 3.89 (m, 2H), 
3.78 – 3.66 (m, 2H), 3.58 – 3.51 (m, 0.5H), 3.36 – 3.28 (m, 0.5H). 
13C NMR (151 MHz, Deuterium Oxide, pD 7.0) δ 170.73, 136.84, 132.46, 131.52, 77.85 
(t, J = 38.6 Hz), 77.09 (t, J = 38.6 Hz), 75.62 (t, J = 38.8 Hz), 72.63 (td, J = 38.8, 6.6 
Hz). 
HRMS (ESI/Orbitrap) m/z: [M + H]+ calcd. for C713C6H17O7 291.1170; Found 291.1166. 
 
 
Xylyl-protected [13C6]benzoyl myo-inositol (16) 
Xylyl-protected [13C6]benzoyl myo-inositol (16) was synthesized according to a 
procedure of Godage and coworkers.19 To a solution of S16 (200 mg, 0.7 mmol) and 
5-phenyltetrazole (1.01 g, 6,89 mmol) in dry DCM (4.9 mL) under nitrogen atmosphere 
was added  Xy phosphoamidite (1.24 g, 5.17 mmol). The suspension was sonicated 
(1 min) and further stirred overnight at rt. The reaction mixture was cooled to -40 °C, 
and mCPBA (1.70 g, 6.89 mmol) was added portion-wise while stirring. The cooling 
bath was removed, and the mixture was allowed to reach rt and diluted with DCM (50 
mL), washed with 10% sodium sulfite solution (2 × 100 mL), dried and solvent 
evaporated in vacuo. The crude was immobilized on Telos® and purified by 
CombiFlash® chromatography on silica gel (120 g column, gradient: 1% → 4% → 10% 
MeOH in DCM) to afford the product 16 (651 mg, 0.54 mmol) as white solid in 79% 
yield. 
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1H NMR (600 MHz, Chloroform-d) δ 8.06 (d, J = 7.1 Hz, 2H), 7.61 – 7.53 (m, 1H), 7.49 
– 7.45 (m, 2H), 7.43 – 7.35 (m, 10H), 7.35 – 7.30 (m, 6H), 7.29 – 7.27 (m, 1H), 7.26 – 
7.23 (m, 2H), 6.53 (s, 0.5H), 6.27 (s, 0.5H), 5.64 (ddd, J = 17.9, 13.9, 8.1 Hz, 4H), 5.58 
– 5.47 (m, 3H), 5.41 (dd, J = 13.7, 9.4 Hz, 2H), 5.27 (s, 1H), 5.21 (dd, J = 13.5, 10.9 
Hz, 3.5H), 5.16 (d, J = 9.8 Hz, 1H), 5.12 (d, J = 8.7 Hz, 1H), 5.05 (ddd, J = 22.1, 13.8, 
5.8 Hz, 8H), 4.96 (s, 1.5H). 
13C NMR (151 MHz, Chloroform-d) δ 78.00 – 76.46 (m), 74.25 (td, J = 38.4, 36.8, 6.5 
Hz), 70.59 (t, J = 38.5 Hz). 
31P NMR (122 MHz, CDCl3) δ -3.32, -4.25, -4.90. 
HRMS (ESI/Orbitrap) m/z: [M + Na]+ Calcd for C4713C6H51NaO22P5 1223.1613; Found 
1223.1613. 
 
 
 [13C6]Benzoyl InsP5 (S17) 
[13C6]Benzoyl InsP5 (S17) inositol was synthesized according to a procedure of 
Godage and coworkers.19 16 (50 mg, 0.04 mmol) was dissolved in methanol (3.8 mL), 
and water (0.95 mL) and 20% Pd(OH)2/C (50% wetted with water) (25 mg, 0.18 mmol) 
were added. The resulting suspension was stirred at rt overnight under hydrogen 
atmosphere. The catalyst was filtered through a PTFE syringe filter, and the filtrate 
neutralized by the addition of 1 M Et3NHCO3 until the pH 7.5 was reached. 
Lyophilization afforded the product S17 (50 mg, 0.037 mmol, 8 × EtN3 salt) as white 
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solid in 88% yield. The amount of the TEA-counter ion was determined by NMR 
spectroscopy. 
1H NMR (600 MHz, Deuterium Oxide, pD 7.0) δ 8.19 (dd, J = 8.2, 1.9 Hz, 2H), 7.74 (t, 
J = 7.2 Hz, 1H), 7.61 (dd, J = 9.0, 6.6 Hz, 2H), 6.10 (s, 0.5H), 5.84 (s, 0.5H), 4.58 – 
4.45 (m, 2H), 4.39 (s, 0.5H), 4.27 (s, 1H), 4.16 (d, J = 11.1 Hz, 0.5H), 3.21 (qd, J = 7.3, 
2.5 Hz, EtN3), 1.30 (td, J = 7.3, 2.6 Hz, EtN3). 
13C NMR (151 MHz, Deuterium Oxide, pD 7.0) δ 77.65 (t, J = 39.7 Hz), 76.46 (t, J = 
39.7 Hz), 73.93 (t, J = 38.6 Hz), 72.53 (t, J = 39.9 Hz), 46.60, 8.23. 
31P NMR (122 MHz, Deuterium Oxide, pD 7.0) δ 0.33, -0.00, -0.80. 
HRMS (ESI/Orbitrap) m/z: [M – 2H]2- calcd. for C713C6H19O22P5 343.9634; Found 
343.9954. 
 
 
[13C6]InsP5 
 [13C6]InsP5 was synthesized according to a procedure of Godage and 
coworkers.19 Compound S17 (50 mg, 0.037 mmol) was dissolved in concentrated 
aqueous ammonia solution (2.0 mL) and heated at 60 °C overnight in a Pyrex pressure 
tube. After evaporation of the solution under vacuum, the residue was dissolved in 
water and the benzamide byproduct was removed by washing with DCM. The 
ammonium salt of the product was obtained by evaporation of the ammonia and 
converted into the free acid by quick filtration (Note: Prolonged exposure causes 
phosphoryl group migration.) through DOWEX 50W x 8 (H+ form) (10-fold molar 
109 
 
excess, previously washed with MilliQ® water) and then to its hexasodium salt by 
titration to pH 7.40 with 0.1 M sodium hydroxide solution. Lyophilization afforded 
[13C6]InsP5 (17 mg, 0.024 mmol) as white solid in 65% yield. 
1H NMR (300 MHz, Deuterium Oxide, pD 7.5) δ 4.72 – 4.53 (m, 1.5H), 4.47 – 4.25 (m, 
1.5H), 4.24 – 4.02 (m, 1.5H), 3.96 – 3.74 (m, 1.5H). 
13C NMR (75 MHz, Deuterium Oxide, pD 7.5) δ 78.28 – 74.98 (m), 73.92 (t, J = 37.7 
Hz), 70.68 (t, J = 37.6 Hz). 
31P NMR (122 MHz, D2O, pD 7.5) δ 1.49, 1.23, 0.86. 
 
Chemoenzymatic Synthesis of [13C6]Inositol pyrophosphates 
 
[13C6]5PP-InsP5 
The synthesis of [13C6]5PP-InsP5 was done according the synthesis of 5PP-
InsP5 which is described in the method section of chapter 2. 
1H NMR (600 MHz, Deuterium Oxide, pD 7.5) δ 5.05 – 4.95 (m, 0.5H), 4.69 – 4.58 (m, 
1H), 4.49 – 4.36 (m, 1.5H), 4.35 – 4.26 (m, 1H), 4.25 – 4.15 (m, 0.5H), 4.12 – 4.00 (m, 
1H). 
13C NMR (151 MHz, Deuterium Oxide, pD 7.5) δ 80.74 – 79.46 (m), 79.32 – 77.17 (m), 
76.03 (t, J = 38.7 Hz). 
31P NMR (243 MHz, D2O, pD 7.5) δ -1.45, -2.00, -2.45, -10.32, -13.41. 
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[13C6]1PP-InsP5 
The synthesis of [13C6]1PP-InsP5 was done according the synthesis of 1PP-
InsP5 which is described in the method section of chapter 2. 
1H NMR (600 MHz, Deuterium Oxide) δ 5.28 – 5.21 (m, 0.5H), 5.04 – 4.96 (m, 0.5H), 
4.64 – 4.57 (m, 0.5H), 4.55 – 4.45 (m, 2H), 4.41 – 4.33 (m, 0.5H), 4.31 – 4.21 (m, 1H). 
13C NMR (151 MHz, Deuterium Oxide) δ 77.47 (t, J = 40.0 Hz), 76.70 – 74.61 (m), 
73.50 (dt, J = 82.6, 40.4 Hz). 
31P NMR (243 MHz, Deuterium Oxide) δ -1.82, -2.35, -2.95, -3.91, -13.25 (d, J = 21.9 
Hz), -14.14 (d, J = 19.9 Hz). 
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[13C6]1,5(PP)2-InsP4 
The synthesis of [13C6]1,5(PP)2-InsP4 was done according the synthesis of 
1,5(PP)2-InsP4 which is described in the method section of chapter 2. 
1H NMR (600 MHz, Deuterium Oxide) δ 5.27 – 5.20 (m, 0.5H), 5.01 – 4.94 (m, 0.5H), 
4.65 – 4.58 (m, 1H), 4.56 – 4.47 (m, 1.5H), 4.41 – 4.33 (m, 1H), 4.31 – 4.21 (m, 0.5H). 
13C NMR (151 MHz, Deuterium Oxide, pD 5.0) δ 77.53 (t, J = 39.4 Hz), 76.68 – 74.55 
(m), 73.48 (q, J = 42.5, 39.9 Hz). 
31P NMR (243 MHz, Deuterium Oxide, pD 5.0) δ 0.55, 0.30, -0.19, -1.04, -10.53 (t, J 
= 21.3 Hz), -11.10 (dd, J = 50.4, 20.0 Hz). 
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Chapter 4 Identification of Endogenous Protein 
Pyrophosphorylation by Mass Spectrometry 
 
 
Reproduced in part with permission from (1) R. K. Harmel, D. Fiedler, Nat. Chem. Biol. 
2018, 14, 244–252. 
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Introduction: Design of a Pyrophosphoproteomics Workflow 
 PP-InsPs transmit information via two distinct signaling mechanisms.1,2 Figure 
4.1) They can either directly modulate protein activity by binding to positively charged 
domains or transfer their structurally unique β-phosphoryl group onto phosphoproteins, 
a process coined protein pyrophosphorylation.  
 
Figure 4.1: Proposed mechanisms of PP-InsP signaling. Protein binding and protein 
pyrophosphorylation, a covalent posttranslational modification. 
 
Especially, the latter process is poorly understood. Radiolabeling experiments 
indicated that PP-InsPs could phosphorylated proteins in vitro and with this technique, 
a handful of substrates were identified.3–7 However, the existence of this 
posttranslational modification in vivo and its dependence on PP-InsPs is still under 
debate because there are currently no methods available to directly detect 
endogenous pyrophosphorylation sites. To establish the biological significance for this 
putative PTM, new analytical approaches must be explored that can unambiguously 
detect pyrophosphorylated proteins in complex samples. 
Modern MS techniques have succeeded in sensitive, rapid identification and 
interrogation of many PTMs in a high-throughput format.8,9 The development of these 
methods required the design and optimization of bespoke proteomic workflows that 
overcame challenges associated with the chemical properties inherent to particular 
modifications. One of the best characterized modifications is protein phosphorylation. 
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In most cases, this PTM is investigated using a bottom-up phosphoproteomics 
approach.10 (Figure 4.2) In this process, cells are lysed and the denatured proteins 
are enzymatically digested into peptides with specific proteases such as trypsin, which 
cleaves after the C-terminus of arginine and lysine. Like many other PTMs, 
phosphopeptides are usually present in substoichiometric amounts as compared to the 
pool of non-modified peptides. 
 
Figure 4.2: Schematic representation of the phosphoproteomics workflow. Denatured 
proteins are extracted from cells and enzymatically digested into peptides using 
specific proteases. Subsequently, the phosphopeptides are enriched and further 
analyzed by LC-MS/MS followed by database analysis of the obtained fragments.  
 
In addition, the negative charge of the phosphoryl group reduces the ionization 
efficiency during traditional positive ion mode MS. Therefore, non-phosphorylated 
peptides had to be separated from tryptic digests to maximize discovery rates of 
phosphopeptides during MS analysis. Selective enrichment of phosphate-containing 
peptides is achieved by positively charged affinity reagents like IMAC or MOAC, 
through immunoprecipitation, chemical derivatization or chromatography.10 Finally, 
enriched samples are mostly fractionated based on hydrophobicity and sequenced by 
tandem-MS (MS/MS). Depending on the residue attached to the phosphoryl group, 
specific fragmentation strategies provide fingerprint fragments that enabled the 
identification of phosphorylated amino acids. Today, phosphoproteomic analyses of 
serine, threonine and tyrosine sites are highly optimized procedures and can detect 
several thousand phosphorylated peptides from a single biological sample. 
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Establishing robust phosphoproteomic workflows with MS strongly accelerated 
the understanding of protein phosphorlylation and their regulation by 
kinase/phosphatase networks. An analogous procedure for unbiased identification of 
protein pyrophosphorylation by MS would probably have a large impact in this fairly 
new field. The chemical similarity of the phosphoryl- and pyrophosphoryl moiety 
inspired our research group to adopt the general phosphoproteomics approach to 
identify endogenous pyrophosphopeptides. It was expected that establishing this 
workflow would be even more challenging than analyzing phosphopeptides. Since 
protein pyrophosphorylation was shown to depend on a priming phosphorylation event, 
the levels of pyrophosphopeptides were expected to be substoichiometric to that of 
phosphopeptides.3,4 Furthermore, pyrophosphopeptides bear an additional negative 
charge and have so far been localized to polyacidic peptide fragments that further 
reduce ionization. Finally, the labile phosphoanhydride bond and the anticipated 
difficulty in distinguishing isobaric pyrophospho- from bisphosphopeptides was 
expected to complicate interpretation of tandem-MS data. To overcome challenges 
associated with pyrophosphorylated peptides, a new set of tools was developed in our 
group. (Figure 4.3)  
 
Figure 4.3: New chemical biology tools to study protein pyrophosphorylation. a) 
Peptide pyrophosphorylation by phosphoimidazolide reagents. b) CID neutral loss 
triggered EThcD fragmentation to identify and sequence pyrophosphopeptides. c) Zn-
DPA affinity reagent for the enrichment of pyrophosphopeptides 
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More specifically, a new methodology was developed to grant access to synthetic 
pyrophosphopeptides using phosphoimidazolide reagents.11 (Figure 4.3 a) In turn, this 
allowed the study of the pyrophosphate moiety during ionization and fragmentation, 
and the development of tailored analysis methodologies.12,13 Gratifyingly, a unique 
neutral loss pattern (pyrophosphoric acid; m/z -178) during collision-induced 
dissociation (CID) fragmentation was identified that could be used to rapidly 
characterize pyrophosphorylated peptides. (Figure 4.3 b) Coupled to electron-transfer 
dissociation combined with higher energy collision dissociation (EThcD) high quality 
MS/MS spectra were obtained that enabled unambiguous annotation of 
pyrophosphosites. This data driven CID-EThcD method was later applied to identify 
pyrophosphorylated peptide standards spiked into HeLa protein digests where 100 
fmol peptide could be reliably detected.12 The detection sensitivity for a given 
pyrophosphopeptide was approximate 100-fold less than for the corresponding 
phosphopeptide. In parallel, pyrophosphopeptides were utilized to develop a selective 
enrichment method based on a Zn-DPA complex.14 (Figure 4.3 c) This novel affinity 
reagent was able to recover spiked-in pyrophosphopeptides from complex cell lysates, 
and showed a 30-fold stronger binding for these peptides compared to 
phosphopeptides. Finally, a preliminary trial to identify endogenous protein 
pyrophosphorylation was conducted using lysates from S. cerevisiae by adopting a 
protocol from Gygi and coworkers.15 Remarkably, high amounts of tryptic digest (6 mg) 
were necessary to find any evidence of sites above the limit of detection. Three 
pyrophosphopeptides were identified with high confidence, derived from proteins 
RRP5, RPA34 and PUF6. (unpublished results) The sequence of these peptides could 
be fully annotated via their representative ion series. Unfortunately, these results were 
not reproducible in further replicates and therefore more optimization appeared 
necessary to produce a stable result. 
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In this Chapter, we optimized the pyrophosphoproteomics workflow and 
detected the first endogenous protein pyrophosphorylation sites in mammalian cells. 
With the improved workflow, we could identify a total of 39 endogenous 
pyrophosphosites from 36 proteins with high confidence. While the corresponding 
proteins were located in a range of cellular compartments, the nucleus and cytoplasm 
were the two most common ones. Gene ontology analysis revealed an enrichment of 
RNA- and cadherin binding proteins and identified regulation of telomerase activity and 
ribonucleoprotein complex assembly among the top 3 enriched biological processes. 
Collectively, these initial results suggest a function for protein pyrophosphorylation in 
ribosome biogenesis, cell-cell adhesion and cell division. 
 
Evaluation of the Initial Pyrophosphoproteomics Workflow 
 To reproducibly detect endogenous pyrophosphorylation sites from eukaryotic 
cells, we first isolated potential bottlenecks by further dissecting the 
pyrophosphoproteomics workflow used previously. The procedure consisted of 7 steps 
as depicted. (Table 4.1) One of the most crucial variables was the cell culture. 
Conceptually, to maximize the discovery of pyrophosphosites, an organism or cell line 
with a high degree of pyrophosphorylated proteins should be chosen as a starting 
point. Moreover, the pyrophosphoproteome should be kept stable to obtain 
reproducible results. Unfortunately, the abundance of pyrophosphorylation as well as 
the fluctuation of this PTM was unknown. Previous work had already successfully 
identified the first endogenous pyrophosphosites in S. Cerevisiae. Therefore, analyzing 
the proteome of this organism was a rational starting point.  
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Table 4.1: Potential bottlenecks that may hamper the detection of protein 
pyrophosphorylation in the first generation pyrophosphoproteomic workflow. 
Entry Step Potential Bottlenecks 
1 cell culture low levels of pyrophosphorylated proteins 
2 cell lysis enzymatic pyrophosphate degradation  
3 protein alkylation pyrophosphate instability 
4 tryptic digestion inefficient tryptic digestion 
5 peptide desalting  loss of peptides 
6 Zn-DPA enrichment no pyrophosphopeptide binding 
7 enriched peptide desalting loss of peptides 
 
 Apart from ensuring the presence of in vivo pyrophosphosites amenable to 
detection in the biological sample, we were also concerned about the stability and 
recovery of pyrophosphorylated peptides throughout the course of the workflow. 
During cell lysis and alkylation, residual phosphatase activity and elevated 
temperatures at pH 8.0 could possibly degrade the endogenous pyrophosphates. 
Seminal work from Yates et al. investigated the hydrolysis of pyrophosphopeptides in 
the presence of different buffer conditions and in S. cerevisiae cell lysates.16 Only 
minor degradation was observed in the presence of Tris at pH 7.5, even at 37 °C over 
24 hours. Complete phosphatase activity in cellular lysates was however only 
abolished through a combination of EDTA and phosphatase inhibitor treatment. The 
original phosphoproteomics workflow was EDTA-free and the addition of this chelator 
potentially complicates subsequent steps. Therefore, we refrained from using EDTA in 
initial experiments as we expected no phosphatase activity under the high denaturing 
conditions generated by the 8 M Urea in the lysis buffer.  
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 Improving the recovery of peptides during processing is particularly relevant to 
steps 4–7. The trypsin/peptide ratio and the desalting conditions were not optimized 
for the highly acidic sequences expected. In addition, pyrophosphopeptides could be 
lost due to a failed enrichment step. To control for these possible risks, we envisioned 
to apply pyrophosphopeptide standards during the workflow or during the validation of 
single steps to estimate the loss of peptides. Together, these measures should help to 
isolate problems of the pyrophosphoprotemics workflow and allow further optimization. 
 
Attempts to Optimize the Pyrophosphoproteomics workflow in S. Cerevisiae 
 After assessing the possible pitfalls of the pyrophosphoproteomics workflow, 
fresh immobilized Zn-DPA reagent was prepared in 15 chemical steps according to a 
procedure from Conway et al. and we tested its ability to bind and elute two 
fluorescently labeled pyrophosphopeptides.14 About 60% of the initial peptide 
concentration was recovered, consistent with the literature. Secondly, we prepared 
three biological replicates of wild type S. cerevisiae and subjected these samples to 
proteomic and phosphoproteomic analysis. While the unmodified proteome remained 
very similar, there were minor differences found within phosphopeptides. These results 
suggested that our growth conditions produce a fairly stable background at the 
proteomic and phosphoproteomic levels.  
 Next, we applied the complete pyrophosphoproteomics workflow to one of the 
S. cerevisiae samples, but MS analysis showed low levels of peptide in this sample. 
We noticed that the enriched peptide desalting (step 7) included a washing step with 
neutral milliQ that might elute the majority of the peptides. Avoiding this step allowed 
the recovery of phosphorylated and unmodified peptides. Notably, MS analysis of 
these samples was complicated by polymer contaminations and missed tryptic 
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cleavage sites were commonly encountered. These problems were reduced by 
switching from plastic to glass tubes and raising the ratio of trypsin/protein from 1:100 
to 1:20 but these changes did not lead to the identification of pyrophosphopeptides. In 
an attempt to identify a specific step within the proteomic workflow where highly acidic 
pyrophosphorylated were lost, we produced four samples where a synthetic standard 
(1–10 pmol) was added at four different steps: during lysis (step 2), before enrichment 
(before step 6); before enriched peptide desalting (before step 7); to the enriched and 
desalted peptide solution. We employed a modified version of the previously found 
PUF6, with the aim of modeling an endogenous peptide sequence but without 
interfering with the detection of the natural peptide. In all cases, the peptide standard 
could be readily detected in the final MS analysis but no endogenous 
pyrophosphopeptides were observed. This suggested two possibilities: either 
pyrophosphorylated peptides were too low in abundance compared to the synthetic 
standards and below the limit of detection, or the enrichment efficiency varied greatly 
between endogenous sequences and the PUF6 model peptide. Finally, two more 
samples were produced either using more lysate (6 mg instead of 1 mg), or treated 
with λ-phosphatase before enrichment to specifically degrade background from 
phosphorylated peptides. However, neither condition appeared to improve detection, 
as no pyrophosphopeptides were detected.  
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Identification of Endogenous Mammalian Pyrophosphopeptides6 
 We speculated that S. cerevisiae might have low levels of endogenous 
pyrophosphorylated proteins and turned to explore mammalian HEK293T cells 
instead. We enriched 6 mg of tryptic peptides with Zn-DPA affinity reagent and included 
the PUF6 standard during lysis. After performing the complete workflow and analyzing 
the output, no pyrophosphorylated peptides were detected. In a parallel approach 
undertaken by our collaborator at the MS core facility, Zn-DPA-enriched peptides were 
subjected to high pH reversed fractionation prior to LC-MS/MS.17,18 Remarkably, this 
approach removed enough background signals to identify the first pyrophosphorylated 
peptide from a mammalian cell line. The observed peptide sequence was derived from 
the dual specificity kinase 1 or 4 (CLK1/4) and the majority of the amino acids, including 
the pyrophosphoserine, were annotated with high confidence by the MS. (Figure 4.4 
a) Surprisingly, the identified site was not phosphorylated by CK2 which was previously 
reported for all in vitro characterized pyrophosphoproteins. Currently, there are no 
reports of other kinases modifying this site. Instead CLK proteins are known to widely 
autophosphorylate itself and this could be a potential priming phosphorylation in this 
case.19 No function has been associated with phosphorylation at this site, despite it 
being among the most prevalent phosphosites observed in CLK1/4 by 
phosphoproteomics experiments. Finally, a crystal structure of CLK1 was published 
that located two phosphorylated residues, one at the identified position of the 
proteomic analysis and a second one immediately adjacent.20 (Figure 4.4 b) 
Interestingly, the phosphoserine is in close proximity to the active site and 
                                                            
6 hSAX fractionation was developed and performed by Dr. J. A. M. Morgan. Optimization of the residual 
workflow was performed by R. K. Harmel including the IMAC or Zn-DPA enrichment in combination with hSAX. 
Preliminary experiments with λ-phosphatase treatment were performed by R. K. Harmel. Further optimization 
including λ-phosphatase treatment and SIMAC enrichment, and identification of the residual 32 sites was 
performed by Dr. J. A. M. Morgan. 
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pyrophosphorylation potentially results in a clash with substrate suggesting a putative 
function in kinase inhibition.  
 
Figure 4.4: Analysis of CLK1/4 pyrophosphosite. a) Observed C+ and Z+1 series for 
pyrophosphorylated peptide of CLK1/4. Colored m/z values were detected. b) Crystal 
structure of CLK1 reported by Knapp and coworkers.20 
 
 Encouraged by these results, the fractionation method was further optimized, 
and we switched to a hydrophilic hSAX column with NH4HCO2 buffer at pH 9 that was 
suitable to enrich highly acidic peptides. Combining this method with Zn-DPA 
enrichment, the identification of CLK1/4 was reproduced in a second biological 
replicate and additionally, a peptide originating from mitochondrial structural protein 
and transcription factor MICOS complex subunit (MIC19) was identified. The hSAX 
chromatography significantly reduced background signals during the MS analysis and 
therefore we reconsidered traditional IMAC as replacement for Zn-DPA and prepared 
two samples for a direct comparison.21 In the IMAC enriched sample we found only 
CLK1 but the ion intensity was approximately 10 fold higher compared to the Zn-DPA 
enriched sample. By contrast, the Zn-DPA displayed 6 hits that were confidently 
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assigned as pyrophosphopeptides. This comparison suggested to us that recovery of 
the peptide was less important than its enrichment and separation from background 
phosphopeptides. To obtain more hits in a single pyrophosphoproteomics experiment, 
the workflow was further optimized. (Figure 4.5) More site were observed by raising 
the amount of mammalian cell lysate to 20 mg. Previously, our group showed that 
phosphorylated peptides were readily dephosphorylated in the presence λ-
phosphatase while pyrophosphorylated peptides were not affected.16 Therefore, an 
incubation step with λ-phosphatase was included which significantly improved data 
quality. This effect was probably due to the removal of a significant number of 
phosphopeptides and the depletion of phosphorylation sites close to 
pyrophosphorlation sites which complicate analysis. In the enrichment step, sequential 
IMAC (SIMAC) spin columns offered the best results.  
 
 
Figure 4.5: Optimized pyrophosphoproteomics workflow. A peptide digest is isolated 
from mammalian cells by lysis, alkylation and enzymatic digestion. Treatment with λ-
phosphatase strongly reduces phosphopeptides followed by enrichment of the 
pyrophosphopeptides using SIMAC. hSAX fractionation produces 21 fractions that are 
individually analyzed by LC-MS/MS.  
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Compared to traditional IMAC this techniques includes an additional elution step to 
separate monophosphorylated from multiphosphorylated peptides.22 
Pyrophosphorylated peptides were eluted in the basic elution step and background 
from phosphorylated peptides was reduced. Finally, the buffer for the hSAX 
fractionation was changed to (NH4)2CO2 at pH 9 to minimize the amount of salt after 
lyophilization. Notably, the low content in fractionated samples eliminated the need for 
the final desalting step, further reducing the risk of peptide loss during the workflow. 
 
Analysis of Identified Pyrophosphorylated Proteins 
 With the improved pyrophosphoproteomics workflow we were able to identify 5–
15 pyrophosphorylated peptides from HEK293 or HCT116 cell lysates in a single 
analysis, and together, 39 sites among 36 proteins were found. (Appendix: Table 4.2, 
Table 4.3) These include therapeutically interesting examples such as tau protein, 
histone deacetylase 2 (HDAC2), phosphohistidine kinase NME1 and the chaperone 
HSP90. The most common hit within all samples so far remained CLK1/4. It was the 
only protein that was consistently found in all our optimization attempts. An abundant 
pyrophosphorylation site in CLK1/4 may be promoted through its ability to install the 
priming phosphorylation by its autophosphorylation activity.19 This modification is likely 
to occur at a high stoichiometry as it is independent of the interaction with other 
kinases. In contrast, prephosphorylation of most target sites was dependent on CK2 
and CDK1 (cyclin dependent kinase 1) . Even though the initial list of hits was relatively 
short, identification of the consensus sequence and gene ontology analysis was 
performed.23 (Figure 4.6)  
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Figure 4.6: Sequence and gene ontology analysis of pyrophosphoproteins. a) 
Consensus sequence. b) Distribution of proteins among cellular compartments. c) GO 
analysis of biological processes. d) GO analysis of molecular function. 
 
The consensus sequence revealed serine residues enclosed in a highly acidic 
environment, consistent with sites previously identified in biochemical assays  via 
mutagenesis. (Figure 4.6 a) Furthermore, protein pyrophosphorylation was not 
specific to a certain group of proteins and occurred in a range of cellular compartments 
but mostly in the nucleus and the cytosol suggesting a fundamental role of this 
modification in cell signaling. Gene ontology analysis showed an enrichment of 
biological processes such as ribonucleoprotein complex assembly and regulation of 
telomerase activity, and among the top enriched molecular functions was binding to 
cadherin and RNA.23 These data suggested that protein pyrophosphorylation is 
involved in ribosome biogenesis, cell-cell adhesion and cell division.  
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Conclusion and Outlook 
 Posttranslational phosphorylation of proteins is a highly regulated process that 
governs many biological processes and is an integral part of signal transduction. 
Consequently, powerful proteomic workflows have been developed to grant thorough 
analyses of this PTM. Here, the development and optimization of a 
pyrophosphoproteomic approach was described and the first endogenous mammalian 
pyrophosphopeptides were identified. Current efforts have accumulated a list of 38 
endogenous targets of pyrophosphorylation and gene ontology analysis revealed a 
putative function in ribosome biogenesis, cell-cell adhesion and cell division. 
 Future work will be directed towards further optimizing the workflow. In 
particular, the reproducibility within technical and biological triplicates need to be 
addressed to create consistency. If we want to understand the biological function of 
this PTM, cells that are either treated differently or possess different genetic 
backgrounds need to be compared, ideally using SILAC to quantify differences. Unless 
background variability can be distinguished from experimentally-induced change, a 
meaningful interpretation of these data will be elusive.  
 Mechanistically, protein pyrophosphorylation is not well understood yet. 
Currently, it is unclear whether PP-InsPs are responsible for protein 
pyrophosphorylation in vivo. Genetic knockouts are useful tools to correlate PP-InsP 
levels with changes in pyrophosphoprotein content, and depletion or increase of 
intracellular PP-InsP concentrations is expected to result in a response on the PTM 
level with a similar trend. To further understand the impact of pyrophosphorylation on 
the structure and function of modified proteins, it is of utmost importance to pick 
pyrophosphoproteins from our current data set and characterize their properties with 
respect to unmodified- and phosphoproteins in vitro. To this end, our group recently 
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established a procedure to produce pyrophosphoproteins by combining the expression 
of phosphoproteins with genetic code expansion followed by pyrophosphorylation with 
phosphoimidazolide reagents.24  
Finally, to further understand the regulation of protein pyrophosphorylation, 
factors that facilitate the introduction and removal of this modification need to be 
assessed. Previously, pyrophosphopeptides were reported to be degraded by several 
unspecific phosphatases in vitro and within S. cerevisiae and HeLa lysates suggesting 
reversibility of protein pyrophosphorylation.25 Identification of a putative 
pyrophosphatase could be achieved by activity enrichment or proteomic pulldowns 
with identified pyrophosphopeptides and would uncover new functional aspects of 
protein pyrophosphorylation. Genetic knockout of the pyrophosphatase potentially 
leads to a massive increase in protein pyrophosphorylation, further enhancing the 
detectability of this PTM. Analogous to phosphatases, substrate-trapping 
pyrophosphatases might be prepared through mutation of the catalytic residues to 
alanine and used a highly selective enrichment strategy for pyrophosphopeptides.26,27  
Taken together, our novel pyrophosphoproteomics workflow will significantly aid 
the identification and the understanding of protein pyrophosphorylation and − 
assuming PP-InsPs install this modification − identify new intersections of PP-InsPs 
within metabolism and signaling networks. 
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Methods 
General Information 
Please see method section of chapter 2. 
 
Chemical Synthesis of Zn-DPA Resin 
 
DPA ligand was synthesized in 13 steps starting described before by Conway 
and Fiedler.14 Analytical data were identical with the values reported in the literature. 
1H NMR (300 MHz, Deuterium Oxide, pD 7.0 ) δ 7.53 (dd, J = 8.9, 7.3 Hz, 4H), 6.68 
(s, 2H), 6.58 (dd, J = 14.5, 8.1 Hz, 9H), 3.76 (s, 8H), 3.55 (s, 4H), 2.88 (dd, J = 10.7, 
6.3 Hz, 2H), 2.58 (dd, J = 10.8, 6.2 Hz, 2H). 
 
 
Zn-DPA resin  was synthesized in 2 steps starting described before by 
Conway and Fiedler.14 Immobilization was followed by disappearance of starting 
material in LC-MS spectra. Zn2+ was freshly loaded right before use. 
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Yeast Cell Culture and Harvest 
S. cerevisiae cells were prepared according to Villen and Gygi.21 Wild type S. 
cerevisiae cells were grown on an agar plate overnight at 30 °C. One colony was 
picked, suspended in YPDA medium and incubated at 30 °C while shaking. The next 
day, cells were diluted to an OD600nm of 0.1 and grown over 5–6 to mid-log phase 
(OD600nm = 0.600–0.700) at 30 °C. Cells were harvested by centrifugation at 3,500 g 
for 10 min at 4 ˚C. The pellet was rinsed with 50 mM Tris-HCl (pH 7.50; 10.0 mL) and 
isolated by centrifugation at 3,200 g for 5 min at 4 ˚C. 1 L of culture gave approximately 
100 mg of undigested protein. 
 
Mammalian Cell Culture and Harvest 
HCT116 or HEK293T cells were grown according to Villen and Gygi.21 Cells 
were grown in 15 cm dishes in DMEM supplemented with FBS and 
Penicillin/Streptomycin at 37 °C and 5 % CO2. Cells were split at 70 % confluency 1:10 
and distributed on 5–10 plates and grown until they reached 80–90% confluency. For 
harvesting, cells were washed with PBS and 0.9 % NaCl solution, and trypsinized. The 
trypsin was quenched with DMEM. The cells were collected and washed two more 
times with PBS before lysis and extraction. One 15 cm dish of culture gave 
approximately 10 mg of undigested protein. 
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Yeast Lysate Preparation  
S. cerevisiae lysate was prepared according to Villen and Gygi.21 To prepare 
yeast lysates, two EDTA-free protease inhibitor cOmplete tablet (Roche Life Sciences) 
was added to the mass spec (MS) lysis buffer containing phosphatase inhibitors (8 M 
urea, 75 mM NaCl, 50 mM Tris (pH 8.2), 50 mM NaF, 50 mM β–glycerophosphate, 1 
mM sodium orthovanadate, 10 mM sodium pyrophosphate, 1 mM PMSF; 10.0 mL) at 
4 ˚ C. All steps of the lysis were performed at 4 ˚ C. The cell pellets of 50 mL media were 
treated with the MS lysis solution (300 μL lysis buffer per cell pellet), and mixed by 
vortexing. The cell suspension (300 μL) was transferred to screw-capped tubes, and 
glass beads were added. The cells were lysed by bead beating (Precellys Evolution, 
Bertin Technologies) at 6500 rpm using 2 cylcles of 15s with 1 min pause in between 
cycles. After the lysis was complete, a hole was poked in the bottom of the tubes, and 
the sample was removed from the glass beads by centrifugation at 16,000 g for 1 min. 
Cellular debris was removed by centrifugation at 16,000 g for 10 min. The supernatant 
was removed, and the protein concentration was determined by BCA kit (Pierce). 
 
Mammalian Lysate Preparation 
HCT116 or HEK293T lysates were prepared according to Villen and Gygi.21 To 
prepare mammalian lysates, one EDTA-free protease inhibitor cOmplete tablet (Roche 
Life Sciences) was added to the mass spec (MS) lysis buffer containing phosphatase 
inhibitors (8 M urea, 75 mM NaCl, 50 mM Tris (pH 8.2), 1 mM NaF, 1 mM β–
glycerophosphate, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 1 mM 
PMSF; 10.0 mL) at 4 ˚C. All steps of the lysis were performed at 4 ˚C. Cells in 15 cm 
dishes were washed with ice cold PBS (5 mL). After aspiration of the PBS, lysis buffer 
was added and the cells chilled for 10 min at 4 °C and the cells were scraped off by a 
156 
 
cell lifter and collected into 15 mL conical tube. Sonication of 3 × 1 min with 2 min rests 
at 15 % output was applied during lysis and cellular debris could be removed by 2,500 
g for 10 min. The supernatant was collected, and the protein concentration was 
determined by BCA kit (Pierce). 
 
Protein Reduction and Alkylation 
Reduction and alkylation was performed according to Villen and Gygi.21 To 
reduce and alkylate the proteins in the lysate, 5 mM DTT (50 μL of a 100 mM frozen 
stock) was added to each 1 mL lysate aliquot, and the samples were incubated at 56 
˚C. After incubation for 25 min, the samples were removed and cooled to room 
temperature. 14 mM iodoacetamide was added to each 1 mL aliquot, and the samples 
were incubated at room temperature in the dark for 30 min. The samples were then 
quenched with another portion of DTT (10 mM final concentration) and incubated for 
15 min at room temperature in the dark. 
 
Tryptic Protein Digestion 
 Tryptic digestion was performed according to Villen and Gygi.21 For the trypsin 
digestion of the lysate, sequencing grade modified trypsin (Promega, cat. V5111) was 
used. The reduced and alkylated samples were diluted 1:5 in 25 mM Tris pH 8.0. To 
each sample was added 1 mM CaCl2 and trypsin at a ratio of 1:50 protease to protein 
from the lysate (as determined by BCA protein concentration). The samples were 
incubated overnight at 37 ˚C with agitation. After 14–16 hours, the samples were 
removed and cooled to room temperature. 
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Desalting of Tryptic Peptides 
 Desalting of tryptic peptides was performed according to Villen and Gygi.21 Neat 
TFA to a final concentration of 0.4% was added to each sample, which was spun for 
10 min at 2,500 g to remove any cellular debris. For the peptide desalting step 500 mg 
Waters C18 SepPak cartridges was used (up to 10 mg loaded). The Waters C18 
SepPak was washed with MeCN (9 mL) and then with 3 mL of 50% MeCN in H2O with 
0.5% AcOH. The column was equilibrated with 0.1% TFA in H2O (9 mL) and then 
loaded with the trypsinized peptide samples in 0.4% TFA in H2O. The column was 
washed with 0.1% TFA in H2O (9 mL) to desalt the peptides. The counter-ion was 
exchanged by a final wash with 0.5% AcOH in H2O (900 μL). Peptides were eluted 
with 5–6 mL of 50% MeCN in H2O with 0.5% AcOH. The eluent was concentrated by 
freeze-drying to isolate the peptides as a white to off-white solid. (For 10 mg of 
undigested protein we usually obtained 6–7 mg of desalted tryptic digest.) 
 
Desalting of Zn-DPA and IMAC Enriched Peptides 
 Desalting of Zn-DPA or IMAC enriched peptides was performed according to 
Villen and Gygi.21 Elution fractions from IMAC or Zn-DPA were combined and acidified 
(pH < 2) by the addition of 10% formic acid for desalting by an Oasis HLB column. For 
the optimized workflow, the acidified elution fraction was then desalted using a 10 mg 
1 cc Oasis HLB cartridge. The Oasis HLB column was conditioned with MeOH (1 mL) 
and then equilibrated with H2O (1 mL). The acidified sample was loaded onto the 
cartridge, and the sample was washed with 5% formic acid in H2O (1 mL). The peptides 
were eluted with 5% NH4OH in 50% MeOH in H2O (1 mL). The eluent was concentrated 
by freeze-drying to yield the enriched peptides that can be directly resuspended for 
mass spectrometry analysis. 
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Zn-DPA Enrichment 
Zn-DPA enrichment was performed according to Conway et al.14 To begin the 
enrichment procedure with the Zn-DPA resin, the incubation buffer (25 mM HEPES, 
pH 7.4, 100 mM KCl), Pi wash buffer (1 mM Pi in incubation buffer), and PPi elution 
buffer (5 mM PPi in incubation buffer) were prepared. Resin loading as determined by 
proton NMR was between 1.0 and 1.7 μmol/mL. All steps of the enrichment were 
carried out at 4 ˚C. Zn-DPA resin slurry (200 μL, ~200–300 nmol) was transferred to 
Eppendorf tubes (1 tubes for ~6.5 mg of desalted tryptic peptides). The resin was 
washed with incubation buffer (3 × 500 μL) and spun at  3,000 g for 3 minutes to 
precipitate resin. The supernatant was removed and discarded. The Zn-DPA resin was 
incubated with fresh ZnBr2 (10 mM, 26.1 mg in 10 mL incubation buffer) for 10 minutes 
with agitation. The samples were spun, and the supernatant was discarded. The resin 
was washed with incubation buffer (2 × 950 μL). The samples were spun, and the 
supernatant was discarded. 1 mL of tryptic digested peptides (6.5 mg/mL) in incubation 
buffer were added to each 200–300 nmol resin portion and agitated for 1 hour. The 
samples were spun at 3,000 g for 3 minutes, and the supernatant was saved as the 
flow-through containing non-phosphorylated peptides. The resin was washed with 
incubation buffer (2 × 950 μL), spun, and the supernatant was discarded. 1 mM Pi 
wash buffer (500 μL) was added to the resin, and the samples were incubated for 10 
minutes with mixing. The samples were spun, and the supernatant was saved. The Pi 
wash step was repeated 2 times. The pyrophosphorylated peptides were then eluted 
from the resin by treating the Zn-DPA reagent with 5 mM PPi elution buffer (500 μL) 
and mixing for 10 minutes. The samples were spun at 3,000 g for 3 minutes, and the 
supernatant was saved as the elution fraction. The PPi elution step was repeated once. 
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IMAC Enrichment 
IMAC enrichment was performed according to Villen and Gygi.21 The binding 
buffer containes 40% MeCN in H2O with 25 mM formic acid. The elution buffer 
contained 50 mM K2HPO4, pH adjusted to 10 with NH4OH. All steps of this enrichment 
will be conducted at room temperature. IMAC beads (3 × 120 μL for 3.4 mg of tryptic 
peptide) are washed with 1.2 mL of binding buffer and will be spun at 10,000 rpm for 
30 sec to precipitate beads. The supernatant will be removed, and this step will be 
repeated 3 times. After the last wash supernatant will be removed, each bead portion 
is resuspended in 120 μL of binding buffer to make a 50% resin slurry. 120 μL of the 
slurry will be added to Eppendorf tubes and then treated with 1 mL of tryptic digested 
peptides in binding buffer (6.5 mg peptide in 1 mL of binding buffer, 6.5 mg/mL 
concentration). The samples will be incubated with agitation for 60 minutes. At the 
completion of the incubation, the samples will be spun at 10,000 rpm for 2 minutes, 
and the supernatant will be removed containing the non-phosphorylated peptides. The 
resin is washed (3 × 720 μL) with binding buffer. The peptides are eluted from the resin 
using the elution buffer (3 × 240 μL). The elution fractions will be combined, and further 
desalted. 
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SIMAC Enrichment  
SIMAC enrichment was performed with A ‘High-Select™ Fe-NTA Phosphopeptide 
Enrichment Kit’ from Thermo. The digest from the previous step was dissolved in 
SIMAC loading buffer (1348 µl, 0.1% TFA, 50% ACN). 800 µl (20 mg) of the digest 
solution was loaded onto 4 supplied spin columns (4 columns used in total, 200 µl 
loading per column) and the manufacturer’s protocol followed with minor adjustments. 
(The remaining digest solution was frozen at –80 and lyophilized.) 
Spin column equilibration: Remove the bottom closure and loosen screw cap. The 
column was placed in a 2 mL microcentrifuge tube and storage buffer was removed at 
1,000 g for 30 sec. Remove the screw cap and save it for "Bind phosphopeptides" step 
2. Add 200 μL of Binding/Wash Buffer. Centrifuge at 1000 × g for 30 seconds and 
discard the flowthrough. Repeat this step once. Cap the bottom of the column with a 
white Luer plug. Place the column with the plug into the empty microcentrifuge tube. 
Bind phosphopeptides: Add 200 μL of the suspended peptide sample to the 
equilibrated spin column. Close the screw cap. Mix the resin with the sample by holding 
the screw cap and very gently tapping the bottom plug for 10 seconds until the resin is 
insuspension. Do not vortex or invert the column to avoid splashing the resin inside the 
column wall. (Note: Mixing samples by vortexing or inversion results in significantly 
higher nonspecific peptide binding.) Incubate for 30 minutes. Mix the resin gently every 
10 minutes as described in step 2. Carefully remove the bottom plug and the screw 
cap. (Note: Do not squeeze the bottom of the plug during removal as liquid inside the 
plug can backflow into the spin column.) Place the column into the microcentrifuge 
tube. Centrifuge at 1000 × g for 30 seconds. Discard the flow through.  
Wash column: Wash column by adding 200 μL of Binding/Wash Buffer. Centrifuge at 
1000 × g for 30 seconds. Repeat this step two additional times for a total of 3 washes. 
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Discard the flowthrough. Wash column by adding 200 μL of LC-MS grade water. 
Centrifuge at 1000 × g for 30 seconds. Wash with SIMAC buffer A (1% TFA, 20% 
MeCN, 2 × 100 µL).  
Elute column: Place column in a new microcentrifuge tube. Add 100 µL SIMAC buffer 
B (10 mL of 25% NH3(aq) in 500 mL MilliQ, 0.5%). Centrifuge at 1000 × g for 30 seconds. 
Repeat this step once. (Note: Resin color may turn brown, but this is normal.) Combine 
eluents from all column in a 2 mL low binding tube, flash freeze and lyophilize. 
 
λ-Phosphatase Treatment 
Using a NEB 𝜆 −phosphatase kit, the desalted protein digest from the previous step 
were dissolved in 5 ml of reaction buffer (homemade, 50 mM HEPES, 100 mM NaCl, 
2 mM DTT, 0.01% Brij 35) and treated with 40000 units of 𝜆 −phosphatase (10000 
units per 10 mg) in a 50 ml falcon tube. The sample was incubated at 37°C at 300 RPM 
for 5 hours in a heater shaker.  The sample was then desalted. Neat TFA was added 
(0.4%, 40 µL), the pH checked (less than pH 2), and the sample spun for 10 min at 
2,500 g to remove any cellular debris. For the peptide desalting step, one 500 mg 
Waters tC18 SepPak cartridge were used (38 mg/ 5 ml loading per cartridge). Air 
pressure was used speed up washing and elution steps but was not used during the 
loading steps. The SepPak columns were washed with MeCN (9 mL) and then with 3 
mL of 50% MeCN in H2O with 0.5% AcOH. The columns were equilibrated with 0.1% 
TFA in H2O (9 mL) and then loaded with the peptide samples in 0.4% TFA in H2O. 
The column was washed with 0.1% TFA in H2O (9 mL) to desalt the peptides. The 
counter-ion was exchanged by a final wash with 0.5% AcOH in H2O (1 mL). Peptides 
were eluted with 6 mL of 50% MeCN in H2O with 0.5% AcOH sequentially into 15 ml 
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falcon tubes, with 15-20 min equilibration time before air pressure was used to elute. 
The eluent was combined in a single 50 ml falcon tube and freeze-dried to isolate the 
peptides as a white solid.  
 
hSAX fractionation 
Enriched samples were fractionated on a hSAX column (dionex ionpac As24) using an 
Agilent 1260 Infinity Quaternary analytical HPLC system with quaternary solvent 
delivery system, an auto sampler, a diode-array detector, and a fraction collector. 
Buffer A: 20 mM (NH4)2CO3 pH 9.0, 20% MeCN. Buffer B: 500 mM (NH4)2CO3 pH 9.0, 
1% MeCN. Gradient: 0% B for 5 min, 0–50% B from 5–65 min, 50–100% B from 65–
95 min, 100% B from 95–105 min. 
The lyophilized and enriched peptides were dissolved in 100 µL buffer A and 
fractionated in one HPLC run using a gradient depicted and collecting 21 fraction (5 
min per fraction). The fractions were flash frozen and lyophilized and handed to the 
MS corefacility. 
 
LC-MS/MS 
LC-MS/MS was performed based on Penkert et al.12 Prior to every measured 
sequence of samples, the trapping and analytical column was flushed with 0.1% citric 
acid in 1% acetonitrile to chelate any residual metal ions. For LC-MS/MS experiments, 
enriched peptides were dissolved in water and analyzed by a reversed-phase capillary 
liquid chromatography system (Dionex Ultimate3000 NCS-3500RS Nano, Thermo 
Scientific, San Jose, CA) connected to a Thermo Scientific Orbitrap Fusion 
massspectrometer (Thermo Fisher Scientific). LC separation was performed on an in-
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house packed 75μm inner diameter Pico Tip column (25 cm) packed with ReproSil-Pur 
C18AQ particles, 3μm, 120 Å (Dr. Maisch, Germany). The flow rate was 200 nL/min 
using gradient of 2−30% B in 60 min. Mobile phase solvent A contained 0.1% formic 
acid in water, and mobile phase solvent B contained 0.1% formic acid in acetonitrile.  
Mass spectra were acquired in data dependent acquisition mode with a FT 
survey scan in the range from 350 to 1500 m/z at a resolution of 120 000 (full width at 
half-maximum, fwhm). The maximum injection time for MS scans was set to 50 ms and 
the AGC target value, to 2 × 105. Doubly and triply charged precursor ions were 
selected with precursor priority to the higher charge state. Precursor ions were isolated 
with a mass selecting quadrupole within an isolation window of 1.6m/z. Dynamic 
exclusion was enabled with an exclusion interval of 10 or 40 s. CID MS/MS scans were 
performed with a normalized collision energy of 25% and an AGC target value of 5 × 
103. MS/MS spectra were acquired in the ion trap with a maximum injection time of 50 
ms. If neutral losses of 49 and 89 m/z from doubly charged precursor ions were 
measured above a threshold of 15% and belonged to the five most abundant ions, an 
additional EThcD spectrum of the same precursor ions was acquired. If triply charged 
precursor ions showed neutral losses of 32.7 and 59.3 m/z during CID fragmentation, 
an additional EThcD scan was only performed if the observed signals exhibit relative 
intensities above 15% and were ranked among the 6 most intense signals. EThcD 
spectra were measured in the Orbitrap with a resolution of 15 000 and the maximum 
accumulation time for an AGC target value of 1 × 105 was set to 1 s. Calibrated charge 
dependent ETD parameters were used for the ETD process, and HCD supplemental 
activation was enabled. SA collision energy was set to 50% for charge state 2 and 
between 25% and30% for charge state 3 (calculated on m/z and charge state of the 
precursor ion). 
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MS/MS data analysis 
MS/MS data analysis was performed based on Penkert et al.12 MS raw data 
were analyzed with Proteome Discoverer 2.1 software (Thermo Fisher Scientific, 
Bremen, Germany). To simplify EThcD spectra, the nonfragment filter was used with 
the following parameters: Precursor ions and charged reduced precursors were 
removed within a 4 Da window and neutral losses within a 2 Da window. MS/MS 
spectra were searched against the Yeast proteome data base using SEQUEST or 
Mascot (Matrix, Science, UK). Up to two missed cleavages were allowed for protease 
digestion with trypsin. Precursor mass tolerance and fragment mass deviation was set 
to 10 ppm and 20 mmu, respectively. Oxidation of methionine, phosphorylation (STY), 
pyrophosphorylation (S,T), and carbamidomethyl (C) were searched as variable 
modifications. Results were filtered with the Target Decoy PSM Validator and a Target 
false discovery rate (FDR) of 0.01 at peptide identification level. EThcD MS/MS spectra 
of pyrophosphorylated peptides were additionally, manually verified. Manual 
verification was performed considering potential gas-phase rearrangements to other 
phosphoacceptors, the degree of neutral loss of labile modifications, the sequence 
coverage of the peptide, and the signal-to-noise ratio. 
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Appendix 
Table 4.2: Protein pyrophosphorylation sites identified in HEK293T. 
 Protein GN Sequence (red: PP-site) PP-Site 
Cell Comparment 
(Uniprot) 
Priming Kinase 
1 Dual specifity protein kinase 1/4 CLK1/4 VVDFGSATYDDEHHSTLVST
RHYR 
Ser 341 Nucleus Auto? 
2 MICOS complex subunit  CHCHD3 YSGAYGASVSDEELK Ser 50 Nucleus, Mitochondria   
3 Elongation factor 1-delta  EEF1D KPATPAEDDEDDDEDLFGSD
NEEEDKEAAQLR 
Ser 162 Nucleus CK2A1 
4 Nucleophosmin NPM1 CGSGPVHISGQHLVAVEEDA
ESEDEEEEDVK 
Ser 125 Nucleus, Cytoskeleton ATR, PRP4  
5 Heat shock protein HSP 90-alpha HSP90AA1 ESEDKPEIEDVGSDEEEEKK
DGDK 
Ser 263 Nucleus, cell 
membrane, cytoplasm 
  
6 Nucleoside disphosphate kinase A  NME1 VMLGETNPADSKPGTIR Thr 94 Nucleus CDK1 
7 Myosin- 9  MYH9 KGAGDGSDEEVDGKADGAE
AKPAE 
Ser 1943 Cytoskeleton CK2A1 
8/9 Heterogeneous nuclear ribonucleoprotein D0 HNRNPD IDASKNEEDEGHSNSSPR Ser 82/ 
Ser 83 
Nucleus GSK3B 
10 Nucleolar RNA helicase 2  DDX21 NEEPSEEEIDAPKPK Ser 121 Nucleus   
11 Negative Elongation Factor E NELFE SISADDDLQESSR Ser 115 Nucleus PRP4, TBK1 
12 Membrane associated progesterone receptor 
component 1 
PGRMC1 LLKEGEEPTVYSDEEEPKDE
SAR 
Ser 181 Endoplasmic reticulum   
13 Coiled-coil domain containing protein 168 CCDC168 LENGTSAVTSASEMLLPHTL
QNHSVK 
Ser 1901 -   
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 Protein GN Sequence (red: PP-site) PP-Site 
Cell Comparment 
(Uniprot) 
Priming Kinase 
14 Calnexin CANX QKSDAEEDGGTVSQEEEDR
KPK 
Ser 564 Endoplasmic reticulum PLK1  
15 Histone Deacetylase 2  HDAC2 MLPHAPGVQMQAIPEDAVHE
DSGDEDGEDPDKR 
Ser 394 Nucleus CK2A1 
16 Heat shock protein HSP 90-beta HSP90AB1 IEDVGSDEEDDSGKDKK Ser 255 Nucleus, cell 
membrane, cytoplasm,  
CK2A1, AurB  
17/
18 
Proline-rich protein PRCC PRCC IAAPELHKGDSDSEEDEPTK Ser 157/ 
Ser159 
Nucleus   
19 THUMP domain-containing protein 1 THUMPD1 FTDKDQQPSGSEGEDDDAE
AALKK 
Ser 86 Nucleus   
20 Plasminogen activator inhibitor 1 RNA-
binding protein 
SERBP1 SKSEEAHAEDSVMDHHFR Ser 330 Nucleus, cytoplasm PRKD1  
21 Formin-binding protein 4 FNBP4  IDENSDKEMEVEESPEKIK Ser 499 Lysosome, cell 
membrane 
  
22 Hepatoma-derived growth factor HDGF GNAEGSSDEEGKLVIDEPAK
EK 
Ser 133 Nucleus, cytoplasm   
23 Pyruvate dehydrogenase E1 component 
subunit alpha 
PDHA1 YHGHSMSDPGVSYR Ser 293 Mitocondron matrix PDHK1-4, 
PDK1, PDP1  
24 Nuclear ubiquitous casein and cyclin-
dependent kinase substrate 1 
NUCKS1 NSQEDSEDSEDKDVK Ser 61 Nucleus   
25 Charged multivesicular body protein 2b CHMP2B ATISDEEIER Ser 199 Cytosol TBK1  
26 N-acetyl-D-glucosamine kinase NAGK SLGLSLSGGDQEDAGR Ser 76 Cytosol AurB, CDK1  
27 Nucleolar protein 58 NOP58 HIKEEPLSEEEPCTSTAIASPE
KK 
Ser 502 Nucleolus, 
nucleoplasm 
PRP4  
28 Monocarboxylate transporter 1 SLC16A1 KESKEEETSIDVAGKPNEVTK Ser 461 Cell membrane   
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 Protein GN Sequence (red: PP-site) PP-Site 
Cell Comparment 
(Uniprot) 
Priming Kinase 
29 Gamma-soluble NSF attachment protein NAPG KKSPATPQAKPDGVTATAAD
EEEDEYSGGLC 
Ser 284 Membrane   
30 Nucleosome assembly protein 1-like 1 NAP1L1 LDGLVETPTGYIESLPR Thr 62 Cytoplasm, nucleus   
31 Phosphoglucomutase-1 PGM1 AIGGIILTASHNPGGPNGDFGI
K 
Ser 117 Cytoplasm  
32 Microtubule-associated protein tau MAPT TDHGAEIVYKSPVVSGDTSP
R 
Ser 713 Cytoplasm  
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Table 4.3: Protein pyrophosphorylation sites identified in HCT116. 
 Protein GN 
Sequence  
(red: PP-site) 
PP-Site 
Cell Comparment  
(Uniprot) 
Priming Kinase 
 
1 Microtubule-associated protein tau MAPT AKTDHGAEIVYKppSPVVSGD
TSPR 
Ser 713 Cytoplasm 
 
2 Dual specifity protein kinase CLK1 CLK1 VVDFGSATYDDEHHSTLVpp
STR  
Ser 341 Nucleus Auto? 
3 Nucleolar Protein 58 NOP58 HIKEEPLppSEEEPCTSTAIAS
PEK 
Ser 502 Nucleus/nucleoplas
m 
PRP4 
4 Nucleoside disphosphate kinase A /B NME1 VMLGEppTNPADSKPGTIR Thr 94 Nucleus CDK1 
5 Serine/Arginine-rich splicing factor 5 SRSF5 SVppSRSPVPEK Ser 231 Nucleus  
6 Ubiquitin-conjugating enzyme E2  UBE2Z LHNENAEMDSDSSppSSGTE
TDLHGSLR 
Ser 341 Nucleus/cytoplasm - 
7 Activated RNA polymerase II transcriptional 
coactivator p15 
SUB1 SKELVSSSSppSGSDSDSEV
DKK 
Ser 13 Nucleus - 
8 Nucleolar and coiled-body phosphoprotein 1 NOLC1 KKASppSSDSEDSSEEEEEV
QGPPAK 
Ser 84 Nucleus/cytoplasm   
9/ 
10 
Pre-mRNA 3'-end-processing factor FIP1 FIP1L1 VTETEDDSDppSDSDDDEDD
VHVTIGDIK 
VTETEDDppSDSDSDDDEDD
VHVTIGDIK 
Ser 85/87 Nucleus   
11 Nucleophosmin NPM1 CGSGPVHISGQHLVAVEEDA
EppSEDEEEEDVK 
Ser 125 Nucleus, 
Cytoskeleton 
ATR, PRP4 
12 N-acetyl-D-glucosamine kinase NAGK SLGLSLppSGGDQEDAGR Ser 76 Cytosol, secreted AurB, CDK1 
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13 MICOS complex subunit MIC19  CHCHD3 SQRYppSGAYGASVSDEELK Ser 50 Nucleus, 
Mitochondria 
  
14 Hepatoma-derived growth factor-related 
protein 2 
HDGFL2 APSASDSDppSKADSDGAKP
EPVAMAR 
Ser 236 Nucleus   
 
 
